Lupus myocarditis : diagnostic characteristics and outcome of myocardial injury by Du Toit, Riette
L U P U S  M Y O C A R D I T I S :   
D I A G N O S T I C  C H A R A C T E R I S T I C S   
A N D  O U T C O M E  O F  M Y O C A R D I A L  I N J U R Y
RIËTTE DU TOIT 
MBChB, MMed, Cert Rheum (CMSA) 
Dissertation presented for the degree of Doctor of Philosophy 
in the Faculty of Medicine and Health Sciences 




Prof AF Doubell 
Division of Cardiology 
Department of Medicine 
CO-SUPERVISOR 
Prof H Reuter 
Division of Clinical Pharmacology 
Department of Medicine 
DECLARATION 
By submitting this dissertation electronically, I declare that the entirety of the work contained therein  is 
my  own,  original  work,  that  I  am  the  sole  author  thereof  (save  to  the  extent  explicitly otherwise 
stated),  that  reproduction  and  publication  thereof  by  Stellenbosch  University  will  not infringe any 
third party rights and that I have not previously in its entirety or in part submitted it for obtaining  any 
qualification. 
This dissertation includes four original papers published / accepted for publication in peer 
reviewed journals and one paper currently under peer review. The development and writing of the 
papers (published and unpublished) were the principal responsibility of myself and for each of the 
instances where this is not the case a declaration is included in the dissertation indicating the 
nature and extent of the contributions of co-authors. 
CHAPTERS 1 AND 2 
These chapters consist of two published manuscripts, reporting on the results of a retrospective 
analytical study.   
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of echocardiographic imaging. I conducted the data collection and capturing and did the statistical 
analyses with ongoing support from Stellenbosch University Division of Epidemiology and Biostatistics.  
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(including echocardiography and cardiovascular magnetic resonance [CMR]) of all patients.  I was 
responsible for specific CMR analyses (reporting on early gadolinium enhancement ratios as well as 
T2 signal reporting), overseen by PG Herbst.  I captured all data with the support of a research 
assistant. I did the statistical analyses with guidance from Stellenbosch University Division of 
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Doubell. 
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Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. 
R du Toit, H Reuter, G Walzl, C Snyders, NN Chegou, PG Herbst, and AF Doubell. 
Accepted for publication in Rheumatology on 21 July 2020 (RHE-20-0702.R1). 
• G Walzl was involved in the planning of the cytokine analyses and reviewed the final manuscript.
• C Snyders and NN Chegou were responsible for the cytokine analyses and interpretation. Both
authors reviewed the final manuscript.
• PG Herbst was involved in the planning and execution of CMR analyses. He formed part of the
team who reported on the CMR images and oversaw and co-ordinated the CMR and
echocardiography procedures and reporting. He reviewed the final draft of the manuscript.
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echocardiography and CMR) of all patients.  I was responsible for specific CMR analyses (reporting on 
early gadolinium enhancement ratios as well as T2 signal reporting) overseen by PG Herbst.  I captured 
all data with the support of a research assistant. I did the statistical analyses with guidance from 
Stellenbosch University Division of Epidemiology and Biostatistics. I wrote the manuscript included in 
this chapter. 
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• C Ackerman was involved in the planning of the CMR component of the study and formed part of
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forming part of the team who reported on the echocardiographic images, he oversaw and co-
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He reviewed the final draft of the manuscript.
• D Claassen assisted me with clinical data collection and the clinical conduct of the study. He
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• HP Cyster formed part of the team performing echocardiography on patients and reporting the
imaging. He reviewed the final draft of the manuscript.
• H Reuter and AF Doubell were the co-supervisor and supervisor respectively. They supervised
the study design and execution. Both reviewed the final draft of the manuscript.
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LUPUS MYOCARDITIS:  
DIAGNOSTIC CHARACTERISTICS AND OUTCOME OF MYOCARDIAL INJURY 
Lupus myocarditis is a rare but serious manifestation of systemic lupus erythematosus (SLE). Through 
this dissertation I have aimed to describe the outcome of both clinical as well as subclinical myocardial 
injury in SLE. I have also aimed to define the diagnostic characteristics of myocardial injury, identified by 
cardiac magnetic resonance imaging with regards to clinical, echocardiographic and cytokine profiles.  
CHAPTER 1 
Clinical features and outcome of lupus myocarditis in the Western Cape, South Africa. 
In a retrospective cohort study, we described the clinical characteristics and outcome of SLE patients 
with clinically evident lupus myocarditis (LM). Our population included SLE patients of 
predominantly mixed racial ancestry and at the time of publication it was the largest reported cohort 
of patients with LM. Patients presented early in the course of their disease, had a high SLE disease 
activity and frequently presented with concomitant lupus nephritis (LN).  In comparison to 
international literature, we documented a similar prevalence (6.1%), but significantly higher 
mortality (17.8% related to LM). A low left ventricular ejection fraction (LVEF) at diagnosis was of 
prognostic significance, associated with both LM-related mortality as well as a persistent LVEF<40% 
after treatment. These findings emphasise the importance of early recognition and treatment of LM.  
CHAPTER 2 
Speckle tracking echocardiography in acute lupus myocarditis: comparison to conventional 
echocardiography. 
Speckle tracking echocardiography (STE) is a sensitive measure of left ventricular (LV) function. The role 
of STE in the diagnosis of clinical LM has not been established. In the same cohort, echocardiographic 
images were re-analysed to include STE and compared to that of a healthy control group. Strong 
correlations existed between STE (global longitudinal strain [GLS]) and other parameters of LV function, 
including LVEF. A poor LVEF and/or GLS at presentation were associated with a poor echocardiographic 
outcome (final LVEF<40%). In patients with LM who presented with a preserved LVEF (≥50%), the GLS 
(STE) was significantly impaired compared to that of a control group, enabling the detection of subtle LV 
dysfunction. Echocardiography, including STE is a non-invasive tool with prognostic and diagnostic value 




Myocardial injury in systemic lupus erythematosus according to cardiac magnetic resonance 
tissue characterisation: clinical and echocardiographic features. 
In a prospective cohort study, we screened SLE patients for myocardial injury according to 
cardiovascular magnetic resonance (CMR) criteria. Clinical and echocardiographic features of patients 
with and without myocardial injury were compared. Predictors of myocardial tissue characteristics 
(inflammation / fibrosis / necrosis) according to CMR (Lake Louise criteria) were identified. Of 106 
SLE patients screened for inclusion, 57 were excluded due to intolerance of or contra-indication to 
CMR (27/57 due to renal impairment). The high exclusion rate highlights the limitations of CMR in 
SLE patients, in particular due to LN. On multivariable analyses, right ventricular function (tricuspid 
annular plane systolic excursion) was predictive of inflammation (OR:0.045; p=0.006; 
CI:0.005-0.415) and GLS (assessed by STE) predicted necrosis / fibrosis on CMR (OR:1.329; 
p=0.031; CI:1.026-1.722). A model including clinical and echocardiographic parameters was 
predictive of increased early gadolinium enhancement (inflammation) on CMR (sensitivity: 
88.9%; specificity: 76.3%). Where CMR is unavailable or contra-indicated, echocardiography can be 
used as a cost effective screening tool for the detection of myocardial tissue injury. 
CHAPTER 4 
Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. 
Literature exploring the immunopathogenetic and cytokine pathways involved in myocardial injury in 
SLE is limited. In the same cohort of patients (n=41), we evaluated serum cytokines, markers 
of endothelial activation (serum vascular cell adhesion molecule-1 [sVCAM-1]) and myocyte strain 
(soluble-ST2 [sST2]) associated with myocardial injury in SLE (classified according to CMR criteria). 
As a novel finding, we observed increased serum levels of interleukin-18 (IL-18) (p=0.003), IL-1 
receptor antagonist (IL-1Ra) (p=0.012), IL-17 (p=0.045), and sVCAM-1 (p=0.062) in SLE patients 
with CMR evidence of myocardial injury compared to those without. On multivariable logistic 
regression analyses, IL-1Ra was independently associated with different stages of myocardial 
injury according to CMR tissue characterisation whereas anti-Ro/SSA (OR:1.197;p=0.035) 
and the SLE damage index (OR:4.064;p=0.011) predicted fibrosis/necrosis. Future studies 
evaluating myocardial tissue expression of these cytokines (through endomyocardial biopsy) 
will provide further insight of the exact pathogenetic role of these cytokines in the 





Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus – a 
prospective cohort study 
We have demonstrated in chapters one and two that more advanced clinical LM at presentation is 
associated with a poor outcome. The significance and prognostic implications of subclinical LM are 
however not well researched. After 12 months, follow-up analyses were available in 36/49 SLE patients 
from our original cohort. Although SLE disease activity improved, 80.6% of patients still had mild to 
moderately active disease. We observed ongoing CMR evidence of subclinical myocardial injury in our 
patients, regardless of improved serological markers and global echocardiographic function. Subclinical 
LM did not progress to clinically evident LM and had no significant prognostic implications over the 
twelve month period. These findings question the rationale of CMR as a screening tool in the 
asymptomatic SLE patient. Intensified immunosuppressive therapy during follow-up had no 
demonstrable effect on the changes in CMR parameters observed. Our findings do not support the use of 
immunosuppressive therapy in subclinical LM identified through CMR tissue characterisation. 
Improvement in CMR left ventricular mass index (LVMi) correlated with an improvement in T2-weighted 
signal (myocardial oedema), a novel finding in SLE. CMR LVMi may be used as an additional measurement 




LUPUS MIOKARDITIS:  
DIAGNOSTIESE EIENSKAPPE EN UITKOMS VAN MIOKARDIALE BESERING 
Lupus miokarditis (LM) is ‘n raar maar ernstige manifestasie van sistemiese lupus eritematose (SLE). 
Met hierdie verhandeling beoog ek om die uitkoms van kliniese asook subkliniese miokardiale besering 
in SLE te beskryf. Ek beoog om die diagnostiese eienskappe van miokardiale besering, geïdentifiseer deur 
kardiale magnetiese resonansie (KMR) te beskryf ten opsigte van kliniese, eggokardiografiese en sitokien 
profiele.   
HOOFSTUK 1 
Kliniese eienskappe en uitkoms van lupus miokarditis in die Weskaap, Suid Afrika 
Ons het die kliniese eienskappe en uikoms van klinies beduidende lupus miokarditis in sistemiese lupus 
eritematose (SLE) pasiënte beskryf in ‘n retrospektiewe kohort studie. Die studie populasie het 
SLE pasiënte van ‘n oorwegend veelrassige-afkoms groep ingesluit en ten tyde van publikasie was 
dit die grootste gerapporteerde kohort van pasiënte met LM. Pasiënte het vroeg in die verloop van 
hul siekte gepresenteer, het ‘n hoë SLE siekte aktiwiteit gehad en het dikwels gepresenteer met 
bykomende lupus nefritis (LN). In vergelyking met internasionale literatuur het ons ‘n soortgelyke 
voorkoms (6.1%), maar betekenisvolle hoër mortalitieit gedokumenteer (17.8% LM verwant).  ‘n Lae 
linker ventrikulêre uitwerp fraksie (LVUF) by diagnose was van prognostiese waarde, 
geassosieer met beide LM-verwante mortaliteit asook ‘n persisterende LVUF<40% na behandeling. 
Hierdie bevindings beklemtoon die belang van vroëe herkenning en behandeling van LM.  
HOOFSTUK 2 
Spikkelspoor eggokardiografie in akute lupus myokarditis: vergelyking met konvensionele 
eggokardiografie.  
Spikkelspoor eggokardiografie (SSE) is ‘n sensitiewe maatstaf van linker ventrikulêre (LV) funksie.  Die 
rol van SSE in die diagnose van LM is nog nie vasgestel nie. In dieselfde kohort is eggokardiografiese 
beelde geheranaliseer met die insluiting van SSE en vergelyk met die van ‘n gesonde kontrole groep. Sterk 
korrelasies is gevind tussen SSE (globale longitudinale stremming [GLS]) en ander parameters van LV 
funksie, insluitend LVUF. ‘n Lae LVUF  en / of GLS met aanvanklike presentering was geassosieër met ‘n 
swak eggokardiografiese uitkoms (finale LVUF<40%). In LM pasiënte wat presenteer het met behoud 
van hul LVUF (≥50%), was die GLS betekenisvol ingekort in vergelyking met die van ‘n kontrole groep. 
GLS stel ons in staat om subtiele LV disfunksie te herken. Eggokardiografie, insluitend SSE, is ‘n nie-
xi
Stellenbosch University https://scholar.sun.ac.za
indringende hulpmiddel met prognostiese en diagnostiese waarde in pasiënte met LM, veral ook in 
pasiënte wat presenteer met behoud van hul LVUF.   
HOOFSTUK 3 
Miokardiale besering in sistemiese lupus eritematose volgens kardiale magnetiese resonansie 
weefsel karakterisering:  kliniese en eggokardiografiese eienskappe.   
SLE pasiënte is ondersoek vir miokardiale besering volgens kardiale magnetise resonansie (KMR) 
kriteria in ‘n prospektiewe kohort studie. Kliniese en eggokardiografiese eienskappe van pasiënte met en 
sonder miokardiale besering is vergelyk. Parameters wat miokardiale weefsel eienskappe (inflammasie 
/ fibrose / nekrose) voorspel volgens KMR (Lake Louise kriteria) is geïdentifiseer.  Uit 106 SLE pasiënte 
wat oorweeg is vir insluiting, is 57 uitgesluit weens intoleransie van of kontra-indikasies vir KMR (27/57 
as gevolg van nierinkorting). Die hoë uitsluitingsfrekwensie beklemtoon die beperkings van KMR in SLE 
pasiënte, veral as gevolg van gepaardgaande LN. Met meervoudige logistiese analises was regter 
ventrikulêre funksie (trikuspidale annulêre vlak sistoliese ekskursie) voorspellend van inflammasie 
(kansverhouding (KV):0.045; p=0.006; vertrouensinterval (VI):0.005-0.415) en die globale longitudinale 
stremming (bepaal deur spikkelspoor eggokardiografie) voorspellend van nekrose / fibrose om KMR 
(KV:1.329; p=0.031; VI: 1.026-1.722). ‘n Model wat kliniese en eggokardiografiese parameters insluit was 
voorspellend van vroeë gadolinium versterking (inflammasie) op KMR (sensitiwiteit:88.9%; 
spesifisiteit:76.3%). Indien KMR nie beskikbaar is of gekontra-indikeerd is, kan eggokardiografie as 'n 
koste-effektiewe hulpmiddel gebruik word om miokardiale weefsel besering te bespeur.   
HOOFSTUK 4 
Serum sitokien vlakke geassosieer met miokardiale besering in sistemiese lupus eritematose. 
Literatuur wat die immunopatogenetiese en sitokien paaie betrokke by miokardiale besering in SLE 
ondersoek is gebrekkig. In dieselfde kohort van pasiënte (n=41) het ons sitokien vlakke, merkers van 
endoteel aktivering (vaskulêre sel adhesie molekule [sVSAM-1] en miosiet stremming (oplosbare-ST2 
[oST2]) geassosieër met miokardiale besering in SLE (geklassifiseer volgens KMR kriteria) geëvalueer. 
As ‘n nuwe bevinding, het ons verhoogde serum vlakke van interleukin-18 (IL-18) (p=0.003), IL-1 
reseptor antagonis (IL-1Ra) (p=0.012), IL-17 (p=0.045), en sVSAM-1 (p=0.062)  geobserveer in SLE 
pasiënte met KMR bewys van miokardiale besering in vergelyking met pasiënte daarsonder. Met 
meerveranderlike logistiese regressie analise was die IL-1Ra onafhanklik geassosieërd met verskillende 
stadiums van miokardiale besering volgens KMR weefsel karakterisering, terwyl anti-Ro/SSA 
(OR:1.197;p=0.035) en die SLE skade indeks (OR:4.064;p=0.011) fibrose/nekrose voorspel het. 
Toekomstige studies wat miokardiale weefsel uitdrukking van hierdie sitokiene evalueer (deur 
endomiokardiale biopsies) sal verdere insig verskaf ten opsigte van die rol van hierdie sitokiene in die 
xii
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ontwikkeling van miokardiale besering in SLE en uiteindelik aanleiding kan gee tot meer geteikende 
terapieë vir lupus miokarditis.  
HOOFSTUK 5 
Uitkoms van kliniese en subkliniese miokardiale besering in sistemiese lupus eritematose – ‘n 
prospektiewe kohort studie  
In hoofstukke een en twee het ons gedemonstreer dat meer gevorderde kliniese LM ten tyde van 
presentering geassosieer is met n swak uitkoms. Die belang en prognostiese implikasies van subkliniese 
LM is egter nog nie deeglik ondersoek nie. Na twaalf maande was opvolg analise beskikbaar in 36/49 SLE 
pasiënte van ons oorspronklike kohort. Alhoewel die SLE siekte aktiwiteit verbeter het, het 80.6% van 
pasiënte steeds gering to matige siekte aktiwiteit gehad. Ons het aangaande KMR bewys van subkliniese 
miokardiale besering in ons pasiënte geobserveer, ongeag die verbetering in serologiese merkers en 
globale eggokardiografiese funksie. Subkliniese LM het nie geprogresseer tot kliniese LM nie en het geen 
betekenisvolle prognostiese implikasies oor die twaalf maande periode gehad nie. Hierdie bevindings 
bevraagteken die rasionaal van KMR as ‘n siftingshulpmiddel in die asimptomatiese SLE pasiënt. ‘n 
Verhoogde intensiteit van immuunonderdrukkings tydens opvolg het geen beduidende effek gehad op 
die geobserveerde veranderings in KMR parameters nie. Ons bevindings ondersteun nie die gebruik van 
immuunonderdrukkende terapie in subkliniese LM geïdentifiseer deur KMR weefsel karakterisering nie. 
Verbetering in die KMR linker ventrikulêre massa indeks (LVMi) het gekorrelleer met ‘n verbetering in 
die T2-geweegde sein (miokardiale edeem), ‘n nuwe bevinding in SLE. KMR LVMi kan gebruik word as ‘n 
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Clinical and subclinical lupus myocarditis 
Cardiac involvement in systemic lupus erythematosus (SLE) occurs in more than 50% of patients and 
includes a spectrum of pericardial, myocardial, endocardial and coronary artery disease.(1,2) Lupus 
myocarditis (LM) is a rare but serious cardiac manifestation with clinically evident myocarditis occurring 
in 5-10% of SLE patients.(3,4)  
Reports on the prevalence of subclinical LM are conflicting. Post-mortem studies describe histological 
evidence of inflammatory myocardial injury in 37 to 80% of patients in the absence of clinical features of 
myocardial involvement ante mortem.(5,6) Considering the clinical prevalence of 5-10%, these findings 
suggest a significant degree of subclinical involvement.  
Outcome of clinical and subclinical LM 
Although international literature reports the outcome of clinical LM to be generally favourable, LM is 
known to have a negative effect on overall survival and damage accrual.(7–9) In the South African 
context, most clinical studies done in SLE are in the setting of predominantly black 
SLE populations.(10,11) Studies done specifically in the mixed ancestral population, predominant in the 
Western Cape, have mainly focused on lupus nephritis (LN) which tends to be disproportionately 
more frequent and more severe compared to LN in other ethnic groups.(12,13) No regional or 
national data exists on the prevalence and outcome of clinically evident LM. 
More advanced imaging modalities such as cardiovascular magnetic resonance imaging (CMR) has the 
ability to detect subclinical myocardial involvement ante mortem, yet very few studies focus 
specifically on the outcome of subclinical LM.(14–16) In some reports, subclinical imaging 
abnormalities tend to correlate with SLE disease activity, but it is not clear from the literature whether 
the early detection of subclinical LM predicts the development of clinically significant 
myocardial involvement.(16) A better understanding of the relevance and prognostic implications 
of subclinical LM is essential to guide clinical decisions regarding the optimal screening and 
management of SLE patients. Insight into the outcome of subclinical LM will guide informed decision 
making regarding the need for therapeutic intervention of asymptomatic patients with evidence of 
subclinical LM. (14,17)  
Immunopathogenesis of myocardial injury in SLE 
Current knowledge of the immunopathogenesis of myocardial injury in SLE is based on 
immunohistochemistry reports.(18) Immune complex deposition, activation of the complement 
cascade and subsequent endothelial cell activation and tissue injury appears to be similar to what is 
described in 2
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other organ manifestations in SLE.(19)  Although auto-antibodies are known to play a central role in the 
pathogenesis of SLE, the prevalence of circulating auto-antibodies [including antinuclear antibody (ANA), 
anti-double stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm)] in patients with LM appear to be no 
different from that found in the general SLE population.(8,20) The exception is that of anti-Ro/SSA and 
anti-ribonuclear protein (anti-RNP) which have been reported at an increased frequency of 69% and 
62% respectively, compared to up to 40% in the general lupus population.(8,21)  
In addition to immune complex deposition, the innate immune system plays an important role in the 
pathogenesis of SLE. Cytokines in the form of interleukins (ILs) act as mediators orchestrating the 
pathological immune response that lead to a vast spectrum of SLE manifestations.(22,23) Various 
cytokine patterns have been associated with the expression of SLE phenotypes.(23,24) Literature 
exploring the specific immunopathogenetic pathways and cytokines involved in non-ischemic 
myocardial injury in SLE is however limited.  
Various other potential biomarkers have been identified in non-lupus inflammatory cardiomyopathies 
(CMO). The expression of endothelial cell adhesion molecules (CAM) promotes trans-endothelial 
migration of circulating immunocompetent cells into the myocardial interstitium and correlates with the 
presence of lymphocytic inflammation of the myocardium (non-SLE patients).(25) Soluble vascular cell 
adhesion molecule-1 (sVAM-1) has been associated with SLE disease activity as well as specific organ 
manifestations, including LN.(26,27) sVCAM-1 as a potential marker in SLE related myocarditis had not 
been explored.  
Identification of specific cytokine pathways as well as markers of myocyte strain or endothelial injury in 
clinical as well as subclinical LM may not only provide biomarkers as non-invasive diagnostic tools, but 
also highlight new potential targets for therapeutic intervention in SLE associated myocardial injury. 
Diagnostic modalities 
Currently, no single clinical feature or imaging technique is diagnostic of clinical LM. The diagnosis is 
therefore usually based on a clinical impression of congestive cardiac failure or unexplained arrhythmia, 
supported by non-invasive tests including markers of myocyte injury and cardiac imaging.(28,29)   
Although regarded as the gold standard and a low risk procedure in experienced hands, endomyocardial 
biopsy (EMB) remains an invasive procedure.(30) Very few studies have specifically evaluated the role 
of EMB in LM.(31,32) Recommendations on the use of EMB in suspected myocarditis are based on 
research done in predominantly non-lupus myocarditis, limiting the application of these 
recommendations in the setting of SLE. (30,33)  
Although unable to detect specific myocardial tissue injury (inflammation / fibrosis), 
echocardiography is frequently used to support a diagnosis of LM through the detection of functional 
3
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and structural abnormalities.(8,34,35) Current echocardiographic studies are focusing on the 
earlier detection of myocardial dysfunction through new techniques and measurements. Speckle 
tracking echocardiography (STE) has the ability to detect multidirectional dysfunction separately 
in the three layers of the myocardium with different patterns of involvement in different disease 
processes.(36) STE detects abnormalities in left ventricular function and structure that correlates with 
overall SLE disease activity, in the absence of clinically evident cardiac involvement or 
abnormalities as detected by standard two-dimensional imaging.(37) In patients with non-lupus 
myocarditis, STE provides diagnostic as well as prognostic information, predicting 
deterioration and event free survival.(38) The role of STE in patients with clinically evident LM has not 
been established.   
Evidence supports the use of CMR as the non-invasive investigation of choice for the diagnosis 
of myocarditis by identifying different stages of myocardial injury through tissue characterisation.
(29) Inflammation is characterised by an increased T2-weighted signal, reflecting cell injury and 
regional oedema. Increased early gadolinium enhancement ratios (EGEr) represent inflammation 
associated hyperaemia and capillary leak. More recent development of pixel-wise mapping of T1 and 
T2 relaxation times have further improved the accuracy of CMR for the detection of myocardial 
inflammation.(39) Further progressions to cellular necrosis and/or fibrosis is characterised by late 
gadolinium enhancement (LGE), representing less reversible injury.(29) The specific distribution of 
injury also allows CMR  to differentiate ischaemic from non-ischaemic myocardial injury.(40) 
CMR detects both clinical as well as subclinical myocardial injury in SLE, also in the absence of 
abnormalities on other non-invasive imaging such as echocardiography.(14,41)  
Despite the clear benefit of CMR, access to this facility may be limited in resource-constrained 
settings. Further limitations include intolerance of / contra-indications to CMR including renal 
impairment, an important consideration in SLE due to the high incidence of LN.(3,41,42) 
Echocardiography on the other hand is cost effective and can be utilized at the bedside, even in 
the unstable, ventilated patient. Comparative literature between echocardiography, in particular STE 
and CMR on myocardial function and structure in SLE patients is sparse, limiting our interpretation of 
STE.  





i. To give a comprehensive description of speckle tracking echocardiography (STE) findings in
comparison to conventional echocardiography, including tissue Doppler imaging in a group of
patients with clinically evident LM and compare the results to that of a healthy control group.
CHAPTER 3 
ii. To determine the prevalence of myocardial injury (including clinical and subclinical LM) in
SLE according to cardiovascular magnetic resonance (CMR) criteria.
iii. To compare clinical and echocardiographic features of patients with and without
myocardial injury and identify predictors of myocardial tissue characteristics according to
CMR criteria.
CHAPTER 4 
i. To identify cytokines and markers of myocyte strain and endothelial activation associated with
the presence of myocardial injury in SLE as identified by CMR criteria.
ii. To describe associations between cytokine levels and clinical manifestations of SLE.
CHAPTER 5 
i. To determine the outcome of subclinical LM over twelve months with regards to:
a. Mortality
b. Incidence of clinical LM
c. Change in imaging parameters (echocardiography and CMR).
ii. To evaluate the impact of immunosuppression on CMR evidence of myocardial tissue injury.
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i. To describe the prevalence, clinical phenotype and treatment outcome of LM in SLE patients from 
a  rheumatology clinic at a tertiary referral centre in the Western Cape
ii. To provide a comprehensive description of the standard echocardiographic findings, including
functional and structural detail of the LM group
iii. To identify factors associated with a poor treatment outcome of LM
CHAPTER 1 
OBJECTIVES OF DISSERTATION 
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Clinical features and outcome of lupus myocarditis
in the Western Cape, South Africa
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Background: African American ethnicity is independently associated with lupus myocarditis
compared with other ethnic groups. In the mixed racial population of the Western Cape,
South Africa, no data exists on the clinical features/outcome of lupus myocarditis. Objectives:
The objective of this study was to give a comprehensive description of the clinical features and
outcome of acute lupus myocarditis in a mixed racial population. Methods: Clinical records
(between 2008 and 2014) of adult systemic lupus erythematosus (SLE) patients at a tertiary
referral centre were retrospectively screened for a clinical and echocardiographic diagnosis of
lupus myocarditis. Clinical features, laboratory results, management and outcome were
described. Echocardiographic images stored in a digital archive were reanalysed including
global and regional left ventricular function. A poor outcome was defined as lupus myocar-
ditis related mortality or final left ventricular ejection fraction (LVEF) <40%. Results:
Twenty-eight of 457 lupus patients (6.1%) met inclusion criteria: 92.9% were female and
89.3% were of mixed racial origin. Fifty-three per cent of patients presented within three
months after being diagnosed with SLE. Seventy-five per cent had severely active disease
(SLE disease activity index 12) and 67.9% of patients had concomitant lupus nephritis.
Laboratory results included: lymphopenia (69%) and an increased aRNP (61.5%).
Treatment included corticosteroids (96%) and cyclophosphamide (75%); 14% of patients
required additional immunosuppression including rituximab. Diastolic dysfunction and regio-
nal wall motion abnormalities occurred in> 90% of patients. LVEF improved from 35% to
47% (p¼ 0.023) and wall motion score from 1.88 to 1.5 (p¼ 0.017) following treatment.
Overall mortality was high (12/28): five patients (17.9%) died due to lupus myocarditis
(bimodal pattern). Patients who died of lupus myocarditis had a longer duration of SLE
(p¼ 0.045) and a lower absolute lymphocyte count (p¼ 0.041) at diagnosis. LVEF at diagnosis
was lower in patients who died of lupus myocarditis (p¼ 0.099) and in those with a persistent
LVEF< 40% (n¼ 5; p¼ 0.046). Conclusions: This is the largest reported series on lupus myo-
carditis. The mixed racial population had a similar prevalence, but higher mortality compared
with other ethnic groups (internationally published literature). Patients typically presented with
high SLE disease activity and the majority had concomitant lupus nephritis. Lymphopenia and
low LVEF at presentation were of prognostic significance, associated with lupus myocarditis
related mortality or a persistent LVEF< 40%. Lupus (2017) 26, 38–47.
Key words: Systemic lupus erythematosus; myocarditis; echocardiography; ethnicity; lupus
mortality; lupus nephritis
Introduction
Lupus myocarditis is a rare but serious manifest-
ation of systemic lupus erythematosus (SLE)
with clinically evident myocarditis occurring at a
prevalence of 5–10%.1 Although the outcome of
lupus myocarditis tends to be favourable in case
series and case reports, lupus myocarditis has been
shown to shorten overall survival, especially in
patients with a disease duration of more than five
years.2,3
The prevalence and outcome of lupus myocardi-
tis appears to be influenced by ethnicity. African
American ethnicity was independently associated
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with lupus myocarditis when compared with other
ethnic groups in the LUMINA (Lupus in
Minorities: Nature vs. nurture) cohort, the first
description of this association.3,4 In the South
African context, most clinical studies done in SLE
had been done in the setting of predominantly
Black lupus populations, with no data regarding
lupus myocarditis.5-7
The Western Cape, comprising 6.02 million
people (11.4% of total population), is the only
one out of the nine provinces in South Africa
where a mixed racial or coloured population dom-
inates (48.8%) rather than Black Africans.8,9 The
term ‘coloured’ is an ethnic label, referring to a
mixed racial ancestry from European, Asian and
Khoisan and Bantu ethnic groups of southern
Africa.10 SLE studies done specifically in this
mixed racial population have mainly focused on
lupus nephritis, which tends to be disproportion-
ately more frequent and more severe compared
with lupus nephritis in other ethnic groups.11-14
Our clinical experience is that the mixed racial
population also has more aggressive lupus myocar-
ditis with a poor outcome compared with what is
described in other ethnic groups worldwide. Our
aim was to retrospectively analyse a cohort of
lupus myocarditis patients and compare the clinical
features and disease outcome with published data
from international literature.
Patients
A retrospective study was done at Tygerberg
Hospital, a tertiary referral centre in the Western
Cape, South Africa. Our institution is a 1300-bed
hospital, one of two academic referral centres in the
Cape Town area and renders a tertiary service to a
population of approximately 3.6 million people.
Clinical records of all SLE in- and out-patients
between January 2008 and January 2014 were
screened for inclusion. Adult (13 years and older)
patients fulfilling the 1997 revised American
College of Rheumatology criteria with a diagnosis
of lupus myocarditis were included.15 Lupus myo-
carditis was defined as clinical and echocardio-
graphic evidence of impaired myocardial function
attributed to active SLE. Patients with impaired
myocardial function attributed to causes other
than SLE were excluded.
Clinical and laboratory data
Data included: demographics (gender, age, ethni-
city and comorbid conditions); duration of SLE
at diagnosis of lupus myocarditis; SLE disease activity
index (SLEDAI) at time of diagnosis; detail of sys-
temic involvement; symptoms and signs of lupus myo-
carditis.16 Laboratory data included autoantibody 
results, complement levels, inflammatory markers,
full blood counts and chemistry (serum-creatinine,
cardiac enzymes and urine analysis).
Detail of therapy in the month preceding the
diagnosis of lupus myocarditis was documented.
Treatment of lupus myocarditis was specified in
terms of dose, route and duration of corticosteroid
as well as other immune suppressive therapy and
anti-failure therapy. Treatment related complica-
tions necessitating hospitalization or change of
therapy were noted.
Imaging data
All available echocardiographic images were
retrieved from a digital image archive and reanalysed
by a clinician experienced in echocardiography.
Serial images (where available) were described in
relation to the time of lupus myocarditis diagnosis.
Structural and functional measurements (global and
regional) were done in accordance with the British
Society of Echocardiography guidelines.17,18 Detailed 
analysis of regional left ventricular (LV) function was
not included in the original echocardiographic assess-
ment of the study population. Reanalysis included
regional wall motion abnormalities (RWMAs)
based on the 16-segment model. Segments were
described as normal (assigned a score of 1), hypoki-
netic (2), akinetic (negligible thickening: 3), dyski-
netic (paradoxical systolic motion: 4) and
aneurysmal (diastolic deformation: 5). The wall
motion score (WMS) for an individual patient was
derived as the sum of all scores divided by the number
of segments visualized.17 Electrocardiogram (ECG), 
chest radiograph (CXR) and angiography findings
were noted where available.
Outcomes
Follow-up was concluded on 31 October 2014.
Clinical outcomes were described in terms of
length and number of hospital admissions, high
care/intensive care admission and treatment related
complications. Recurrence of lupus myocarditis
during follow-up was noted. Mortality was speci-
fied as lupus myocarditis related, other lupus
related, treatment related and unknown/other
causes. Where follow-up echocardiograms were
available, functional and structural parameters
were described in terms of change from time of
diagnosis. A poor outcome was defined as lupus
Lupus myocarditis




myocarditis related mortality or final left ventricu-
lar ejection fraction (LVEF)< 40%.19
Statistical analysis
Descriptive analysis was done using frequency
tables and bar charts in the case of categorical vari-
ables, while numerical variables were summarized
as mean, standard deviation and range with 95%
confidence intervals for continuous variables (nor-
mally distributed) and median and interquartile
range ((IQR) not normally distributed). The
paired Wilcoxon signed rank test was used to com-
pare initial and final echocardiograms while the
Mann–Whitney U test was used to compare clin-
ical, laboratory and echocardiographic data in
patients with a poor outcome with those without.
The Fisher’s exact test was used to determine the
relationship between various treatment options
(binary variables) and outcome. A p< 0.05 was
considered as statistically significant.
Results
A total of 457 SLE folders were screened. Twenty-
seven patients were excluded due to myocardial
dysfunction attributed to causes other than SLE
(including rheumatic and ischaemic heart disease,
thyroid cardiomyopathy and viral myocarditis). A
total of 28 patients (6.1%) fulfilled the inclusion
criteria. The majority of patients were female
(92.9%) of mixed racial ethnicity (89.3%) that pre-
sented early after the onset of their lupus (median
11.5 weeks). Twenty-one patients (75%) presented
with severely active disease (SLEDAI> 12) and
seven patients with mild/moderately active disease
(SLEDAI 3–12).20 A total of 19 patients had con-
comitant lupus nephritis of which 14 were a class
III or IV lupus nephritis. Two patients had a com-
bination of class III/IV and class II/V respectively.
Two patients had clinical features of lupus nephritis
but were too unstable to undergo a renal biopsy.
Detailed demographics and clinical features at the
time of diagnosis are summarized in Table 1.
Medication pre-diagnosis of lupus myocarditis
In the month preceding the diagnosis of lupus myo-
carditis, 53% (15/28) of patients were on chloro-
quine; 43% (12/28) of patients were taking oral
prednisone of which nine (32%) were taking a dose
of 0.5mg/kg or more. Six patients were receiving
cyclophosphamide: five patients for lupus nephritis
and one patient for central nervous system lupus.
A single patient received azathioprine, also for
lupus nephritis. Other immunosuppressive thera-
pies included methotrexate (2/28 patients) for myo-
sitis and arthritis respectively and danazol (1/28)
for immune thrombocytopenia. Antihypertensive
therapy was used by five patients while cholesterol
lowering therapy and oral anticoagulants (antipho-
spholipid syndrome) were used by two patients
respectively.
Laboratory results
Detailed laboratory results are summarized in
Table 2. Anti-nuclear antibodies (ANA) and anti-
double stranded DNA (anti-dsDNA) were positive
in the majority of patients (27/27 and 25/27 respect-
ively). The 28th patient had a positive ANA and
anti-dsDNA six months prior to presenting, done
at a peripheral hospital. Anti-ribonuclear protein
Table 1 Demographics and clinical features at the time of
diagnosis of lupus myocarditis
Number of patients
(%) Total n¼ 28
Ethnicity:




Female gender 26 (92.9)
Mean SD
or median (IQR)
Age, years, meanSD 28.32 11.35
Duration of SLE, weeks,
median (IQR)
11.5 (0–119)












Lupus nephritis total: 19 (67.9)
Lupus nephritis class III/IV 14 (50)




Antiphospholipid syndrome 1 (3.6)
Hypertension 7 (25)
Diabetes mellitus 1 (3.6)
Dyslipidaemia 2 (7.1)
SD: standard deviation; SLE: systemic lupus erythematosus; IQR:
interquartile range; SLEDAI: SLE disease activity index.
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(anti-RNP) was positive in 61.5% of patients while
anti-Ro/SSA antibodies were not routinely done.
Antiphospholipid antibodies were also very infre-
quently positive, although a full screen was not
done in the majority of patients.
Diagnostic features of lupus myocarditis:
clinical and echocardiographic
The most frequent clinical features of myocarditis
were dyspnoea (91.3%), respiratory crackles
(85.7%) and a tachycardia (92.9%) while three
patients (10.7%) presented in cardiogenic shock.
Sinus tachycardia and non-specific ST-segment and
T-wave abnormalities were commonly seen on the
ECG (75% and 67.9% respectively). Arrhythmia
occurred in 14.3% and included ventricular extra
systoles, atrial fibrillation and ventricular tachycar-
dia. CXRs most frequently showed features of pul-
monary congestion (78.6%) and pleural effusions
(64.3%). A single patient underwent coronary angi-
ography, which revealed normal coronary arteries.
Detail of initial and final echocardiographic find-
ings are summarized in Table 3. LV chamber size
was preserved in 60.7% of patients at diagnosis.
Seventeen patients (63%) had severely impaired
LVEF ( 35%), three patients (11.1%) moderately
impaired LVEF (36–44%) while 25.9% of patients
had a normal to only mildly impaired LVEF
( 45%). Diastolic dysfunction was present in
90.5% of patients. RWMAs in a non-coronary
artery distribution were found in all 24 patients
where reanalysis of this parameter was possible.
Mild to moderate mitral and tricuspid regurgitation
occurred in 51% of patients, without any signifi-
cant structural abnormalities or Libman Sacks
endocarditis. Follow-up echocardiograms were
available in 19 patients after a median of 390
days (IQR: 93; 680). After receiving treatment for
lupus myocarditis, there was a significant improve-
ment in the median LVEF (p¼ 0.023) and WMS
(p¼ 0.017). Five patients (26.3%) had a persistent
LVEF of <40% after treatment.
Table 2 Laboratory results at the time of diagnosis of lupus myocarditis
Parameter n/total done % positive
Median of
parameter Range IQR
Serology ANA titre> 1:40 27/27 100 280 160–1280 320–1280
Anti-dsDNA> 25, IU/ml 25/27 92.6 164 4–200 124–200
Anti-Sm> 25, U/ml 10/26 38.5 12.38 0.09–200 6.68–52.25





Low C3 and/or C4 24/26 92.3
Inflammatory markers
CRP> 10 (mg/l) 22/23 95.7 80 4–382 41–103
ESR> 15 (mm/h) 8/10 80 54.5 5–117 26–82
Haematology
Hb< 12 (g/dl) 8.8 5.8–17 8.0–10.7
Anaemia other 15/28 53.6
AIHA 7/28 25
TTP 3/28 10.7
Leukopenia< 4 109 4/28 14.3 7.25 2–32.7 4.65–8.85
Lymphopenia< 1 109 18/26 69.2 0.7 0.17–2.46 0.34–1.14
Thrombocytopenia< 100 109 5/28 17.9 251 22–811 145–341
Biochemistry
13/28 46.4 86 32–773 53–170
8/28 28.6 122 8–214 56–168
20/24 83.3 2.91 0.08–13.99 0.65–7.43
10/25 40 105 12–7510 45–778
16/22 72.7 0.109 0.006–10.616 0.04–2.77
sCr > 90, mmol/l
GFR < 60, ml/min per 1.73m2 
UPCR > 0.5, g/24 hours
CK > 174, mg/l
Troponin-I > 0.04, mg/l
S-cholesterol > 5, mmol/l 3/6 50 4.6 2–6.5 3.1–6.5
IQR: interquartile range; ANA: anti-nuclear antibody; anti-dsDNA: anti-double stranded DNA; anti-Sm:
anti-Smith antibody; anti-RNP: anti-ribonuclear protein; ACA: anticardiolipin antibody; LA: lupus anticoagulant;
anti-b2GP1: anti-beta-2 glycoprotein-1; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; Hb: haemo-
globin; AIHA: auto-immune haemolytic anaemia; TTP: thrombotic thrombocytopenic purpura; sCr: serum cre-
atinine; GFR: glomerular filtration rate; UPCR: urinary protein-creatinine ratio; CK: creatine kinase
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Nineteen patients (67.9%) received intravenous
Solumedrol pulse therapy (500–1000 mg/day) 
for three days. Four patients received more than
one pulse for resistant/relapsing lupus
myocarditis. Twenty-seven patients were
prescribed oral pred-nisone, 24/27 at a dose of
1 mg/kg. One patient defaulted all oral
treatment. Cyclophosphamide (CPM) was used as
induction therapy in 21 patients (75%) followed
by azathioprine as maintenance therapy in 14
patients (50%) and mycophenolate mofetil in one
patient. Four patients received add-itional
immunosuppressive therapy (including
azathioprine, intravenous immunoglobulin (IVIG)
and rituximab) given serially for either resistant
lupus myocarditis or a relapse. Two patients
received other immunosuppressive/immune modu-
lating therapy in combination with corticosteroids:
methotrexate (15 mg/week) and plasma exchange
for concomitant thrombotic thrombocytopenic
purpura. Antifailure therapy included angiotensin-
converting enzyme (ACE) inhibitors (71.4%), diur-
etics (75%), beta-blockers (60.7%) and inotropes
(14.3%).
Outcome
Follow-up data was available for a median period 
of 563 days (range 4–1740) after diagnosis. 
Although one patient was lost to follow-up and 
not seen for more than 12 months, follow-up 
detail was available after 555 days since initial
presentation at which time no clinical signs of
lupus myocarditis were documented. Twenty-seven
patients were admitted to hospital (49 admissions
in total) for a median of 24 days (range: 5–226).
Nineteen patients required intensive care unit admis-
sion (total of 30 admissions) with ventilatory support
required in 17 patients. Two patients experienced a
relapse after an initial improvement, one patient
relapsed twice. Time of relapses: 568 days (patient
number 15) and 135 and 447 days respectively after
diagnosis (two relapses, patient number 19).
One or more treatment-related complications
occurred in 13/28 patients (46.4%). This included
bone marrow suppression (25%), septicaemia
(32%) and opportunistic infections (25%).
Total mortality was high: 12 patients (42.9%)
died after a median of 115 days. Mortality was
attributed to lupus myocarditis in five patients
(17.8%), of which three died within one month
after diagnosis. An additional two patients relapsed
and died more than 18 months after their initial
presentation (Figure 1). A further five patients
died due to treatment related complications (neu-
tropenic septicaemia in two patients, pancytopenia
in two patients (complicated by cerebral haemor-
rhage and gram negative septicaemia respectively)
and pneumonia in one patient). A single patient
died due to multisystem involvement which
included lupus nephritis, vasculitis and pancreatitis.
The exact cause of death was unknown in the 12th
patient (after 276 days), who received haemodialy-
sis for end stage renal failure at a private hospital.
Table 3 Echocardiographic findings at the time of diagnosis (initial) and most recent echocardiogram
(latest) following treatment for LM
Initial echocardiogram (n¼ 28) Latest echocardiogram (n¼ 19)
Structural/functional parameter
Ratio (%)
of test done Median (IQR)
Ratio (%)
of test done Median (IQR) p value
Increased LAa diameter 12/27 (44.4) 3.2 (2.8–3.9) 7/19 (36.8) 3 (2.5–3.4) 0.088
Increased LVEDDb 11/28 (39.3) 5.2 (4.4–5.6) 5/19 (26.3) 4.8 (4.5–5.6) 0.106
Valvular dysfunction, mild/moderate 14/27 (51.9) 10/19 (52.6)
Pericardial effusion 10/27 (37) 2/18 (11.1)
Diastolic dysfunction, MA E/E0c 19/21 (90.5) 11.6 (10.3–16.2) 11/17 (64.7) 10 (7.75–15.8) 0.281
LVEFd, numerical 27/28 (96.4) 35 (26–46) 19/19 (100) 47 (37–50) 0.023
WMSe 1.88 (1.69–2.38) 1.50 (1.31–2.00) 0.017
RWMAs present 24/24 (100) 18/19 (94.7)
aLA: normal 3.8 cm.
bLVEDD: normal 5.3 cm.
cMA E/E0: normal 8.
dLVEF: normal 55%; mild impairment: 45–54%; moderate impairment: 36–44%; severe impairment: 35%.
eWMS: increased if> 1.
IQR: interquartile range; LA: left atrium; LVEDD: left ventricular end-diastolic diameter; MA: mitral annular; E/E’:
ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E’); LVEF: left ventricular
ejection fraction; WMS: wall motion score; RWMA: regional wall motion abnormality
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Associations with poor outcome
Ten patients (35.7%) had a poor outcome, defined
as lupus myocarditis related mortality or a final
LVEF of less than 40%. Patients who died of
lupus myocarditis (n¼ 5) had a lower absolute
lymphocyte count at diagnosis (median of
0.3 109 versus 0.9 109; p¼ 0.041) and a longer
duration of SLE preceding the diagnosis of lupus
myocarditis (median of 144 versus four weeks;
p¼ 0.045) when compared with survivors/patients
who died of other causes. Other clinical and labora-
tory parameters were not significantly different
amongst the various outcome groups.
Eighty per cent of patients who died of lupus
myocarditis were on 0.5mg/kg prednisone at the
time of diagnosis compared with 21.7% of patients
who survived or died of other causes (p¼ 0.026).
No further relationships between the various treat-
ment options received (including immunosuppres-
sant therapy, chloroquine and ACE inhibitors) and
a poor outcome were identified. Logistic regression
analysis failed to identify individual risk factors
(demographic, clinical or laboratory parameters)
associated with a poor outcome.
A higher initial WMS (p¼ 0.12) and lower initial
LVEF (p¼ 0.099) was found in the lupus myocar-
ditis mortality group. A significantly lower initial
LVEF was found in patients with a persistent poor
LVEF at follow-up (n¼ 5) compared with those
patients where the LVEF recovered to 40%
(n¼ 14; p¼ 0.046) (Table 4).
Discussion
This is, to the best of our knowledge, the largest
reported series on lupus myocarditis. Our patients
were predominantly that of a mixed racial group, a
lupus population that is not well studied with
regard to cardiac involvement, in particular lupus
myocarditis. The LUMINA cohort was the first to
describe an increased prevalence of lupus myocar-
ditis amongst African American lupus patients in























Figure 1 All-cause mortality in 28 patients treated for lupus myocarditis (LM).






mortality (n¼ 23) p-value
Final LVEF
< 40% (n¼ 5)
Final LVEF
 40% (n¼ 14) p-value
Initial LVEDD, cm, med (IQR) 5.5 (5.1–5.7) 5.2 (4.2–5.5) 0.29 5.6 (5.4–5.7) 5.2 (4.5–5.5) 0.343
Initial LVEF, %, med (IQR) 16 (15–35) 35 (30–46) 0.099 34.0 (30–35) 38 (35–50) 0.046
Initial WMS, med (IQR) 2.13 (2.06–2.63) 1.88 (1.5–2.38) 0.120 2.06 (1.88–2.13) 1.81 (1.5–2.19) 0.506
LM: lupus myocarditis; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter; med: median; IQR: interquartile
range; WMS: wall motion score
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We found the prevalence of lupus myocarditis in
the mixed racial population (6.1%) not to be dis-
similar to what is described in the literature.1
Patients presented early in the course of their
SLE with 53% of patients being diagnosed with
lupus myocarditis within three months of their
SLE diagnosis. Immunosuppressant therapy taken
by patients in the month preceding the diagnosis of
lupus myocarditis included high doses of oral pred-
nisone (17.9%) and CPM (21.4%), highlighting the
fact that patients had very active disease and that
lupus myocarditis developed, in some patients, even
despite high levels of immunosuppressive therapy.
A total of 18 patients were lymphopenic at the
time of presentation. Eight of these patients were
on oral prednisone in the month preceding their
diagnosis, which may have contributed to the abso-
lute lymphopenia. This included four out of the five
patients who died due to lupus myocarditis, all
receiving a prednisone dosage of 0.5mg/kg.
We found a high prevalence of elevated CRP in
our cohort. The median CRP had been skewed by
outliers including two patients treated for concomi-
tant infections. Although reports regarding the
association between CRP and lupus disease activity
are conflicting, various clinical manifestations
including serositis, arthritis, lupus nephritis and
also myocarditis had been associated with increased
CRP levels.21,22
An important finding was that of concomitant
lupus nephritis, present in 67.9% of patients. This
is significantly more than what was found in the
series by Zawadowski and colleagues where only
12% of patients with lupus myocarditis had con-
comitant lupus nephritis.21 In contrast, our findings
are in keeping with that of the LUMINA cohort as
well as a more recent study by Zhang and col-
leagues where the majority of patients with lupus
myocarditis had concomitant lupus nephritis.3,23
This high frequency of lupus nephritis in associ-
ation with lupus myocarditis could be explained by
the common role of immune complex deposition in
the pathogenesis of these serious manifestations of
SLE. An immunofluorescent antibody study done
by Bidani and colleagues showed positive staining
for immune reactants (IgG) in a finely granular
pattern in myocardial blood vessels in eight out
of 10 lupus patients (post-mortem). The histo-
pathological findings correlated with clinically
severe lupus as well as serologically active lupus.24
Similarly, the role of immune complex deposition
and subsequent glomerular injury has been well
established as part of the pathogenesis in lupus
nephritis.25 Although 67.9% of our patients had
lupus nephritis at the time of presentation, patients
did not have advanced renal impairment with a
median glomerular filtration rate of 122ml/min/
1.73m2 (IQR: 56–168ml/min/1.73m2).
The diagnosis of lupus myocarditis is usually
based on a clinical impression of congestive cardiac
failure or unexplained arrhythmia, supported by a
number of non-invasive tests. ECG changes
are known to be insensitive and relatively non-
specific.26 We found sinus tachycardia (75%) and
non-specific ST segment and T-wave abnormalities
(64.3%) to be the most frequently observed ECG
changes. CXRs confirmed pulmonary congestion in
78.6% of patients. Often these investigations were
more important in excluding other causes of dys-
pnoea including respiratory infections and an acute
coronary syndrome.
Our patients were regarded as a low risk for an
acute coronary syndrome – they were young with
limited cardiac risk factors and, in the majority, a
recent onset of SLE. A single patient underwent
coronary angiography as part of his work up. The
patient was a 61-year-old man who was hyperten-
sive and an ex-smoker. He presented with atypical
chest pain, pulmonary oedema and raised troponin-
I and creatine kinase levels. A coronary angiogram
revealed normal, unobstructed coronary arteries.
As markers of myocyte injury, raised troponin-I
levels were more frequently found (72.7%) than
that of creatine kinase (40%). This is in keeping
with findings by Smith et al. that troponin-I is
superior to creatine kinase in the detection of myo-
cyte injury in myocarditis.27
The prevalence of circulating auto-antibodies
(including ANA, anti-dsDNA and anti-Sm) in
patients with lupus myocarditis appears to be
no different from that found in the general SLE
population.21,28 The exception is that of anti-SSA
and anti-RNP. Possible associations between
these antibodies and lupus myocarditis had been
described as early as the 1970s.29,30 We found
a positive anti-RNP in 61.5% of our patients.
Our findings are similar to a frequency of 62%
described by Zawadowski, in contrast to up to
40% described in the general lupus population.21
A higher prevalence of anti-RNP has, however,
been found in both African Americans (49% vs.
28% (Hispanics) and 9% (Caucasians) in the
LUMINA cohort) as well as amongst Black
South African lupus patients (65.5%).4,6 In the
absence of a control group, the relevance of anti-
RNP as a potential marker of lupus myocarditis,
especially in this mixed racial population, therefore
remains uncertain. Anti-SSA antibodies were not
routinely done in our population.
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Antiphospholipid antibodies appear to be
most frequently related to endocardial disease
in lupus.31,32 A single patient in our cohort was
known with antiphospholipid syndrome while anti-
bodies were infrequently present. A full antipho-
spholipid screen was, however, not done in the
majority of patients.
Although endomyocardial biopsy is still
regarded as the gold standard in the diagnosis of
lupus myocarditis, the invasiveness of the proced-
ure as well as the poor negative predictive value
limits its utility in everyday practice.33
Echocardiography is frequently used to support
a diagnosis of lupus myocarditis. Despite being
non-specific, it remains an accessible, cost effective
tool that can be used even in the unstable, venti-
lated patient. Features supportive of a diagnosis of
myocarditis include global/regional left ventricular
wall motion abnormalities in a non-coronary artery
distribution. The LV is often non- or slightly
dilated, reflecting the acute onset of the disease pro-
cess. A reduced ejection fraction and diastolic dys-
function occur in varying degrees.29,34
The majority of our patients (60.7%) had a non-
dilated LV at presentation. Impairment in global
systolic function varied: a significant proportion
(25.9%) of patients had a normal to only mildly
impaired LVEF ( 45%). These results emphasize
the relative insensitivity of using LV dimensions
and LVEF as isolated parameters in the diagnosis
of early myocarditis.
On the other hand, more than 90% of our
patients had diastolic dysfunction and RWMAs
were detected in all 24 patients where this measure-
ment was possible. Although RWMAs persisted in
94.7% of patients following treatment, a significant
improvement was noted in the median WMS,
reflecting improvement in regional function. Both
diastolic dysfunction and RWMAs are known to
frequently occur and often precede the develop-
ment of global systolic dysfunction in patients
with SLE.29,34,35 These parameters should be
regarded as standard measurements when assessing
a lupus patient with suspected lupus myocarditis.
Treatment of our patients was in keeping with the
overall tendency in the literature.2 We had four cases
with resistant disease, either not responding to or
relapsing despite immunosuppressive therapy. There
had been a number of case reports on the use of IVIG
in patients with resistant lupus myocarditis.36-38
Patients generally showed a dramatic, almost imme-
diate improvement. We did not experience a similar
outcome in three of our patients: two patients dete-
riorated further and died while a third showed
no significant improvement after receiving IVIG.
This patient was subsequently treated with rituximab
after which she showed a marked clinical response
and an improvement in LVEF from 27% to 40%.
There are limited reports on the use of rituximab in
lupus myocarditis.39 Although a single case, our
results in a patient with resistant lupus myocarditis
emphasize the potential of B-cell directed therapy in
severe lupus and also the importance of case reports
and case series, including reporting on both positive
and negative results.
The outcome of lupus myocarditis is generally
regarded as favourable. In a 2011 review of 19
case series and case studies, Appenzeller and col-
leagues found a mortality of 6.5% (3/46 patients)
due to lupus myocarditis.2 Similarly, Zawadowski
et al. found a lupus myocarditis related mortality of
8.3% in their series of 24 patients.21 Our overall
mortality was very high at 42.9% with a total of
five patients (17.8%) who died due to lupus myo-
carditis. Patients had, at presentation, a longer SLE
disease duration, a lower absolute lymphocyte
count and more frequently used prednisone at a
dosage of 0.5mg/kg. These variables may
reflect more aggressive/persistent disease despite
immunosuppressive therapy or delayed presenta-
tion masked by concomitant immunosuppression.
While these findings were not supported by a sig-
nificantly higher SLEDAI in patients with a poor
outcome, the SLEDAI had been criticized for not
differentiating between multiple mild manifest-
ations and those with more severe single features
of lupus activity.40
We demonstrated a bimodal pattern in lupus
myocarditis related mortality: patients either died
soon after presenting with lupus myocarditis or at
least 18 months later due to a relapse. In one patient
this concurred with a relapse of lupus nephritis while
the second patient relapsed after discontinuing
maintenance immunosuppression. The late recur-
rence of lupus myocarditis appears to be exceedingly
rare. Gottenberg et al. described a late relapse (72
months after the first episode) in a single patient who
recovered after further immunosuppression.41
Treatment related complications, including bone
marrow suppression and sepsis, contributed to the
overall mortality, emphasizing the importance of
vigilant monitoring of patients receiving immuno-
suppressive therapy.
The LVEF at diagnosis was lower in patients
who died of lupus myocarditis and in those patients
who had persistently poor LVEF after treatment
(Table 4). A low LVEF at presentation may reflect
either a more aggressive/fulminant disease or pos-
sibly a delay in presentation and could help to iden-
tify patients at risk for a poor outcome.
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Long term survival is known to be reduced in
patients with a LVEF of less than 40% due to an
increased cardiovascular and all-cause mortality.19
In the absence of long term follow-up data the out-
come of our patients with a final LVEF< 40% is
unknown.
Due to a relatively small sample size, we were
unable to identify independent risk factors asso-
ciated with a poor outcome. A prospective, multi-
ethnic study in the South African context might
enable us to identify specific risk factors, including
determining whether mixed racial ethnicity is inde-
pendently associated with a poor outcome of lupus
myocarditis.
Considering our high mortality, the entity of sub-
clinical LV dysfunction/lupus myocarditis remains an
important area of interest. A post-mortem study by
Panchal and colleagues showed histological evidence
of myocarditis in 37% of lupus patients, all in the
absence of clinical evidence of lupus myocarditis
ante-mortem.42 New, non-invasive imaging modalities
such as speckle tracking echocardiography and cardiac
magnetic resonance imaging are evolving in the diag-
nostic evaluation of patients with suspected/
confirmed myocarditis, detecting both clinical and sub-
clinical LV dysfunction.43-45 What is not clear from the
literature is whether the early detection of subclinical
disease in the lupus patient predicts the development of
clinically significant myocardial involvement and if
early therapeutic intervention would subsequently
change the outcome of this potentially fatal disease.
Study limitations
Our study has a number of limitations. Due to the
retrospective design of this study we have relied on
the accuracy and completeness of clinical records
for our data. We were unable to use indexed cham-
ber dimensions (including LV end-diastolic diam-
eter) according to body surface area. Although
not specifically recommended by the various echo-
cardiographic societies, we appreciate that the nor-
mality of these parameters may be different if
indexed as such. Reanalysis of all echocardio-
graphic images was not always possible due to
poor quality of the images and/or lack of appropriate
views. At the time of the echocardiographic reanaly-
sis, patients had a known diagnosis of lupus myocar-
ditis. This could have led to expectation bias and/
or diagnostic suspicion bias in the reporting of the
echocardiographic data. In the absence of histological
confirmation we would not be able to exclude other
causes of cardiomyopathy including undiagnosed
antiphospholipid syndrome with microthrombosis
with 100% certainty. Our study lacked a control
group, limiting the statistical strength of our conclu-
sions, especially regarding prognostic factors as well
as effectiveness of therapy.
Conclusion
In comparison with published data on lupus myocar-
ditis, we found a similar prevalence but high mortality
in a cohort of lupus patients from a predominantly
mixed racial ethnicity. Patients presented early in the
course of their SLE and had a high disease activity.
More than two-thirds of our patients had concomitant
lupus nephritis, notably higher than what had been
reported in the literature. Mortality due to lupus myo-
carditis was bimodal with patients dying within one
month after presenting, or after 18 months due to a
relapse of lupus myocarditis. Absolute lymphopenia
and prednisone use at the time of diagnosis was asso-
ciated with a poor outcome. A low LVEF at diagnosis
is of prognostic significance, associated with both
lupus myocarditis related mortality as well as a per-
sistent LVEF< 40% after treatment. Additional par-
ameters including RWMA, WMS and diastolic
function provide valuable information with regard to
diagnosis and response to treatment. The choice of
immunosuppressive therapy is guided by case series
and case reports with the majority of patients respond-
ing to cyclophosphamide and high dosages of cortico-
steroids. We found rituximab but not IVIG to be
effective in patients with resistant/relapsing disease.
Reporting on both positive and negative results in
rare, life threatening conditions such as lupus myocar-
ditis provides insight and guidance to clinicians in
managing these patients.
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Abstract
Aims: Lupus myocarditis occurs in 5–10% of patients with systemic lupus erythematosus 
(SLE). No single feature is diagnostic of lupus myocarditis. Speckle tracking 
echocardiography (STE) can detect subclinical left ventricular dysfunction in SLE patients, 
with limited research on its utility in clinical lupus myocarditis. We report on STE in 
comparison to conventional echocardiography in patients with clinical lupus myocarditis.
Methods and results: A retrospective study was done at a tertiary referral hospital in 
South Africa. SLE patients with lupus myocarditis were included and compared to healthy 
controls. Echocardiographic images were reanalyzed, including global longitudinal strain 
through STE. A poor echocardiographic outcome was defined as final left ventricular 
ejection fraction (LVEF) <40%. 28 SLE patients fulfilled the criteria. Global longitudinal
strain correlated with global (LVEF: r = −0.808; P = 0.001) and regional (wall motion score: 
r = 0.715; P < 0.001) function. In patients presenting with a LVEF ≥50%, global longitudinal
strain (P = 0.023), wall motion score (P = 0.005) and diastolic function (P = 0.004) were 
significantly impaired vs controls. Following treatment, LVEF (35–47% (P = 0.023)) and wall 
motion score (1.88–1.5 (P = 0.017)) improved but not global longitudinal strain. Initial LVEF 
(34%; P = 0.046) and global longitudinal strain (−9.5%; P = 0.095) were lower in patients 
with a final LVEF <40%.
Conclusions: This is the first known report on STE in a series of patients with clinical lupus 
myocarditis. Global longitudinal strain correlated with regional and global left ventricular 
function. Global longitudinal strain, wall motion score and diastolic parameters may be 
more sensitive markers of lupus myocarditis in patients presenting with a preserved LVEF 
≥50%. A poor initial LVEF and global longitudinal strain were associated with a persistent
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Lupus myocarditis is a serious manifestation of systemic 
lupus erythematosus (SLE) with clinically evident 
myocarditis occurring in 5–10% of patients (1, 2). No 
single clinical or imaging feature is diagnostic of lupus 
myocarditis. Although endomyocardial biopsy is regarded 
as the diagnostic gold standard, the invasiveness of the 
procedure and poor negative predictive value limit its 
utility (3). The diagnosis is usually based on a clinical 
impression of cardiac failure or unexplained arrhythmia, 
supported by non-invasive tests including cardiac 
imaging (4, 5).
Echocardiography is frequently used to support a 
diagnosis of lupus myocarditis (6, 7). Accurate assessment 
of ventricular wall motion (velocity) is essential in the 
evaluation of regional myocardial function. 
Cardiac magnetic resonance imaging is regarded as 
the non-invasive investigation of choice for the diagnosis 
of myocarditis, including lupus myocarditis (5, 8, 9). It is 
however an expensive tool especially in resource-limited 
settings. Echocardiography on the other hand is cost 
effective and can be utilized at the bedside, even in the 
unstable, ventilated patient.
The aim of our study was to give a comprehensive 
description of STE findings in comparison to 
conventional echocardiography, including tissue 
Doppler imaging in a group of patients with 
clinically evident lupus myocarditis and compare the 
results to that of a healthy control group.
Methods
Patients and controls
A retrospective study was done at Tygerberg Hospital, a 
tertiary referral center in the Western Cape of South Africa. 
Our institution renders a tertiary service to a population 
of approximately 3.6 million people in the Cape Town 
area. Clinical records of all SLE inpatients and outpatients 
between January 2008 and January 2014 were screened for 
inclusion. Adult (13  years and older) patients (fulfilling 
the 1997 revised American College of Rheumatology 
criteria) with a diagnosis of lupus myocarditis were 
included (10). Lupus myocarditis was defined as clinical 
and echocardiographic evidence of impaired myocardial 
function (regional and/or global) attributed to active SLE. 
Patients with a cardiomyopathy attributed to causes other 
than SLE were excluded. Controls were recruited from 
health care workers as well as medical students at our 
institution and matched to our patient group with regard 
to age, gender and ethnicity. All controls included were 
healthy, non-lupus individuals with no known cardiac 
risk factors or history of cardiovascular disease, a normal 
physical examination and a low pre-test probability of 
cardiac disease.
Clinical and laboratory data
Data collected included demographics (gender, age, 
ethnicity and co-morbid conditions); duration of SLE at 
diagnosis of lupus myocarditis; SLE Disease Activity Index 
(SLEDAI) at the time of diagnosis of lupus myocarditis; 
detail of systemic involvement; symptoms and signs 
of lupus myocarditis (11). Relevant laboratory data 
were documented including auto-antibody results and 
chemistry (serum-creatinine, cardiac enzymes and urine 
analysis). Chest radiographs, electrocardiograms and 
angiogram reports were included where available.
Conventional two-dimensional echocardiography and 
two-dimensional STE analysis
Standard two-dimensional echocardiograms were 
originally performed on all patients with a M4S probe 
using a Vivid 7 Dimension ultrasound system (General 
Electric Medical Systems, South Africa). All the avail-
able original echocardiographic images were retrieved 
from a digital image archive (EchoPAC platform (2DS-
software  package, version 3.3), General Electric 
Medical Systems) and reanalyzed  by a clinician ex-
perienced  in  echocardiography.   Serial images were de-
scribed in  relation  to  the  time  of lupus myocarditis 
diagnosis. Structural and functional  measurements, in-
cluding pulse  wave  and  tissue  Doppler imaging were 
done in accordance with  international echocardiogra-
phy  guidelines  (12, 13, 14).  Global  left   ventricular 
function  was  obtained  using  the   Simpsons biplane 
method or visual estimation  if the endocardial defi-
nition was inadequate.  Right  ventricular function and 
hemodynamic changes were assessed by  determining 
the tricuspid annular plane systolic excursion (TAPSE) and 
tricuspid regurgitation maximal velocity (TR Vmax) (15). 
Diastolic  dysfunction  was  assessed  in terms of mitral 
annular velocity in early  diastole  (MA E′ave) (average 
of lateral and septal measurement) as a marker of active, 
early left  ventricular  relaxation  and  the  ratio  of mitral 
peak   velocity   of   early   filling   to  early   diastolic    mitral 
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Regional left ventricular function was described with 
regard to regional wall motion abnormalities based on 
the 16-segment model. The wall motion score index for 
an individual patient was derived as the sum of all scores 
divided by the number of segments visualized (13).
STE analysis was not included in the original 
echocardiographic assessment of the study population. 
Cine-loops that were stored in DICOM digital format were 
selected from three apical views (3-chamber, 4-chamber 
and 2-chamber views). The images were downloaded from 
a central archive to a computer workstation and analyzed 
offline using customized software within a personal 
computer workstation (EchoPAC platform). Longitudinal 
segmental strain was measured in the basal, mid and 
apical segments (according to the 17-segment model) 
while global peak longitudinal strain or peak systolic 
longitudinal strain rate was averaged from all 3 apical 
views. Only studies with images of sufficient quality were 
used for speckle tracking analysis. All controls underwent 
standard echocardiography, tissue Doppler imaging and 
STE analyses. Analyses were done in accordance with 
international guidelines (14, 16, 17, 18).
Outcomes
Follow-up was concluded on 31 October, 2014. Where 
follow-up echocardiograms were available, functional and 
structural parameters were described in terms of change 
from the time of diagnosis. A poor echocardiographic 
outcome was defined as a final left ventricular ejection 
fraction (LVEF) <40%.
Statistical analysis
Descriptive analysis was done using frequency tables 
with numerical variables summarized as means 
and a standard deviation with 95% confidence 
intervals (normally distributed) and median, range 
and interquartile range (not normally distributed). 
Comparisons between the patient and control group 
were made with the Fisher’s Exact Test (independent 
groups, binary), the Pearson chi-square test (various 
ethnic groups) and the independent samples test 
(normally distributed means).
The paired Wilcoxon signed-rank test (data not 
normally distributed) was used to compare the initial 
and final echocardiograms. The Mann–Whitney U test 
(data not normally distributed) was used to compare 
echocardiographic data in patients with a poor outcome to 
those without as well as in comparing echocardiographic 
data in patient with a preserved LVEF at diagnosis to 
those without.
Variables in the control group and the two different 
categories of LVEF were compared using the Kruskal–Wallis 
test (omnibus-). Dunnet’s post hoc test with adjustment 
for multiple testing was used to determine significant 
differences between the three groups.
Spearman’s correlations were used to determine 
the relationships among continuous variables 
(nonparametric, Spearman’s correlation coefficient) while 
Pearson two-tailed correlations were used to determine 
the relationships between global longitudinal strain 
and clinical parameters. A P < 0.05 was considered as
statistically significant.
Ethical consideration
The study was approved by the Health Research Ethics 
Committee of Stellenbosch University, South Africa. 
Research was conducted according to the ethical 
guidelines and principles of the International Declaration 
of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council Ethical 
guidelines for research. In view of the retrospective nature 
of the study, the difficulty in tracing individual subjects 
and the absence of risk to the subjects, the Health Research 
Ethics Committee, Stellenbosch University granted a 
waiver of informed consent for the patients included into 
the study. Informed consent has been obtained from each 
healthy volunteer after full explanation of the purpose 
and nature of all procedures used.
Results
Clinical and demographic features
A total of 457 SLE patients’ clinical records were screened. 
Fifty-five patients were considered to have had possible 
lupus myocarditis of which 27 patients were excluded due 
to a cardiomyopathy attributed to causes other than SLE. 
Twenty-eight patients (6.1%) fulfilled inclusion criteria. 
Twenty-eight healthy non-lupus controls were included. 
There were no significant differences between the patient 
and control group with regard to gender, ethnicity and 
age. Details of the demographics, clinical and laboratory 
features of patients at the time of diagnosis are summarized 
in Table 1.
The anti-nuclear antibody titer was positive in all 
patients while antiphospholipid antibodies were present 
in two patients. Forty percent of patients had a raised 
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creatine kinase (median: 105 µg/L; interquartile range 
(IQR): 45–778) compared to a raised troponin-I (normal 
range <0.04 µg/L) in 72.7% (median: 0.109 µg/L; IQR: 
0.04–2.77). Although 67.9% of patients had concomitant 
lupus nephritis the median glomerular filtration rate was 
122 mL/min/1.73 m2 (IQR: 56–168).
Eighty-six per cent of patients presented with 
congestive cardiac failure while three patients (11%) 
presented in cardiogenic shock. The most frequent 
electrocardiogram findings were sinus tachycardia (75%) 
and non-specific ST segment and T-wave abnormalities 
(78%). Fourteen per cent of patients developed arrhythmias 
including ventricular extra systoles, atrial fibrillation and 
ventricular tachycardia. Chest radiographs had features 
of pulmonary congestion (78.6%) and pleural effusions 
(64.3%). One patient underwent angiography confirming 
normal coronary arteries.
Treatment of lupus myocarditis
The majority of patients were treated with corticosteroids 
including intravenous Solu-Medrol pulse therapy 
(67.9% of patients) and/or oral prednisone (96.4%). 
Further immunosuppressive therapy used as induction 
or maintenance therapy included cyclophosphamide, 
azathioprine, mycophenolate mofetil, intravenous 
immunoglobulin and rituximab. Four patients received 
more than one form of immunosuppression for either 
resistant lupus myocarditis or a relapse. Anti-failure 
therapy included angiotensin-converting enzyme 
inhibitors (71.4%), diuretics (75%), beta-blockers (60.7%) 
and inotropes (14.3%).
Echocardiographic features
Initial echocardiographic characteristics in patients 
compared to controls are summarized in Table  2. Left 
ventricular chamber size was preserved in 60.7% of 
patients at diagnosis. Seventeen patients (17/27; 63%) 
presented with a severely impaired LVEF (≤35%) while 
25.9% of patients had a normal to only mildly impaired 
LVEF (≥45%). In seven patients (36.8%), the median
LVEF remained unchanged or deteriorated further despite 
treatment (Fig. 1).
Left ventricular filling pressures were normal (MA 
E/E′ <8) in 2/21 patients (9.5%) and increased (MA E/E′
Table 1 Demographic and clinical features of patients at the time of diagnosis of lupus myocarditis compared to a healthy 
non-lupus control group.
Lupus myocarditis group Healthy control group
n/total (%) n/total (%)
Female gender 26/28 (92.9) 26/28 (92.9)
Ethnicity: mixed racial ancestry 25/28 (89.3) 25/28 (89.3)
Age (years) mean ± s.d. 28.32 ± 11.35 28.48 ± 11.33
Duration of SLE (weeks) median (IQR) 11.5 (IQR: 0–119)
SLEDAI median (IQR) 17.5 (IQR: 12.3–24)
Lupus nephritis 19 (67.9)
Co-morbidities
Antiphospholipid syndrome 1/28 (3.6) 0/28 (0)
Hypertension 7/28 (25) 0/28 (0)
Diabetes mellitus 1/28 (3.6) 0/28 (0)
Dyslipidemia 2/28 (7.1) 0/28 (0)
Clinical features of lupus myocarditis
Symptoms
New York Heart Association class 3/more dyspnea 21/23 (91.3)
Orthopnoea/paroxysmal nocturnal dyspnea 6/28 (21.4)
Palpitations 1/28 (3.6)
Chest pain 2/28 (7.1)
Signs
Respiratory crackles/pulmonary edema 24/28 (85.7)
Pleural effusion 9/28 (32.1)
Raised jugular venous pressure 7/28 (25)
Displaced apex 8/28 (28.6)
Tachycardia 26/28 (92.9)
New murmur 1/28 (3.6)
S3 gallop 11/28 (39.3)
Pedal edema 12/28 (42.9)
IQR, inter quartile range; s.d., standard deviation; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.
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>15) in 7/21 patients (33.3%). Left ventricular relaxation
was impaired (MA E′ave <8 cm/s) in 11/23 patients
(47.8%) (22). None of the control patients had evidence 
of impaired left ventricular relaxation or increased left 
ventricular filling pressures. Other parameters of regional 
and global left ventricular function (wall motion score 
and global longitudinal strain) were significantly reduced 
in comparison to the control group (P < 0.001).
At diagnosis, global longitudinal strain correlated well 
with other parameters of global left ventricular function 
(LVEF: r = −0.808; P = 0.001; Fig.  2A) and regional left 
ventricular function (wall motion score: r = 0.715; P < 0.001; 
Fig.  2B). No correlation was demonstrated between 
global longitudinal strain and parameters of diastolic left 
ventricular function (MA E/E′ (r = 0.205; P = 0.523); MA 
E′ave (r = −0.41; P = 0.165)) nor right ventricular function
and – hemodynamics ((TAPSE): r = −0.039; P = 0.905; right 
ventricular systolic pressure (RSVP): r = 0.068; P = 0.841).
A weaker correlation was seen between global longi-
tudinal strain and renal function (glomerular  filtration 
rate: r = −0.502; P = 0.081). No other clinical parameters 
including age (r = −0.263; P = 0.386), SLEDAI (r = −0.277; 
P = 0.359) and duration of SLE (r = 0.304; P = 0.312), nor 
laboratory parameters (C-reactive protein, creatine kinase, 
troponin) showed any significant correlations with global 
longitudinal strain.
Echocardiographic features of patients with a preserved 
left ventricular function at diagnosis
Six patients (6/27) presented with a relatively preserved 
LVEF of ≥50%. In this subgroup of patients, other measures 
of left ventricular function including global longitudinal 
strain, wall motion score and measures of diastolic 
left ventricular function (MA E/E′ and MA E′ave) were
significantly impaired in comparison to the control group 
while measures of right ventricular function (TAPSE) were 
not significantly different (Fig. 3A, B, C and D).
Follow-up data
Clinical follow-up data were available for a median period 
of 563 days (range 4–1740) after diagnosis. Although one 
patient was lost to follow-up, the latest available clinical 
detail (555  days since initial presentation) as well as a 
follow-up echocardiogram (283  days after presentation) 
were obtained from the patient’s medical records. At the 
Table 2 Echocardiographic findings of lupus myocarditis group at diagnosis (initial) compared to those of a healthy 
control group.
Initial echocardiogram in lupus 
myocarditis group
Initial echocardiogram in healthy control 
group
Total n = 28 Median (IQR)/ratio (%) of test done Median (IQR)/ratio (%) of test done P value
Structural parameter
LAa diameter (cm) 3.2 (2.8–3.9) 3.0 (2.8–3.3) 0.105
LVIDb (cm) 5.2 (4.4–5.6) 4.6 (4.3–4.8) 0.046
RVIDc (cm) 3.2 (2.7–3.7) 3.0 (2.9–3.2) 0.176
Valvular dysfunction (mild/moderate) 13/27 (48.2) MR 0/28 MR <0.001
7/27 (25.9) TR 0/28 TR 0.007




RWMA present 24/24 0/28
Wall motion scored 2.0 (1.8–2.6) 1 (1–1) <0.001
Global function parameter
MA E′avee (cm/s) 8.0 (6.0–11.0) 12.0 (11.0–14.5) <0.001
MA E/E′f 11.6 (10.3–16.2) 7.3 (5.3–8.0) <0.001
LVEFg: numerical (%) 35 (26–46) 63.5 (58.0–68.0) <0.001
LVEF: categorical




TAPSEh (cm) 1.7 (1.6–2.1) 2.0 (1.8–2.3) 0.006
GLSi (%) −10.9 (−13.7 to −7.8) −22.1 (−23.5 to −20.8) <0.001
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time, the patient had no clinical signs of lupus myocarditis 
and the LVEF had recovered to 45%.
Nineteen patients (67.9%) had one or more follow-up 
echocardiogram following the diagnosis of lupus 
myocarditis (median 390  days; IQR: 93–680). Repeat 
echocardiograms were not routinely done but requested 
at the discretion of the treating clinician. Of the nine 
patients who did not undergo follow-up imaging, seven 
died (three due to lupus myocarditis) while the remaining 
two patients showed a full clinical recovery without 
recurrence of cardiac manifestations (data available at 639 
and 750  days, respectively after their lupus myocarditis 
diagnosis).
Table 3 provides a detailed summary of the structural 
and functional echocardiographic findings of these 
19 patients at diagnosis as well as at follow-up (latest 
available echocardiogram). Following treatment for lupus 
myocarditis, both the median LVEF and wall motion 
score significantly improved (P = 0.023 and P = 0.017, 
respectively) in contrast to global longitudinal strain 
(P = 0.47) and parameters of diastolic function (MA E′ave:
P = 0.649 and MA E/E′: P = 0.281).
Associations with a poor echocardiographic outcome
Following immunosuppressive therapy, five out of 19 
patients (26.3%) had a final LVEF <40%. A lower initial
(at diagnosis) LVEF (P = 0.046) and global longitudinal 
strain (P = 0.095) were found in patients with a final LVEF 
of <40% compared to those patients where the LVEF
recovered to ≥40% (Table 4).
Discussion
We have recently reported the clinical features and 
outcome of lupus myocarditis in the Western Cape, 
South Africa where we found a high mortality of 17.9% 
among our patients (19). To the best of our knowledge, 
this is the first report on the use of STE in a series of SLE 
patients with clinically evident lupus myocarditis. Our 
patients were predominantly young females with a recent 
onset of SLE and a high SLEDAI.
Huang and coworkers demonstrated the ability of STE 
to detect early impairment in left ventricular function 
in asymptomatic SLE patients (20). Abnormalities 
occurred in the absence of changes on conventional 
echocardiography and global longitudinal strain was 
independently associated with SLE disease activity. The 
relevance and clinical implications of these findings in 
asymptomatic SLE patients have not been clarified.
Echocardiographic findings
The majority of our patients (63%) presented with severe 
left ventricular dysfunction (LVEF ≤35%). Regional wall 
Figure 1
Flow chart depicting the improvement/
deterioration in left ventricular function (LVEF) 
from the time of diagnosis to the final 
echocardiogram in 19 patients where a follow-up 
echocardiogram was available. IQR, interquartile 
range; LVEF, left ventricular ejection fraction.
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motion abnormalities were present in all patients while 
global longitudinal strain was significantly impaired in 
comparison to the control group (P < 0.001). Parameters 
of diastolic function, left ventricular filling pressure 
and relaxation were impaired in 33.3% and 47.8% of 
patients, respectively.
It is well described that the subendocardial region 
is more sensitive to myocardial disease. Early loss of 
diastolic longitudinal relaxation (MA E′ave) is associated
with elevated left ventricular filling pressures (MA E/E′)
with predominantly diastolic dysfunction, while the LVEF 
may still be preserved. Diastolic function is often an early, 
sensitive marker of pathology in a variety of conditions 
affecting the left ventricle (16, 17, 21). Longitudinal strain 
or deformation, measured with STE, represents shortening 
of longitudinal myocardial fibers during systole, again 
an earlier, more sensitive marker of left ventricular 
dysfunction compared to LVEF (22). The midmyocardial 
and epicardial function may therefore remain relatively 
unaffected, with circumferential strain and twist showing 
compensation in order to preserve left ventricular systolic 
function (16).
We demonstrated a significant improvement in both 
the LVEF and wall motion score following treatment for 
myocarditis, in contrast to global longitudinal strain 
and diastolic parameters (MA E/E′ and MA E′), which
did not improve significantly (Table 3).
Correlation between global longitudinal strain and 
other lupus myocarditis parameters
A strong correlation was demonstrated between global 
longitudinal strain and parameters of both global 
(LVEF) and regional (wall motion score) left ventricular 
function at the time of diagnosis. We did however not 
find a correlation between global longitudinal strain and 
parameters of diastolic function. The unexpected absence 
of a correlation between global longitudinal strain and 
these markers of early left ventricular dysfunction may be 
due to the relatively advanced left ventricular dysfunction 
found in the majority of our patients. This should be 
further explored in a larger cohort of SLE patients in the 
absence of clinical myocarditis or myocarditis with a 
relatively preserved systolic left ventricular function.
In contrast to the findings of Huang and coworkers, 
global longitudinal strain did not correlate with SLE disease 
activity (20). The patients from our study population did 
however present with significantly higher lupus activity 
(median SLEDAI of 17.5, IQR 2.3–24) in comparison to 
that of Huang’s study population (SLEDAI 10.5 ± 7.6). 
Whether this correlation between global longitudinal 
strain and lupus disease activity is only evident in patients 
without clinically evident lupus myocarditis or in patients 
with a lower disease activity can only be speculated.
We found a weak correlation between renal function 
and global longitudinal strain (r = −0.502; P = 0.081). 
Although 67.9% of our patients had concomitant lupus 
nephritis, this was of recent onset and in the absence 
of advanced renal dysfunction (median glomerular 
filtration rate 122 mL/min/1.73 m2 (IQR: 56–168)). Left 
ventricular dysfunction (uremic cardiomyopathy) is well 
described in end-stage renal disease (23). Impaired global 
longitudinal strain has been shown to be of diagnostic 
and prognostic value in this subset of patients (24). The 
Figure 2
Correlation between the median global longitudinal strain (%) and 
(A) median left ventricular ejection fraction (%) and (B) median wall 
motion score at diagnosis. GLS, global longitudinal strain; LVEF, left 
ventricular ejection fraction; WMS, wall motion score.
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possible correlation between mild, recent-onset renal 
impairment and left ventricular dysfunction, specifically 
abnormal global longitudinal strain has not previously 
been described and should be studied prospectively.
Lupus myocarditis in patients presenting with a 
preserved LVEF
Although severe left ventricular dysfunction (LVEF ≤35%) 
was found in 63% of patients, a significant proportion 
(22.2%) of patients presented with a relatively preserved 
LVEF of ≥50%. In patients with non-lupus myocarditis
with a LVEF ≥50% on conventional echocardiogram,
Hsiao and coworkers demonstrated significantly impaired 
global longitudinal strain in comparison to that of a 
healthy control group (25). Our results supported these 
findings with various other parameters of left ventricular 
function, including global longitudinal strain, wall 
motion score, MA E/E′ and MA E′ave being significantly
impaired in this subgroup of patients compared to our 
control group.
Our findings also highlight the limitations of using 
the LVEF in isolation when assessing patients for possible 
myocarditis, in particular, before deterioration in left 
ventricular function.
Associations with a poor outcome
Out of 19 patients who had a follow-up echocardiogram, 
five had a poor echocardiographic outcome. We found a 
lower initial LVEF as well as global longitudinal strain in 
this subgroup of patients. An earlier diagnosis of lupus 
myocarditis, before significant left ventricular functional 
impairment occurs is likely to play a central role in an 
improved echocardiographic outcome.
Limitations
Our study had a retrospective design and we relied on the 
accuracy of clinical records. Despite the relatively small 
sample size, this is the largest reported series of patients 
with lupus myocarditis. Our patients were hospitalized, 
symptomatic SLE patients. The results would therefore 
not be applicable in asymptomatic SLE patients with 
possible subclinical myocardial dysfunction. None of 
our patients had histological confirmation of their 
myocarditis. We are therefore not able to exclude other 
causes of cardiomyopathy including undiagnosed 
antiphospholipid syndrome with microthrombosis or 
microvascular occlusion with 100% certainty. Patients 
included into the study had a known diagnosis of lupus 
Figure 3
Box and whisker plots show the comparison between patients who presented with either impaired (LVEF <50%) or preserved left ventricular systolic 
function (LVEF ≥50%) and normal controls by analysis of variance for GLS (A), WMS (B) and parameters of diastolic function, MA E/E′ (C) and MA E′ave 
(D). The numeric values reported denote the median (horizontal line of the box) and the inter quartile range (top and bottom line). E′, early diastolic 
mitral annular velocity, average of lateral and septal measurement; E/E′, ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular 
velocity (E′); GLS, global longitudinal strain; LM, lupus myocarditis; LVEF, left ventricular ejection fraction; MA, mitral annular; WMS, wall motion score.
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myocarditis, which could have led to expectation bias 
or diagnostic suspicion bias in the reanalysis of the 
echocardiographic data. 
Conclusion
STE is a non-invasive, cost effective tool with diagnostic 
and prognostic value in patients with clinically 
evident lupus myocarditis. At the time of diagnosis, 
we demonstrated strong correlations between STE 
(global longitudinal strain) and other parameters of 
left ventricular function, including LVEF and wall 
motion score. Both a poor LVEF and global longitudinal 
strain at presentation were associated with a poor 
echocardiographic outcome (final LVEF <40%). In lupus
myocarditis patients who presented with a relatively 
preserved LVEF (≥50%), global longitudinal strain, wall
motion score and diastolic functional parameters were 
Table 3 Echocardiographic findings at diagnosis (initial) and most recent echocardiogram (latest) following treatment for lupus 
myocarditis.
Initial echocardiogram in lupus 
myocarditis group
Latest echocardiogram in lupus 
myocarditis group
Total n = 19 Median (IQR)/ratio (%) of test done Median (IQR)/ratio (%) of test done P value
Structural parameter
LAa diameter (cm) 3.3 (2.8–3.9) 3 (2.5–3.4) 0.088
LVIDb (cm) 5.3 (4.5–5.6) 4.8 (4.0–5.6) 0.106
RVIDc (cm) 3.1 (3.0–3.9) 3 (2.6–3.2) 0.071
Valvular dysfunction (mild/moderate) 10/19 (52.6) MR 5/19 (26.3) MR
5/17 (29.4) TR 5/17 (29.4) TR
Pericardial effusion 6/18 (33.3) small Small 2/18 (11.1)
1/18 (5.6) large
Regional function parameter
RWMA present 17/17 (100) 16/17 (94.1)
Wall motion scored 1.88 (1.69–2.38) 1.50 (1.31–2.00) 0.017
Global function parameter
MA E′avee (cm/s) 8.0 (6.0–11.0) 8.8 (5.8–10.0) 0.649
MA E/E′f 11.6 (10.0–16.2) 10 (7.75–15.8) 0.281
LVEFg: numerical (%) 35 (32–46) 47 (37–50) 0.023
LVEF: categorical
≥55% 0/19 (0) 3/19 (15.8)
45–54% 5/19 (26.3) 10/19 (52.6)
36–44% 4/19 (21.1) 2/19 (10.5)
≤35% 10/19 (52.6) 4/19 (21.1)
TAPSEh (cm) 1.9 (1.6–2.1) 1.7 (1.6–2.0) 0.395
Impaired GLSi 13/13 (100) 13/13 (100)
GLS(%) −13.0 (−13.5 to −10.3) −15 (−14 to −5) 0.47
aLA diameter: normal ≤3.8 cm; bLVID: normal ≤5.3 cm; cRVID: normal ≤4.2 cm; dWall motion score increased if >1; eMA E′ average: normal <8 cm/s; fMA E/E′: 
normal <8; increased LV filling pressure >15; gLVEF: normal ≥55%; mild impairment: 45–54%; moderate impairment: 36–44%; severe impairment: ≤35%;
hTAPSE: normal ≥1.6 cm; iGLS: normal −19.7% (95% CI, −20.4 to −18.9%).
E′ave, early diastolic mitral annular velocity, average of lateral and septal measurement; E/E′, ratio of mitral peak velocity of early filling (E) to early
diastolic mitral annular velocity (E′); GLS, global longitudinal strain; IQR, interquartile range; LA, left atrium; LVEF, left ventricular ejection fraction; LVID,
left ventricular internal diameter; MA, mitral annular; MR, mitral regurgitation; RVID, right ventricular internal diameter; RWMA, regional wall motion 
abnormalities; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
Table 4 Initial echocardiographic parameters (at time of 
diagnosis; total n = 19) in patients with a final LVEF <40%




Patients with a 
final LVEF <40%
(n = 5) median (IQR)
Patients with a 
final LVEF ≥40%
(n = 14) median (IQR) P value
MA E′ave
(cm/s)
11.5 (8.0–12.0) 7.5 (6.5–9.5) 0.221
MA E/E′ 10.0 (9.6–12.9) 13.3 (10.3–16.2) 0.267
LVID (cm) 5.6 (5.4–5.7) 5.2 (4.5–5.5) 0.343
LVEF (%) 34.0 (30–35) 38 (35–50) 0.046
GLS (%) −9.5 (−13 to −9) −13.5 (−16 to −11) 0.095
Wall motion 
score
2.06 (1.88–2.13) 1.81 (1.5–2.19) 0.506 
E′ave, early diastolic mitral annular velocity, average of lateral and septal
measurement; E/E′, ratio of mitral peak velocity of early filling (E) to early
diastolic mitral annular velocity (E′); GLS, global longitudinal strain; IQR,
interquartile range; LVEF, left ventricular ejection fraction; LVID, left 
ventricular internal diameter; MA, mitral annular.
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significantly impaired compared to a control group. 
The diagnostic role of these parameters as earlier, more 
sensitive markers in clinical lupus myocarditis should be 
defined more clearly through prospective studies. Future 
research is also needed to define the significance of 
echocardiographic evidence of subclinical left ventricular 
dysfunction in asymptomatic SLE patients in comparison 
to clinically evident lupus myocarditis. Such research 
could aid in determining optimal cut-off values for global 
longitudinal strain supporting a diagnosis of clinical 
lupus myocarditis.
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Abstract
Objectives: To determine the prevalence of myocardial injury (MInj) in systemic lupus erythematosus (SLE) according
to cardiac magnetic resonance (CMR) criteria. To compare clinical and echocardiographic features of patients with and
without MInj and identify predictors of myocardial tissue characteristics according to CMR.
Methods: SLE inpatients underwent CMR screening for MInj based on the Lake Louise Criteria (LLC). Tissue character-
istics included inflammation (increased T2-weighted signal or early gadolinium enhancement ratio (EGEr)) and necrosis
or fibrosis (late gadolinium enhancement (LGE)). Echocardiographic parameters included left (left ventricular ejection
fraction (LVEF)) and right ventricular function (tricuspid annular plane systolic excursion (TAPSE)), global longitudinal
strain (GLS), wall motion score (WMSi) and left ventricular internal diameter index (LVIDi). Variables were compared
with regards to the presence/absence of CMR criteria. Logistic regression identified variables predictive of CMR tissue
characteristics.
Results: A hundred and six SLE patients were screened of whom 49 patients were included. Fifty-seven patients
were excluded due to intolerance of or contraindication to CMR (27/57 due to renal impairment). Twenty-three
patients had CMR evidence of MInj, of which 60.9% was subclinical. Inflammation occurred in 16/23 and necrosis/
fibrosis in 12/23 patients. Patients with any evidence of MInj were more frequently anti-dsDNA positive (p¼ 0.026)
and patients fulfilling LLC for myocarditis had higher SLE disease activity (p¼ 0.022). The LVIDi (p¼ 0.005), LVEF
(p¼ 0.005) and TAPSE (p¼ 0.011) were more abnormal in patients with an increased EGEr, whereas WMSi
(p¼ 0.002) and GLS (0.020) were more impaired in patients with LGE. On multivariable logistic regression analyses,
TAPSE predicted inflammation (OR: 0.045, p¼ 0.006, CI: 0.005–0.415) and GLS predicted necrosis/fibrosis (OR: 1.329,
p¼ 0.031, CI: 1.026–1.722). A model including lymphocyte count, TAPSE and LVIDi predicted an increased EGEr on
CMR (receiver operating characteristic-curve analyses: area under the curve: 0.901, p< 0.001, sensitivity: 88.9%,
specificity: 76.3%).
Conclusions: CMR evidence of MInj frequently occurs in SLE and is often subclinical. The utility of CMR in SLE is
limited by a high exclusion rate, mainly due to renal involvement. Models including echocardiographic parameters
(TAPSE, LVIDi and GLS) are predictive of CMR myocardial injury. Echocardiography can be used as a cost-effective
screening tool with a high negative predictive value, in particular when CMR is contraindicated or unavailable.
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Background
Immune mediated myocardial injury (MInj) in systemic
lupus erythematosus (SLE) may manifest as clinically
evident lupus myocarditis (LM) (5–10% of patients) or
remain subclinical, detected only on autopsy (up to
37% of patients).1,2 Although some report a favourable
outcome of clinical LM, more advanced left ventricular
(LV) dysfunction at presentation is associated with a
poor outcome, emphasizing the importance of accurate
early detection and treatment.3,4
Cardiac magnetic resonance (CMR) is the non-
invasive diagnostic modality of choice for suspected
myocarditis by identifying stages of MInj through
tissue characterization.5 Tissue characterization
describes inflammation (increased T2-weighted signal
or early gadolinium enhancement ratios (EGEr)) as
well as cell necrosis/fibrosis (late gadolinium enhance-
ment (LGE)), the latter regarded as less reversible
injury.5 The distribution of injury allows CMR to dif-
ferentiate ischaemic from non-ischaemic MInj.5
CMR detects MInj in SLE not only in patients with
clinical myocarditis, but also subclinical MInj.6,7
Despite a clear benefit, access to CMR may be limited
in resource constrained settings. Further limitations
include intolerance of or contraindications to CMR.8
Echocardiography on the other hand is cost-effective
and can be utilized at the bedside, also in unstable
patients. In contrast to CMR, echocardiography is
not limited by gadolinium exposure and the risk of
nephrogenic systemic fibrosis, a problem in the setting
of accompanying lupus nephritis (LN).8 Literature
comparing echocardiography to CMR in the assess-
ment and interpretation of MInj in SLE is limited.
Objectives
To determine the prevalence of MInj according to
CMR in an SLE population; compare the clinical and
echocardiographic features of patients with and with-




A prospective, cross-sectional study was performed
at a tertiary referral centre in the Western Cape,
South Africa. Adult inpatients fulfilling the 2012
Systemic Lupus International Collaborating Clinics
Classification (SLICC) criteria were screened for inclu-
sion.9 Exclusion criteria included existing myocarditis,
cardiomyopathy (CMO), coronary artery disease and
valvular/congenital heart disease; contraindications to
CMR included magnetic factors and contraindications
to gadolinium contrast (pregnancy, renal impairment).8
Inflammatory myopathy is associated with false nega-
tive CMR when applying criteria for myocarditis,
thereby excluding these patients from the study.5
A physical examination including assessment of dis-
ease activity (SLE disease activity index 2000
(SLEDAI-2K)) and the Systemic Lupus International
Collaborating Clinics/American College of
Rheumatology (SLICC/ACR) Damage Index (SDI)
was performed on all patients by a rheumatologist.10,11
Chronic treatment was documented. Routine laborato-
ry investigations included complement levels, markers
of cardiac myocyte injury (creatine kinase (CK);
high-sensitive troponin T (hs-TropT)), renal function
analysis and an autoantibody screen.
Echocardiographic analysis
Patients underwent a two-dimensional echocardiogram
according to standard guidelines using a M4S probe
with a Vivid E9/E95 ultrasound machine (General
Electric Medical services, Johannesburg, South
Africa).12 Images were analyzed by an echocardiog-
rapher, blinded to the clinical and CMR findings.
Regional LV function included reporting of wall
motion abnormalities (WMA) and a wall motion
score index (WMSi). Speckle tracking echocardiogra-
phy (STE) was performed using Echopac software, ver-
sion 2.0 (General Electric, Johannesburg, South
Africa). Longitudinal segmental strain was measured
in the basal, mid and apical segments, while global lon-
gitudinal strain (GLS) was averaged from all three
apical views.13 A segmental STE score was determined
by the absolute number of segments with impaired
strain according to standard reference values.14
Cardiac magnetic resonance analysis
CMR analyses were performed using a Siemens
Magnetom Aera 1.5 Tesla. This included steady state
free precession cine imaging, T2-short-tau inversion




(EGE) and LGE sequences according to consensus
guidelines.15 Post processing was performed on
Syngo.via and Circle Cardiovascular Imaging software
and reported by imaging specialists, blinded to the clin-
ical and echocardiographic findings. The presence/
absence of MInj was reported according to the Lake
Louise Criteria (LLC).5
Statistical analysis
Continuous variables were summarized as mean (
SD) or median (med) and interquartile range (IQR).
The independent samples t-test and Mann–Whitney
U test were used to compare continuous variables.
Chi square or Fisher’s exact/v2 test was used to deter-
mine relationships between binary variables.
Variables predictive of CMR MInj were identified
through logistic regression analyses. Receiver operat-
ing characteristic (ROC) curves were used to calculate
optimal cut-off values, sensitivity and specificity of
predictive models.
Outcomes
A diagnosis of clinical LM was based on clinical fea-
tures of myocardial dysfunction supported by echocar-
diography and biochemical markers in keeping with
myocarditis but without considering the CMR findings.
CMR LLC were used to classify patients into three
groups: absent criteria (AC), single abnormal criterion
(SC) (increased T2-weighted signal or EGEr or LGE
enhancement) or fulfilling the LLC (two or more crite-
ria present). Predictors of MInj according to CMR
tissue characterization were identified.
Results
A total of 106 SLE patients were screened of whom 49
(46.2%) were included. Exclusions were predomi-
nantly due to contraindications to CMR: renal
impairment (n¼ 27; 47%), pregnancy (n¼ 2; 3.5%),
inflammatory myopathy (n¼ 3; 5%). In total, 11
patients (17.5%) could not tolerate the CMR proce-
dure: distressed/unstable (n¼ 4) or confused patients
(neuropsychiatric SLE (NPSLE)) (n¼ 4) and claus-
trophobia (n¼ 3). In addition, 10 patients were
excluded due to established cardiac pathology
(Supplementary Figure 1).
Clinical characteristics
Patients included were predominantly young females
(87.8%, mean age 29 years, SD11) with a high SLE
disease activity (median SLEDAI-2K: 13, IQR: 9–19.5)
but low SDI (median: 0, range: 0–9). The median dura-
tion of SLE at inclusion was 158 days (range: 0–7800).
A total of 42 patients were admitted with an SLE flare.
SLE characteristics included haematological (75.5%),
mucocutaneous (67.3%) and musculoskeletal (51%)
manifestations. In total, 15 patients (30.6%) had LN
of which 10 had class III/IV. Details of clinical and
laboratory characteristics as well as treatment are
available in Supplementary Table 1.
CMR groups according to the Lake Louise Criteria
A total of 23 patients (47%) had CMR evidence of
MInj (1 criteria). In total, 17 patients fulfilled a SC
whereas 6 fulfilled the LLC for myocarditis
(Supplementary Figure 2).
A clinical and echocardiographic diagnosis of LM
was made in all six patients who fulfilled the LLC, in
3/17 in the SC group, but not in any patients in the
AC group. In 14/23 patients (60.9%) CMR evidence
of MInj occurred in the absence of clinical myocar-
ditis. Compared with the AC group, patients fulfill-
ing LLC had a higher SLEDAI-2K (Med: 22
(IQR:16-26) versus 13 (9-15); p=0.022) whereas
anti-double stranded DNA (anti-dsDNA) was more
frequently positive in patients with one/more criteria
for MInj (23/23 (100%) versus 21/26 (80.8%);
p=0.026). Other laboratory parameters (including
CK and hs-TropT), clinical features (including car-
diovascular risk factors and antiphospholipid syn-
drome) as well as medication use were not
significantly different between CMR groups
(Supplementary Table 2).
Both structural and functional echocardiographic
parameters were more impaired in patients with one/
more criteria for MInj (Figure 1(a) to (d)).
CMR tissue characterization
In patients with CMR evidence of MInj, tissue charac-
terization included inflammation in 16/23 and fibrosis/
necrosis in 12/23 patients.
All 16 patients with inflammatory CMR changes
were admitted with an SLE flare compared with
26/33 patients without inflammation (p¼ 0.047).
Patients with an increased EGEr had a lower lympho-
cyte count (median: 0.51 109IU/l (IQR: 0.39–1.0))
than those with a normal EGEr (1.31 109IU/l (IQR:
0.65–1.94), p¼ 0.013). Other laboratory results (includ-
ing CK, hs-TropT), clinical parameters (including age,
gender, SLEDAI-2K and SLE duration) as well as car-
diovascular risk factors (including antiphospholipid
syndrome) were not significantly different amongst
groups.
Echocardiographic parameters were grouped
according to CMR tissue characterization (Table 1).
The LV internal diameter index (LVIDi), regional
du Toit et al. 3
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function (WMSi; segmental strain) and global left (left
ventricular ejection fraction (LVEF)) and right ventric-
ular function (tricuspid annular plane systolic excur-
sion (TAPSE)) were more impaired in particular in
patients with an increased EGEr. WMSi and GLS
were more impaired in patients with LGE.
Univariate logistic regression analyses identified
clinical, laboratory and echocardiographic parameters
predictive of inflammation and fibrosis/necrosis.
Selected univariate predictors (p  0.16) were entered
into multivariable regression analyses (Table 2).
TAPSE remained a significant predictor (p< 0.05) of
inflammatory CMR changes and GLS of LGE
(p¼ 0.043). In a ROC-curve analysis, the model pre-
dicting an increased EGEr (Table 2) had the best
area under the curve (area under the curve: 0.901,
p< 0.001, sensitivity: 88.9%, specificity: 76.3%, nega-
tive predictive value: 97.4%) .
Discussion
We report one of the largest series on MInj in SLE,
classified according to CMR tissue characterization
and one of a limited number of studies comparing
echocardiography and CMR in SLE.16 We docu-
mented CMR evidence of MInj in 47% of a population
with predominantly active SLE. In 14/23 patients
(60.9%), MInj was subclinical.
Clinical lupus myocarditis
Nine patients in our study population had clinically
evident LM. Although all nine patients had CMR
evidence of MInj, only six fulfilled the LLC for myo-
carditis. The LLC detects clinical LM in 29–80%
of cases.17,18 Functional parameters (including WMA
and strain) used in echocardiography as markers of
dysfunction in the early stages of LM are not
Figure 1. Box and whisker plots depicting a comparison of echocardiographic parameters between patients with cardiac magnetic
resonance evidence of myocardial injury (1 criteria) to those without. (a) Comparison of global LV function (LVEF) in patients with
and without one or more CMR criteria for myocardial injury; (b) comparison of global longitudinal strain (GLS) (measured by speckle
tracking echocardiography) in patients with and without one or more CMR criteria for myocardial injury; (c) comparison of regional
LV function (wall motion score) in patients with and without one or more CMR criteria for myocardial injury; and (d) comparison of
LV internal diameter index in patients with and without one or more CMR criteria for myocardial injury.
The numeric values reported denote the median (horizontal line of box) and inter quartile range (top and bottom line of box). LV: left
ventricle; LVEF: left ventricular ejection fraction; CMR: cardiac magnetic resonance; STE GLS: speckle tracking echocardiography,

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































du Toit et al. 5
38
Stellenbosch University https://scholar.sun.ac.za
incorporated into the LLC.16,19 Diagnostic accuracy
trials quoted in the Journal of the American College
of Cardiology White Paper (with reference to the
LLC) were performed on patients with predominantly
non-connective tissue disease related myocarditis.5
Considering the different pathophysiological processes
involved we have to question the generalization of
these criteria in rheumatic diseases.20
Subclinical myocardial injury
We found evidence of subclinical MInj in 14/49
SLE patients (28.6%). Although inflammatory CMR
injury was associated with an SLE flare and lower
lymphocyte count, the majority of clinical and labora-
tory parameters correlated poorly with CMR tissue
characterization.
Some authors have described a correlation between
both T2- and EGEr and SLE disease activity, yet sim-
ilar CMR changes have also been described in the
absence of significant cardiovascular symptoms, often
irrespective of SLE disease activity.7,21 This disconnect
between cardiovascular symptoms, SLE activity and
myocardial involvement is not dissimilar to other sys-
temic involvement in SLE and has also been described
with regards to NPSLE.22 This may be a reflection of
the persistent burden of inflammation in active SLE,
irrespective of organ-specific clinical manifestations.
Limitations of CMR
Despite clear benefits, the utility of CMR in SLE is
limited in clinical practice. We excluded 54% of
patients screened for our study, the majority due to
contraindications to or intolerance of CMR. A high
incidence of LN and subsequent risk of nephrogenic
systemic fibrosis, limits CMR as a diagnostic tool in
SLE.1,4,8 In addition, patient cooperation is required
to obtain sequences performed by breath-holding pro-
tocols.5 Unstable, tachypnoeic or confused patients
(NPSLE), compromises the quality of images obtained.
Predictors of MInj according to CMR tissue
characterization
Our multivariable analyses identified models predictive
of myocardial inflammation, in particular an increased
EGEr. Right ventricular dysfunction (including
TAPSE) is a recognized predictor of adverse cardiac
outcomes in CMO and in patients with heart failure
with a preserved LVEF.23 Impaired TAPSE is found
in clinical as well as subclinical LM.19,24 To our knowl-
edge, the association with and predictive value of
TAPSE for the presence of EGE in SLE is a novel
finding. As an echocardiographic measure with low
interobserver variability, the assessment of TAPSE in
patients with SLE may provide a useful screening mea-
sure to identify patients with MInj.
We could not confirm previous findings of more
extensive LGE in patients with longstanding SLE.21
We have demonstrated an impaired GLS (STE) and
increased WMSi in patients with LGE compared with
those without. GLS also remained an independent pre-
dictor of LGE on multivariable analysis. Since LGE
represents fibrosis/necrosis and potentially less
Table 2. Prediction of myocardial injury according to CMR tissue characterization: multivariable logistic regression analyses.
95% CI for OR
Variable p OR Lower Upper
Model predicting inflammatory CMR changes
TAPSE 0.006 0.045 0.005 0.415
Variables excluded from equation: LVIDi (p¼ 0.155); mid segmental STE score (p¼ 0.570); apical segmental STE score (p¼ 0.509)
Model predicting EGE enhancement on CMR
Absolute lymphocyte count 0,096 0.300 0.073 1.239
LVID index 0.104 1.246 0.956 1.624
TAPSE 0.043 0.044 0.002 0.908
Variables excluded from equation: SLEDAI (p¼ 0.657); wall motion score index (p¼ 0.741)
Model predicting T2-enhancement on CMR
TAPSE 0.045 0.102 0.011 0.95
Variable excluded from equation: apical segmental STE score (p¼ 0.681)
Model predicting LGE on CMR
STE GLS 0.031 1.329 1.026 1.722
Variable excluded from equation: LVIDi (p¼ 0.398)
CMR: cardiac magnetic resonance; CI: confidence interval; OR: odds ratio; TAPSE: tricuspid annular plane systolic excursion; LVIDi: left ventricular
internal diameter index; STE: speckle tracing echocardiography; SLEDAI: SLE disease activity index; EGE: early gadolinium enhancement; GLS: global




reversible MInj, follow-up studies are required to eval-
uate the long-term consequences of these findings.
Relevance of subclinical myocardial injury
The clinical relevance of subclinical MInj remains
unclear. Does subclinical injury represent an
early stage of myocarditis? Could early immunosup-
pressive therapy prevent full clinical expression of the
disease or does it merely reflect background systemic
inflammation in SLE, amenable to less aggressive
immunosuppression?
Limited information exists on the long-term conse-
quences of subclinical MInj in SLE. Two series
(four and six SLE patients respectively) reported an
improvement in T2-enhancement following immuno-
suppressive therapy with no significant improvement
in LGE.25,26 Although these series suggest treatment
responsiveness of inflammatory MInj, there remains a
sparsity of evidence to inform our decision making.
Limitations
We acknowledge that our sample size was small. The
exclusion of a significant number of patients due to
intolerance of or contraindications to CMR may also
have contributed to selection bias. This does however
reflect the practical limitations of CMR in the manage-
ment of sick SLE patients.
CMR was used as our diagnostic standard of MInj
in the absence of histological confirmation. Although
regarded as the gold standard and a low-risk proce-
dure, endomyocardial biopsy remains invasive and
could not be justified in the asymptomatic patient.27
Conclusion
CMR evidence of MInj frequently occurs in active SLE
patients, in keeping with the inflammatory injury of the
lupus heart seen at autopsy. MInj may occur in the
absence of clinical LM or biochemical evidence of car-
diomyocyte injury.
The utility of CMR in clinical practice is limited
by a high exclusion rate in SLE, mainly due to renal
disease. Predictive models including echocardiographic
parameters (TAPSE and LVIDi) are sensitive for the
detection of potentially reversible inflammatory
changes on CMR, while GLS is associated with
fibrosis/necrosis. Echocardiography can be used as a
cost-effective screening tool with a high negative pre-
dictive value, in particular when CMR is contraindi-
cated or unavailable.
The relevance of subclinical myocardial injury
remains unclear. Follow-up studies are required to
guide clinical decisions regarding the optimal screening
and management of these patients.
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Clinical and demographic detail of patients	
IQR: inter quartile range; SD: standard deviation; SLEDAI-2K: SLE disease activity index; SDI: Systemic 
Lupus International Collaborating Clinics / American College of Rheumatology damage index 
Indications for immunosuppressive therapy: 
aCyclophosphamide: NPSLE (n=3); lupus nephritis (LN) (n=1).bMycophenolate mofetil: LN (n=3). 




Age	(years)	 29 (±11) 
SLE	duration	at	inclusion	(days)	 158 (0-7800) (range) 
SLEDAI‐2K	 13 (9-19.5) 
SDI		 0 (0-9) (range) 
Female			n/	total	(%)	 43 (87.8) 
Admitted	with	SLE	flare		n/	total	(%)	 42 (85.7) 
SLE	manifestations:		 n/	total	(%) 
 Haematological 37 (75.5) 
 Mucocutaneous 33 (67.3) 
 Musculoskeletal 25 (51) 





 Neuropsychiatric	SLE	(NPSLE) 8 (16.3) 
 Clinical	lupus	myocarditis 9 (18.4) 
 Vasculitis 9 (18.4) 
Cardiovascular	risk	factors		 n/	total	(%) 
 Hypertension 10 (20.4) 
 Dyslipidemia 1 (2) 
 Diabetes	Mellitus 1 (2) 
 Current	smoker 6 (12.2) 
Antiphospholipid	syndrome	 6 (12.2) 
Medication	use,	month	preceding	admission	 n/	total	(%) 
 Antihypertensive	medication 15 (30.6) 





 Prednisone 41 (83.7) 
 Prednisone	mg/day	(med;	IQR) 16 (8-32) 
 Cyclophosphamidea 4 (8.2) 
 Mycophenolate	mofetilb 3 (6.1) 
 Azathioprinec 5 (10.2) 































































SLEDAI‐2K 13(9-15) 12(9-20) 0.813 22(16-26) 0.022 13 (9-22) 0.452 
SDI	 0 (0-1) 1 (0-2) 0.285 0 (0-1) 0.655 1 (0-2) 0.514 
Female	gender 24 (92) 14(82) 0.319 5 (83) 0.497 19 (82.6) 0.301 
Cardiovascular	risk	
factors 
8 (30.8) 6 (35) 0.757 1 (17) 0.489 7 (30.4) 0.980 
APL	syndrome 2 (8) 4 (24) 0,085 0  0.483 4 (17.4) 0.154 
Lupus	Nephritis 9 (35) 3 (18) 0.225 3 (50) 0.483 6 (26.1) 0.518 
Clinical	Lupus	
myocarditis 0 3 (18) 0.026 6 (100) <0.001 9 (39.1) <0.001
Neuro	lupus	 2 (7.7) 5 (29.4) 0.059 1 (16.7) 0.497 6 (26.1) 0.082 


































10 (38.5) 4 (23.5) 0.307 1 (16.7) 0.311 5 (21.7) 0.205 
Chloroquinea	 11 (42.3) 10 (58.8) 0.289 1 (16.7) 0.242 11 (47.8) 0.698 
Prednisone	use	 22 (84.6) 14 (82.4) 0.844 5 (83.3) 0.938 19 (82.6) 0.850 
Prednisone	
mg/day;	Med	(IQR)	
17 (9-32) 15 (6-30) 0.699 15 (15-
50)
0.436 16 (6-32) 0.976
Cyclophosphamide	 2 (7.7) 2 (11.8) 0.653 1 (16.7) 0.497 3 (13) 0.537 
Mycophenolate	
mofetil	
1 (3.8) 1 (5.9) 0.757 1 (16.7) 0.242 2 (8.7) 0.480 
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Azathioprine	 3 (11.5) 1 (5.9) 0.532 1 (16.7) 0.732 2 (8.7) 0.743 

























































































































































































































8 (5-28) 0.474 
18.5 (6-
64)
0.321 8 (5-30) 0.316
CK	(IU/L)	 36 (25-58) 
47 (26-
58)




CRP	(mg/l)	 32 (10-65) 16 (8-59) 0.456 
44.5 (1-
60)
0.981 16 (7-60) 0.541
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CMR: cardiac magnetic resonance; AC: absent CMR criteria; SC: single CMR criterion; LLC: Lake Louise 
criteria; Med: median; IQR: interquartile range; SLEDAI-2K: SLE disease activity index; SDI: Systemic 
Lupus International Collaborating Clinics / American College of Rheumatology Damage Index; 
APL: antiphospholipid; ANA: antinuclear antibody; anti-dsDNA: anti-double stranded DNA: anti-
Sm: anti-smith; anti-RNP: anti-ribonuclear protein; ACA: anti-cardiolipin antibody; LA: lupus 
anticoagulant; aB2GP1: anti-B2 glycoprotein 1; Std Dev: standard deviation; CK: creatine kinase; CRP: C-
reactive protein; ESR: erythrocyte sedimentation rate; eGFR: estimated glomerular filtration rate; 
UPCR: urinary protein creatinine ratio. 
aChloroquine used for minimum of 30 days at time of inclusion 
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Supplementary Figure 1 
Reasons for excluding patients form the study 
CMR: cardiac magnetic resonance 
1. Contra-indication to CMR: inflammatory myopathy (Lake Louise criteria not interpretable)
(n=3); pregnancy (n=2); renal impairment (n=27)
2. Intolerance to CMR: unstable / respiratory distress (n=4); confused / unable to co-operate or
give consent (neurolupus) (n=4); claustrophobia (n=3)
3. Cardiac pathology:  Newly diagnosed congenital heart lesion (n=1); known rheumatic heart





















Supplementary Figure 2 
Flow chart depicting patients classified according to cardiac magnetic resonance criteria 
for myocardial injury, including detail of tissue characterisation.  
Myocardial injurya: myocardial tissue injury according to cardiac magnetic resonance (CMR) criteria; LLC: 



















- LGE and T2 / EGEr: 5/6
AC





Supplementary  Figures 3A-D (not included in manuscript) 
Receiver operating characteristic curve analysis of various models correctly predicting 
the presence of myocardial injury according to CMR tissue characterization:  
3A   Model correctly predicting inflammatory changes on CMR 
Variable included in model: TAPSE 




3B   Model correctly predicting an increased EGEr on CMR 
Variable included in model: Absolute lymphocyte count; LVID index; TAPSE 
Variables excluded from equation: SLEDAI-2K; WMS index 
3C   
Model correctly predicting T2-enhancement on CMR 
Variable included in model: TAPSE ; Variables excluded from equation: Apical segmental STE score 
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3D   
Model correctly predicting LGE on CMR 
Variable included in model: GLS 
Variables excluded from equation: LVID index; 
ROC curve: receiver operating characteristic curve; CMR: cardiac magnetic resonance; AUC: area under the 
curve; CI: confidence intervals; PPV positive predictive value; NPV: negative predictive value; EGEr: early 
gadolinium enhancement ratio; LGE: late gadolinium enhancement; TAPSE: tricuspid annular plane systolic 
excursion; LVID: left ventricular internal diameter; STE: speckle tracking echocardiography; SLEDAI-2K; 




Serum cytokine levels associated with myocardial injury in systemic 
lupus erythematosus 
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Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. 
Riëtte Du Toit1, Helmuth Reuter2,3, Gerhard Walzl4, Candice Snyders4, Novel N Chegou4, Phillip G 
Herbst5, and Anton F Doubell5. 
1Division of Rheumatology, Department of Medicine, Faculty of Medicine and Health Sciences, 
Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. 
2Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health 
Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. 
3Institute of Orthopaedics and Rheumatology, Stellenbosch, South Africa 
4DST-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical 
Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human 
Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape 
Town, 8000, South Africa 
5Division of Cardiology, Department of Medicine, Faculty of Medicine and Health Sciences, 
Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.  
Corresponding author: 
Dr Riëtte du Toit  
Division of Rheumatology 
Department of Medicine 
Po Box 241 
Cape Town  
8000 
South Africa 







To identify cytokines, markers of endothelial activation (soluble vascular cell adhesion molecule 
[sVCAM-1]) and myocyte strain (soluble-ST2 [sST2]) associated with myocardial injury (MInj) in 
systemic lupus erythematosus (SLE), classified by cardiac magnetic resonance (CMR) criteria. 
Methods 
CMR was performed on patients with SLE, identifying stages of MInj (inflammation and 
necrosis/fibrosis). Data captured included: clinical assessment, laboratory and serological 
analyses, cytokine (IL-1β, IL-1Ra, IL-2, IL-6, IL-10, IL-17, IL-18, TNF-alpha), sVCAM-1 and sST2 
levels. Cytokines were compared with regards to SLE features and evidence of CMR MInj. 
Predictors of CMR MInj were determined through regression analyses.  
Results 
Forty-one patients with high disease activity (SLEDAI-2K:13;IQR:3-17) were included. SLE 
features included: lupus nephritis (LN) (n=12), neuropsychiatric SLE (NPSLE) (n=6) and clinical 
lupus myocarditis (LM) (n=6). Nineteen patients had CMR evidence of MInj. Patients with a 
SLEDAI-2K≥12 had higher sVCAM-1 (p=0.010) and sST2 (p=0.032) levels. NPSLE was 
associated with higher IL-1Ra (p=0.038) and LN with lower IL-1Ra (p=0.025) and sVCAM-1 
(p=0.036) levels. Higher IL-1Ra (p=0.012), IL-17 (p=0.045), IL-18 (p=0.003), and sVCAM-1 
(p=0.062) levels were observed in patients with CMR MInj compared to those without. On 
multivariable logistic regression, IL-1Ra predicted CMR inflammation and fibrosis/necrosis 
(p<0.005) while anti-Ro/SSA (OR:1.197;p=0.035) and the SLE damage index 
(OR:4.064;p=0.011) predicted fibrosis/necrosis. 
Conclusion 
This is a novel description of associations between cytokines and SLE MInj. IL-18 and IL-1Ra were 
significantly higher in patients with MInj. IL-1Ra independently predicted different stages of CMR 
MInj. Exploration of the role of these cytokines in the pathogenesis of SLE MInj may promote 
targeted therapies for LM. 
Keywords 
cytokines, IL-18, IL-17, IL-1Ra, lupus myocarditis, sVCAM-1, cardiac magnetic resonance 
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Serum cytokine levels associated with myocardial injury in systemic lupus 
erythematosus. 
Background     
Myocardial inflammation in systemic lupus erythematosus (SLE) varies from subclinical disease, 
reported in up to 37% of patients at post-mortem, to clinically evident lupus myocarditis (LM) in 
5-10% of patients.(1) Clinical LM impacts on damage accrual as well as survival in SLE.(2) More 
advanced left ventricular dysfunction at presentation is associated with a poor outcome, 
emphasising the importance of an early, accurate diagnosis and appropriate immunosuppressive 
therapy.(3)
Cardiac magnetic resonance (CMR) is the non-invasive modality of choice for the diagnosis of 
myocarditis.(4) Stages of myocardial injury (MInj) are identified through tissue 
characterisation.(4) An increased T2- short-tau inversion recovery [STIR] signal or early 
gadolinium enhancement (EGE) represents myocardial inflammation. Cell necrosis and/or 
fibrosis is associated with late gadolinium enhancement (LGE), representing potentially 
irreversible injury.(4,5) CMR detects clinical as well as subclinical MInj in SLE.(6-8) 
CMR provides limited insight as to the initial trigger causing inflammatory MInj. Tissue 
characterisation represents the result of a variety of possible insults, including viral infections 
and other immune mediated injuries.(4,9) 
Current knowledge of the immunopathogenesis of LM is based on immunohistochemistry 
reports. Bidani et al identified immune complex aggregates in blood vessels of the lupus 
myocardium.(10) In addition to auto-antibodies and immune complex deposition, the innate 
immune system plays an important role in the pathogenesis of SLE.(11) Interleukins (ILs) act as 
mediators orchestrating the pathological immune response leading to a vast spectrum of SLE 
phenotypes.(12,13) Identifying messengers involved in specific organ manifestations may be the 
key to directed immunotherapies in SLE.(12,14) 
A variety of cytokines are linked to SLE disease activity as well as organ specific manifestations 
(Table 1). Reports are however conflicting, with both increased as well as decreased levels of 
specific cytokines described in the context of SLE phenotypes.(12-23) Heart failure and dilated 
cardiomyopathies (CMO) are also associated with an increased expression of cytokines (IL-17; 
IL-18; IL-6; tumour necrosis factor [TNF]) whereas IL-1 beta (IL-1β) and IL-18 have been 
implicated in the pathogenesis of viral myocarditis (Table 1).(24-31) Soluble suppressor of 
tumourgenesis 2 (sST2) is a member of the IL-1 receptor family and a decoy receptor for IL-33.(32) 
sST2 (but not IL-33) levels correlate with SLE disease activity and increased sST2 levels have 
54
Stellenbosch University https://scholar.sun.ac.za
been observed in a murine model of auto-immune myocarditis.(32-34) (Table 1) Currently, there 
are no reports on potential associations between cytokines and myocardial injury in SLE.  
In patients with inflammatory CMO, endothelial cell adhesion molecules (CAM) promote trans-
endothelial migration of circulating immunocompetent cells into the myocardial 
interstitium.(35) Pro-inflammatory cytokines stimulate vascular cell adhesion molecule 1 
expression on the endothelium which may be released as a soluble form (soluble vascular CAM 
[sVCAM-1]) into the circulation.(36) Increased sVCAM-1 levels have been found in patients with 
LN and levels correlate with disease activity and low complement.(36,37) Findings support the 
hypothesis of immune complex deposition, endothelial cell activation and subsequent tissue 
injury. sVCAM-1 needs to be explored as a potential role player in the pathogenesis of myocardial 
injury in SLE. 
While acknowledging the complexity of the immunopathogenesis of SLE, certain cytokine 
patterns play a role in the phenotypical expression of the disease. Despite this expanding 
knowledge, literature exploring the immunopathogenetic pathways in MInj in SLE is lacking. A 
better understanding of the relevant cytokines, markers of myocardial strain and endothelial 
activation may not only provide biomarkers as non-invasive diagnostic tools, but also highlight 
new potential targets for therapeutic intervention in LM. 
Objectives:  
Primary: To identify cytokines and markers of myocyte strain and endothelial activation 
associated with the presence of MInj in SLE as identified by CMR criteria. 
Secondary: To describe associations between cytokine levels and clinical manifestations of SLE. 
Methods:   
Patient selection 
A prospective, cross-sectional study was performed at Tygerberg Academic Hospital, a tertiary 
referral centre in the Western Cape, South Africa. Our hospital services a drainage area of 3.4 
million people. Approximately 500 SLE patients are seen at the rheumatology outpatient 
department annually. Between August 2016 and May 2018, all hospitalised patients fulfilling the 
2012 Systemic Lupus International Collaborating Clinics Classification (SLICC) criteria were 
screened for inclusion.(38)  Patients with a previously documented CMO, myocarditis (LM or 
other), coronary artery disease or significant structural heart disease were excluded. Contra-
indications to undergo CMR were additional exclusion criteria: factors related to magnetic factors 
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(metallic prosthesis, implants or foreign bodies) or contra-indications to gadolinium contrast 
(pregnancy, renal impairment).(39)  
Clinical data 
A detailed history and physical examination were undertaken by an experienced rheumatologist. 
SLE duration, clinical features as well as validated measures of disease activity (SLE disease 
activity index [SLEDAI-2K]) were recorded.(40) The Systemic Lupus International Collaborating 
Clinics (SLICC) / American College of Rheumatology damage index for SLE (SDI)) as measure of 
permanent organ damage was also documented.(41) Chronic treatment and immunosuppression 
in the month preceding admission was recorded. Chloroquine use for at least 30 days was 
documented.   
Laboratory data      
Laboratory investigations included inflammatory markers (C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR)), complement levels (C3, C4), markers of cardiac myocyte injury 
(creatine kinase (CK); high-sensitive troponin-T (hs-tropT)) and urine analysis. An autoantibody 
screen included anti-nuclear antibody (ANA), anti-double stranded DNA (anti-dsDNA), anti-
Smith (anti-Sm); anti-ribonucleoprotein (anti-RNP), anti-Ro/SSA, anti-La/SSB and 
antiphospholipid antibodies. An EILSA kit (Autoimmune EIA 96SA Assay, Bio-Rad Laboratories) 
was used for the detection of autoantibodies and included SSA/Ro60 antigens. 
A Luminex® kit (R&D Systems Inc. [Bio-Techne] Minneapolis, USA) was used to measure cytokine 
levels (IL-1β, IL-1Ra, IL-2, IL-6, IL-10, IL-17, IL-18, TNF-alpha), markers of endothelial activation 
(sVCAM-1) and myocyte strain (sST2). Cytokine samples were collected within 24hrs from the 
CMR analyses, batched and analysed by the Stellenbosch University Immunology Research Group 
in an International Organization for Standardization 15189 accredited facility. The Luminex® kit 
protocol was followed and analysed using the Bio Plex platform (Bio Rad Laboratories, Hercules, 
USA). Concentrations of all the biomarkers were assessed in an internal quality control sample 
included on the Luminex® plates. The Bio Plex Manager version 6.1 software (Bio rad 
Laboratories) was used for data acquisition and analysis of the median fluorescent intensity.  
Imaging 
Two-dimensional echocardiograms were performed on all patients using an M4S probe with a 
Vivid E9/E95 ultrasound machine (General Electric Medical services, South Africa). Analyses 
were done by an experienced echocardiographer, blinded to detail of the clinical and CMR 
findings of the participant. Measurements were done in accordance with standard guidelines.(42) 
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CMR was performed on a Siemens Magnetom Aera 1.5 T. Analyses included steady state free 
precession cine imaging (TrueFISP in two, three and four chamber and short axis views), STIR 
imaging as well as EGE and LGE sequences according to consensus guidelines.(43) Post 
processing was done on Syngo.via and Circle Cardiovascular Imaging software. The studies were 
reported by specialists blinded to the clinical and echocardiographic findings of the participant. 
The presence of inflammatory injury (increased T2-weighted STIR signal or calculated global 
myocardial EGE ratio to skeletal muscle [EGEr]) and/or necrosis/fibrosis (LGE with a non-
ischemic regional distribution) was determined.(4)  
Statistical analysis 
Numerical variables were summarised as mean, standard deviation (SD) and range with 95% 
confidence intervals (CI) for continuous variables (normally distributed) and median (med) and 
interquartile range (IQR) (not normally distributed).  
The independent sample’s T-test and Mann-Whitney test were used to compare numerical data. 
Cross tabulation (Chi square or Fisher’s exact/x2 test) was used to evaluate relationships between 
binary variables.   
Relationships amongst continuous variables were determined by Spearman’s (non-parametric) 
and Pearson’s (parametric) correlations. Univariate logistic regression analyses identified 
variables associated with CMR tissue characteristics. Significant variables (p≤0.16) were included 
in the multivariable logistic regression analyses (method: backward likelihood ratios) to identify 
variables predictive of MInj according to CMR tissue characterisation. Receiver operating 
characteristic (ROC) curves were used to calculate optimal cut-off values, sensitivity and 
specificity of predictive models. 
Outcomes 
A diagnosis of clinical LM was based on clinical features of myocardial dysfunction supported by 
echocardiography and biochemical markers in keeping with myocarditis. Patients were 
categorised based on the presence or absence of MInj according to CMR criteria. CMR tissue 
characterisation was used to identify predictors of different subtypes of MInj (inflammation 
and/or necrosis/fibrosis).(4)  
Results   
Clinical detail 
One hundred and six hospitalised SLE patients were screened for inclusion. Fifty-seven patients 
were excluded due to intolerance of or contra-indications to CMR. Twenty-seven of these (47.4%) 
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were excluded due to renal impairment. Eleven patients could not tolerate the procedure due to 
haemodynamic instability / respiratory distress (n=4), confusion (neuropsychiatric SLE [NPSLE], 
n=4) and claustrophobia (n=3). Cytokine analyses were available in 41 patients from the total 
cohort of 49.  
The majority of patients (36/41) were young females (mean age 29 years; SD±10) with high 
disease activity (SLEDAI-2K (med):13; IQR:3-17) and median SLE duration of 158 days (IQR:8-
1590). Sixteen patients were diagnosed with SLE less than one month prior to inclusion. 
Haematological (75%), mucocutaneous (65.9%) and musculoskeletal (46.3%) manifestations 
were the most frequently observed SLE manifestations. Six patients had neuropsychiatric SLE 
(NPSLE) and twelve patients had LN of which seven (58.3%) were diagnosed as class III or IV. Six 
patients had clinical and echocardiographic features of LM. Organ damage (SDI≥1) was present 
in 19/41 patients. 
Although all patients were initiated or continued on chloroquine during hospitalisation, only 
nineteen patients were on chloroquine for at least 30 days. Thirty-four patients were taking 
prednisone (med daily dosage 15.5mg; IQR:7.5-32.5) in the month preceding admission. Sixteen 
patients were taking immune modulatory therapies, including cyclophosphamide (CPM) (n=4), 
mycophenolate mofetil (MMF) (n=2), azathioprine (n=5), methotrexate (n=4) and sulphasalazine 
(n=1). Both CPM and MMF were initiated at the time of admission and used for <30 days at the 
time of inclusion (CMP: median 2.5 days, range 1-14; MMF: 2 and 26 days).  Indications for CPM 
and MMF included LN and NPSLE. Azathioprine was used by five patients, of which two took it for 
more than 30 days (auto-immune haemolytic anaemia (AIHA) and NPSLE respectively). 
Myocardial injury (MInj) according to CMR tissue characterisation 
Nineteen patients (46.3%) fulfilled one or more CMR criteria for MInj (Table 2). Inflammatory 
changes were present in 13/19 patients (68.4%) while evidence of myocyte necrosis/fibrosis 
with LGE was present in 9/19 patients (47.4%). Six patients with MInj fulfilled clinical diagnostic 
criteria for LM versus none in the group without CMR MInj (p=0.004). NPSLE occurred more 
frequently in patients with CMR evidence of MInj compared to those without (5/19 versus 2/22; 
p=0.049). 
Detail of clinical features, medication use and routine laboratory / serological markers of patients 
with and those without CMR evidence of MInj are summarised in Table 2. 
Cytokine, sVCAM-1 and sST2 analyses 
The majority of laboratory samples were collected within one day of the CMR analyses. IL-1Ra, 
IL-18, sVCAM-1 and sST2 were detectable in 100% of SLE patients at varying levels (Table 3). 
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Detail of correlations between cytokines and laboratory and serological markers as well as 
correlations among cytokines are available as Supplementary Tables S1-3.  
Significantly higher cytokine levels (p<0.005) were found in patients with certain SLE 
manifestations such as musculoskeletal disease (IL-1β, IL-6, TNF-alpha and sVCAM-1)) and 
NPSLE (IL-1Ra) compared to those without these features. Patients with LN had lower levels of 
IL-1Ra (p=0.025) and sVCAM-1 (p=0.036) than patients without LN. Higher sST2 (p=0.032) and 
sVCAM-1 (p=0.010) levels were observed in patients with a high disease activity (SLDEAI-2K 
≥12) (Supplementary Table S4). 
In patients with CMR evidence of MInj, levels of IL-1Ra (p=0.012), IL-17 (p=0.045), IL-18 
(p=0.003), and sVCAM-1 (p=0.062) were higher compared to those without MInj (Figure 1A-D). 
Other cytokines as well as sST2 levels (p=0.565) were statistically not significantly different 
between the two groups.  
Predictors of myocardial injury (MInj) according to CMR tissue characterisation 
The predictive value of individual clinical and laboratory parameters were analysed by univariate 
logistic regression analyses. IL-1Ra was a significant predictor of both subtypes of inflammatory 
myocardial tissue injury (increased EGEr as well as T2-STIR enhancement). In addition, SDI, anti-
Ro/SSA-antibody titre and IL-2 were significant predictors of LGE on CMR (Table 4). On 
multivariable logistic regression analyses IL-1Ra remained a significant predictor for all types of 
myocardial tissue injury while anti-Ro/SSA and SDI (OR: 4.064) remained predictive of LGE 
(Table 4).  
IL-1Ra had a low positive (PPV) but high negative predictive value (NPV) for the presence of 
inflammatory myocardial injury, including increased T2-STIR and EGE (Table 4). The sensitivity 
and specificity of the various models (identified in Table 4) for the detection of myocardial tissue 
injury were determined by ROC curves. The model predicting the presence of LGE had the best 
area under the curve (AUC:0.910; p<0.001) with a sensitivity: 88.9% and specificity: 87.5%; cut-
off: 0.319; PPV: 77.8% and NPV: 96.9% (Figure 2A). As an individual parameter, an anti-Ro/SSA 
antibody titre of ≥80 IU/ml had a sensitivity of 77.8% and specificity of 75% for the detection of 
LGE on CMR (AUC:0.729; p=0.038; 95% CI:0.528-0.930) (Figure 2B).  
Discussion   
As far as we are aware, this is the first study to describe an association between specific serum 
cytokines and MInj in SLE. We have demonstrated significantly higher levels of IL-18, IL-1Ra and 
IL-17 in SLE patients with CMR evidence of MInj compared to those without. On multivariable 
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logistic regression, IL-1Ra was predictive of inflammatory as well as necrotic/fibrotic stages of 
MInj according to CMR tissue characterisation.  
Benefit and limitations of CMR in SLE related myocardial injury 
Thirteen patients (31.7%) had CMR evidence of myocardial injury in the absence of clinically 
evident LM, in keeping with the incidence of subclinical injury described on post-mortem 
studies.(1) The detection of both inflammation as well as fibrosis/necrosis on CMR is well 
described in the SLE patient.(6) Changes may occur in the absence of associated cardiac 
symptoms and irrespective of disease activity.(7) Although this early detection of MInj may 
provide an important screening tool in SLE, our study highlighted significant limitations of the 
utility of CMR in the SLE patient. Fifty-seven SLE patients screened (53.8%) were excluded from 
our study, the majority due to contra-indications to or intolerance of CMR. A high incidence of LN 
and subsequent risk of nephrogenic systemic fibrosis in particular limits the utility of CMR as a 
diagnostic measure in SLE.(39) 
IL-18 
IL-18 is recognised as an important cytokine in the pathogenesis of SLE, with increased levels 
associated with organ specific manifestations, in particular LN.(15,16) We found higher levels of 
IL-18 in patients with CMR evidence of MInj (inflammation and LGE) compared to those without. 
Increased levels were not associated with other SLE phenotypes nor disease activity. The lack of 
an association between IL-18 and LN in our population stands in contrast to previous reports.(15) 
Our results may be influenced by the fact that we have excluded patients with potentially more 
aggressive LN and associate renal impairment (due to contra-indications to gadolinium contrast 
use).  
IL-18 has been implicated in the pathogenesis of viral myocarditis where the severity of 
myocarditis correlates with IL-18 levels rather than viral replication.(24,25) Increased IL-18 
expression is also associated with both ischaemic and dilated CMO, contributing to myocardial 
dysfunction through its negative inotropic effect.(26,27) Although IL-18 levels have been linked 
to LN, this is the first description of an association with and possible role in the pathogenesis of 
MInj in SLE.  
IL-1Ra 
An intricate balance between IL-1 and its naturally occurring antagonist, IL-1Ra is essential in the 
regulation of the innate inflammatory process. IL-1 can induce cardiac myocyte apoptosis and is 
known to have a negative inotropic effect.(28,29) Reduced IL-1Ra gene expression occurs in the 
left ventricle of patients with a dilated CMO compared to patients with ischaemic heart disease as 
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well as controls.(26)  The reduced IL-1Ra/IL-1 ratio supports the hypotheses that an imbalance 
of IL-1Ra/IL-1 contributes to cardiac myocyte apoptosis and reduced contractility.  
Various auto-immune diseases are linked to an imbalance between IL-1Ra/IL-1. In inflammatory 
bowel disease, a decreased ratio of mucosal IL-1Ra/IL-1 is associated with chronic intestinal 
inflammation and correlates with disease severity.(44) A similar imbalance exists in the 
rheumatoid synovium, favouring IL-1 production.(45)  
In SLE, findings have been less clear. Sturfelt et al described a relative absence of IL-1Ra response 
as a feature of renal involvement in SLE, while increased levels of IL-1Ra were associated with 
other systemic involvement.(19) More recent publications however, demonstrated increased 
levels of IL-1Ra in SLE in comparison to controls, and even higher levels in patients with 
LN.(17,20,46)   
We detected IL-1Ra in all 41 SLE patients in our study group. We did not find a significant 
correlation between IL-1Ra levels and SLEDAI-2K. Similar to Sturfelt’s study, our LN patients had 
significantly lower levels of IL-1Ra while NPSLE patients demonstrated higher levels of IL-1Ra 
compared to SLE patients without these clinical features. No correlation was observed between 
IL-1Ra levels and renal function (glomerular filtration rate) or urine protein/creatinine ratio 
(UPCR). This observation makes significant urinary protein loss an unlikely explanation to 
account for lower levels of IL-1Ra in LN patients.  
An important consideration is that the association between reduced IL-1Ra/IL-1 and non-lupus 
CMO as well as inflammation in other auto-immune conditions have all been demonstrated with 
regards to tissue IL-1Ra/IL-1 expression. Studies on IL-1Ra in SLE, including our own, have 
measured circulating levels of IL-1Ra rather than tissue expression. The high serum IL-1Ra levels 
may be in response to a significant production and subsequent binding of IL-1 in the peripheral 
circulation. To clarify the relevance of increased serum IL-1Ra associated with MInj 
demonstrated in our study and understand the exact role of the IL-1Ra/IL1 balance in the 
pathogenesis of lupus MInj, myocardial tissue expression of these cytokines will need to be 
evaluated.   
IL-17 and sVCAM-1 
We found significantly higher levels of IL-17 in patients with MInj. IL-17 is known to be associated 
with cardiac myocyte apoptosis, but has not previously been linked to MInj in SLE.(30) On 
univariate logistic regression analysis, IL-17, IL-2, IL-10 and sVCAM-1 were associated with 
myocardial tissue injury in our population. Yet, these variables were not independently predictive 
of MInj in the multivariable analyses. Significant collinearity existed between these cytokines as 
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well as sVCAM-1 (Supplementary Table 3), reflecting the important and complex interplay 
between different cytokines in the pathogenesis of SLE.  
sVCAM-1 levels correlated with SLE disease activity, and increased levels were associated with 
the presence of various clinical SLE features in our study group, including musculoskeletal 
manifestations, vasculitis and MInj. Our findings are in keeping with previous reports, supporting 
the central role of immune complex deposition and subsequent endothelial activation, not only in 
myocardial but also other types of tissue injury in SLE.(36,47)  
Anti-Ro/SSA antibodies 
The association between maternal anti-Ro/SSA antibody positivity and foetal heart block is well 
established.(48) Evidence is also growing for conduction disturbances in the adult SLE patient 
with anti-Ro/SSA positivity.(49) In a post-mortem study, ongoing inflammation with apoptosis 
and myocardial fibrosis was demonstrated in cases of fatal congenital heart block secondary to 
maternal anti-Ro/SSA antibodies.(50)  
We found no association between anti-Ro/SSA antibodies and conduction abnormalities. The 
anti-Ro/SSA antibody titre was however an independent predictor of MInj (specifically LGE) in 
the multivariable regression analyses. The association between anti-Ro/SSA antibodies and LGE 
(representing myocardial fibrosis) may suggest a mechanism of injury to the adult myocardium, 
similar to what was described in the foetal heart on post-mortem.(50) 
Variables predictive of myocardial injury 
On multivariable regression analyses, IL-1Ra was an independent predictor of inflammatory MInj 
on CMR whereas the model including SDI, anti-Ro/SSA and IL-1Ra predicted fibrosis/necrosis 
(LGE) with a high sensitivity and specificity.   
As far as we are aware, there are no previous reports of models predicting SLE associated 
inflammatory MInj as the dependant variable. Previous authors have not been able to 
demonstrate a significant association between SLE disease activity and inflammatory CMR tissue 
characteristics nor between CMR findings and typical clinical cardiac findings.(6,7) A single study 
identified age as a predictor of LGE on CMR.(51) In comparison to our results, cytokines, SDI and 
anti-Ro/SSA were not recorded in the study.    
LGE of the myocardium is indicative of a stage that is regarded as less reversible with poor 
prognostic implications for non-lupus myocarditis.(52) SDI represents chronic SLE changes and 
damage accrual. The association between SDI and chronic CMR changes is therefore not an 
unexpected finding. The significance of IL-1Ra and LGE however needs to be evaluated 
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prospectively. Follow-up CMR studies in SLE are necessary to evaluate the long-term 
consequences and prognostic implications of our findings.   
Limitations 
Patients included were hospitalised SLE patients with predominantly active SLE, limiting the 
generalisation of our findings. We have excluded patients with significant renal impairment due 
to contra-indications to gadolinium use. Participants may therefore not represent the full 
spectrum of patients with LN and their associated cytokine profiles. Our study was a cross-
sectional design with analyses done at a single time point. The relevance of observed associations 
with and predictors of chronic CMR changes need to be evaluated further by longitudinal cohort 
studies. 
Determining the biological activity of IL-18 by measuring levels of IL-18 binding protein was 
beyond the scope of this study and needs to be determined in future mechanistic studies. The 
levels of IL-17 and IL-1β may have fallen below the assay detection limits in some of the study 
participants. This limits the statistical analyses of these two cytokines, requiring a careful 
interpretation of the related data. We have determined the presence of antibodies against the 
Ro/SSA60 and not the Ro/SSA52 antigen. Anti-Ro/SSA60 is however known to be independently 
associated with SLE and our findings need to be seen in that context.(53) 
Tissue characterisation was based on validated CMR criteria and not endomyocardial biopsy 
(EMB).(4) Although EMB is regarded as the gold standard and a low risk procedure in 
experienced hands, it remains an invasive procedure. The majority of our patients did not have 
clinical features of myocarditis and performing an EMB could therefore not be justified.  
Conclusion 
We have demonstrated that elevated serum levels of IL-18 and IL-1Ra are associated with MInj 
in SLE. Considering the known role of IL-18 in the pathogenesis of viral myocarditis, we have 
identified IL-18 as a possible role player in the pathogenesis of MInj in SLE. An IL-1Ra/IL-1 
imbalance contributes to the inflammatory process in auto-immune disease and has been 
associated with LN. On multivariable logistic regression analyses, IL-1Ra was an independent 
predictor of different stages of MInj according to CMR tissue characterisation. Future EMB studies 
evaluating myocardial tissue expression of IL18 and IL-1Ra/IL-1 may provide better insight into 
the exact pathogenetic role of these cytokines in the development of MInj in SLE and ultimately 
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Summary from published literature of cytokines associated with SLE and their role in 
myocardial injury (non-lupus). 
Cytokine Role in SLE Reference Role in myocardial injury Reference 
IL-1β No association to weak correlation with SLE activity 13, 15 Implicated in viral myocarditis 24 
IL-18 Increased in LN 12, 15, 16 
Implicated in viral myocarditis 
Increased expression in 
ischaemic and dilated CMO 
Negative inotropic effect 
24, 
25, 26, 27 
IL-1 / IL-
1Ra 
Both increased and decreased 
IL-1Ra expression described 
in relation to disease activity 
and LN  
17, 18, 19, 
20 
Increased IL-1 associated with 
cardiac myocyte apoptosis and 
negative inotropic effect 
Reduced IL-1Ra/IL-1 expression 
observed in dilated CMO 
26, 28, 29 
IL-17 
Weak correlations with SLE 
disease activity 
None to strong associations 
with organ specific 
manifestations (LN) 
12, 21, 22 Induce cardiac myocyte apoptosis 30 
IL-6 
Associated with LN, NPSLE, 
musculoskeletal 
manifestations 
Promotes B-cell activation and 
auto-antibody production 
12, 14, 18, 
21 
Increased in ischaemic and 
dilated CMO compared to 
controls 




Inconsistent / contradictory 
Associated with drug-induced 
SLE 
12, 13, 14, 
18 
23 
Increased in ischaemic and 
dilated CMO compared to 
controls  
Induce cardiac myocyte 
apoptosis 
31 






Correlates with SLE disease 
activity 32 
Increased levels observed in 
heart failure and murine model 
of auto-immune myocarditis 
Of prognostic value post 
myocardial infarction 
33, 34 
asST2 acts as regulator and decoy receptor for IL-33. IL-33 levels do not correlate with SLE disease 
activity.(32) 
IL: interleukin; IL-1β: IL-1 beta; IL-1Ra: IL-1 receptor antagonist; sST2: soluble suppressor of 
tumorigenesis two; TNF-α: tumour necrosis factor alpha; SLE: systemic lupus erythematosus; LN: lupus 




Comparison of clinical and laboratory parameters between patients with and without CMR 
evidence of myocardial injury 
Myocardial injury according to CMR criteria  
Absent CMR criteria 
Total n=22 
Any ≥1 criteria 
Total n=19 
Clinical parameter 
 Total n=41 
Med (IQR) / mean (SD) 
n/total (%) 
Med (IQR) / mean (SD) 
n/total (%) 
p 
Age in years 29 (±11.4) 30 (±9.3) 0.834 
SLEDAI-2K 13 (10-15) 13 (9-21) 0.906 
SDI 0 (0-1) 1 (0-2) 0.263 
Duration of SLE (days) 43 (6-1332) 239 (25-1928) 0.302 
Female gender 21/22 (95.5) 15/19 (78.9) 0.107 
Ethnicity 
• Mixed ethnicitya (n=24) 13 (59) 11 (57.9) 0.938 
• Black (n=14) 8 (36.4) 6 (31.6) 0.747 
• Caucasian (n=3) 1 (4.5) 2 (10.5) 0.463 












• Lupus Nephritis 8/22 (36.4) 4/19 (21.1) 0.283 
• Clinical Lupus
myocarditis 0/22 6/19 (31.6) 0.004 
• NPSLE 1/22 (4.5) 5/19 (26.3) 0.049 
• Musculoskeletal 9/22 (40.9) 10/19 (52.6) 0.453 
• Mucocutaneous 14/22 (63.6) 13/19 (68.4) 0.747 
• Haematological 17/22 (77.30 14/19 (73.7) 0.790 
• Vasculitis 2/22 (9) 3/19 (15.8) 0.513 
Medication use 30 days 
preceding inclusion 
Daily prednisone dosage (mg) 17 (9-33) 15 (6-32) 0.783 
Chloroquinec 8/22 (36.4) 11/19 (57.9) 0.168 
Immune modulatory treatmentd 8/22 (36.4) 8/19 (42.1) 0.707 
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Warfarinb 0/22 1/19 (5.3) 0.276 
Antihypertensive medication 7/22 (31.8) 4/19 (21.1) 0.438 
Laboratory parameter Med (IQR) or mean (SD) Med (IQR) or mean (SD) p 
WCC x109 /l 7.16 (5.58-9.8) 6.31(3.64-8.15) 0.196 
Absolute lymphocyte count x109 
/l 1.36 (0.9-1.94) 0.65 (0.49-1.2) 0.016 
Haemoglobin g/dl 8.4 (7.7-11.3) 10.6 (8.4-11.5) 0.117 
Platelets x109 /l 391 (196-505) 266 (214-317) 0.080 
High sensitive CRP (mg/l) 36 (9-65) 16 (7-59) 0.403 
ESR (mm/1st hour) 50 (31-95) 63 (40-103) 0.632 
Serum albumin (g/l) 32.1 (±7) 31.8 (±8.6) 0.917 
eGFR (ml/min/1.73m2) 118 (±32) 125 (±21) 0.363 
UPCR  (g/24 hours) 0.54 (0.21-1.45) 0.54 (0.36-1.03) 1 
hs-TropT (ng/L)  8 (4-21) 8 (4-28) 0.830 
CK (IU/L) 41 (25-59) 47 (26-58) 0.948 

















Anti-SM antibody (IU/ml) 







Anti-RNP antibody (IU/ml) 























C3 g/l 0.74 (0.41-1.3) 1.02 (0.48-1.27) 0.647 
C4 g/l 0.09 (0.04-0.21) 0.14 (0.06-0.24) 0.359 
ACA (IgG) U/ml 5 (4-7) 5 (3-6) 0.543 
LA ratio 1.02 (0.86-1.17) 1.12 (0.95-1.31) 0.200 
aβ2GP1 U/ml 2 (1.2-2.6) 1.9 (1.2-3.6) 0.838 
aMixed ethnicity refers to a mixed racial ancestry from European, Asian and Khoisan and Bantu ethnic 
groups of southern Africa 
bOne patient was diagnosed with antiphospholipid syndrome at the time of inclusion, hence not yet on 
warfarin and one patient defaulted treatment. 
cChloroquine: frequency of patients using for ≥30 days 
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dImmune modulatory treatment include cyclophosphamide (n=4), mycophenolate mofetil (n=2), 
azathioprine (n=5), methotrexate (n=4), and sulphasalazine (n=1) 
CMR: cardiac magnetic resonance; Med: median; IQR: interquartile range; SLEDAI-2K: SLE disease activity 
index; SDI: SLICC/ACR damage index; SD: standard deviation; APL: antiphospholipid syndrome; NPSLE: 
neuropsychiatric SLE; WCC: white cell count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; 
eGFR: estimated glomerular filtration rate; UPCR: urinary protein creatinine ratio; CK: creatine kinase; hs-
TropT: high-sensitive troponin T;  APL: antiphospholipid; ANA: anti-nuclear antibody; anti-dsDNA: anti-
double stranded DNA; anti-SM: anti-smith antibody; anti-RNP: anti-ribonuclear protein; ACA: 
anticardiolipin antibody; LA: lupus anticoagulant; aβ2GP1: anti-beta-2 glycoprotein-1 
Table 3 

















IL-1β (pg/ml) 19.5 - 4744 5 (12.2) 7 (17.1) 0 0 - 113.79c 
IL-1Ra (pg/ml) 28.0 - 6793 41 (100) 41 (100) 2131.87 
1279.69 - 
4865.42 
IL-2 (pg/ml) 29.6 - 7200 23 (56.1) 25 (61) 60.70 0 - 327.72 
IL-6 (pg/ml) 4.8 - 1154 35 (85.4) 40 (97.6) 14.38 7.76 - 42.07 
IL-10 (pg/ml) 4.8 - 1162 26 (63.4) 29 (70.7) 6.57 0 - 19.28 
IL-17 (pg/ml) 12.8 - 3110 10 (24.4) 22 (53.7) 0.7 0 - 11.46 
IL-18 (pg/ml) 10.1 - 2460 41 (100) 41 (100) 411.79 249.58 - 873.01 
TNF-α (pg/ml) 9.7 - 2359 20 (48.8) 38 (92.7) 9.28 4.40 - 22.66 
sVCAM-1 (ng/ml) 7.78 - 1890.78 41 (100) 41 (100) 1848.4 1212.1 - 2705.7 
sST2 (ng/ml) 0.569 - 13.26 41 (100) 41 (100) 44.10 28.9 - 74.7 
aRange as per manufacturer 
bMedian of observed concentration 
cRange reported and not IQR  
IQR: interquartile range; IL: interleukin; IL-1β: interleukin 1 beta; IL-1Ra: interleukin 1 receptor 
antagonist; TNF-α: tumour necrosis factor-alpha; sVCAM-1: soluble vascular cellular adhesion molecule 1; 




Logistic regression analyses (univariate as well as multivariable) identifying variables predictive 
of myocardial injury according to CMR tissue characterization.  
Univariate logistic regression analyses: 
Predictors of myocardial injury according to CMR tissue characterisation 
Any myocardial inflammatory changes (T2-STIR and/or EGE) 
Parameter OR 95% CI p 
Lymphocyte count 0.461 0.165-1.287 0.140 
IL-1Ra 1.233 0.999-1.496 0.051 
IL-18 1,121 0.972-1.294 0.118 
sVCAM-1 1.041 0.987-1.099 0.137 
T2-STIR enhancement 
IL-1Ra 1.263 1.015-1.571 0.036 
sST2 1.066 0.982-1.156 0.126 
Early gadolinium enhancement 
SLEDAI-2K 1.100 0.979-1.235 0.109 
IL-1Ra 1.244 1.008-1.537 0.042 
IL-18 1.145 0.983-1.333 0.082 
sVCAM-1 1.048 0.989-1.111 0.114 
Myocardial necrosis / fibrosis (late gadolinium enhancement) 
SDI 2.440 1.204-4.926 0.013 
NPSLE 4.833 0.799-30.00 0.091 
Anti-Ro/SSA 
antibody titre 
1.132 1.014-1.263 0.027 
IL-1Ra 1.196 0.976-1.465 0.085 
IL-2 1.641 1.127-2.391 0.010 
IL-10 1.003 0.997-1.071 0.074 
IL-17 1.963 0.887-4.344 0.096 
Multivariable logistic regression analyses: 
Predictors of myocardial injury according to CMR tissue characterisation 
Model predicting inflammatory CMR changes (T2-STIR and/or EGE) 
Parameter OR 95% CI p PPV NPV 
IL-1Ra 1.215 0.993-1.487 0.059 30.8% 92.6% 
Variables excluded from the equation: Lymphocyte count, IL-18, sVCAM-1 
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Model predicting T2-STIR enhancement 
IL-1Ra 1.263 1.015-1.571 0.036 14.3% 97.1% 
Variable excluded from the equation: sST2 
Model predicting early gadolinium enhancement 
IL-1Ra 1.244 1.008-1.537 0.042 37.5% 97% 
Variables excluded from the equation: SLEDAI-2K, IL-18, sVCAM-1 
Model predicting late gadolinium enhancement 
SDI 4.064 1.380-11.963 0.011 77.8% 96.9% 
Anti-Ro/SSA 1.197 1.012-1.415 0.035 
IL-1Ra 1.529 1.069-2.187 0.020 
Variables excluded from the equation: NPSLE, IL-2, IL-10, IL-17 
CMR: cardiac magnetic resonance; T2-STIR: T2-weighted short-tau inversion recovery; EGE: early 
gadolinium enhancement; IL: interleukin; IL-1Ra: interleukin-1 receptor antagonist; sVCAM-1: soluble 
vascular cell adhesion molecule 1; SLEDAI-2K: SLE disease activity index; SDI: SLICC/ACR damage index. 
PPV: positive predictive value; NPV: negative predictive value; SDI: Systemic Lupus International 





Box and whisker plots comparing levels of cytokines (IL-1Ra [1A], IL-17 [1B], IL-18 [1C]) and sVCAM-
1 (1D) (as marker of endothelial activation) in patients with CMR evidence of myocardial injury to 
those without. The numeric values reported denote the median (horizontal line of box) and inter 
quartile range (top and bottom line of box). 






CMR: cardiac magnetic resonance; IL-1Ra: IL-1 receptor antagonist (pg/ml); IL-17 (pg/ml); IL-18 




Receiver operating characteristic curve analysis of the modela correctly predicting the presence of late 
gadolinium enhancement (LGE) according to CMR tissue characterization  




Receiver operating characteristic curve analysis of anti-Ro/SSA antibody titres correctly predicting the 
presence of late gadolinium enhancement (LGE) according to CMR tissue characterization  
ROC: receiver operating characteristic curve; CMR: cardiac magnetic resonance; AUC: area under the 
curve; CI: confidence intervals; PPV positive predictive value; NPV: negative predictive value; SDI: 
Systemic Lupus International Collaborating Clinics (SLICC) / American College of Rheumatology 
damage index for SLE; IL-1Ra: interleukin-1 receptor antagonist 
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Supplementary Table S1 




















-0.035 -0.013 0.213 -0.142 0.054 0.106 -0.176 -0.067 -0.264 0.066 0.098 
p 0.827 0.935 0.181 0.376 0.761 0.508 0.270 0.742 0.100 0.681 0.546 
N 41 40 41 41 34 41 41 27 40 41 40 
IL-1Ra Correlation 
Coefficient 
-0.042 -0.319* 0.139 0.023 0.041 0.137 0.011 0.105 -0.182 -0.081 0.403** 
p 0.796 0.045 0.386 0.887 0.818 0.392 0.947 0.602 0.260 0.616 0.010 
N 41 40 41 41 34 41 41 27 40 41 40 
IL-6 Correlation 
Coefficient 
-0.132 -0.360* -0.195 -0.009 0.368* 0.521** -0.252 -0.299 -0.039 0.266 0.352* 
p 0.412 0.022 0.223 0.954 0.032 0.000 0.111 0.130 0.812 0.092 0.026 





-0.519** -0.523** -0.280 -0.262 0.429* 0.192 0.244 0.070 0.100 0.283 0.249 
p 0.001 0.001 0.077 0.098 0.011 0.229 0.125 0.727 0.539 0.073 0.122 
N 41 40 41 41 34 41 41 27 40 41 40 
IL-18 Correlation 
Coefficient 
-0.252 -0.343* -0.164 -0.388* 0.254 0.064 0.202 0.270 0.007 0.097 0.124 
p 0.112 0.030 0.305 0.012 0.147 0.690 0.205 0.173 0.965 0.545 0.445 
N 41.000 40 41 41 34 41 41 27 40 41 40 
IL-2 Correlation 
Coefficient 
-0.093 -0.094 0.178 -0.191 -0.207 -0.313* -0.305 -0.166 0.004 -0.009 0.084 
p 0.562 0.564 0.265 0.232 0.240 0.046 0.052 0.408 0.981 0.955 0.608 





-0.328* -0.490** 0.073 -0.262 0.045 0.102 -0.152 -0.101 -0.065 0.253 0.141 
p 0.036 0.001 0.651 0.098 0.801 0.527 0.342 0.616 0.688 0.110 0.386 







-0.274 -0.367* -0.081 -0.198 -0.035 0.152 -0.130 -0.012 0.030 0.028 0.060 
p 0.083 0.020 0.614 0.213 0.844 0.344 0.419 0.954 0.855 0.863 0.714 
N 41 40 41 41 34 41 41 27 40 41 40 
sST2 Correlation 
Coefficient 
0.172 -0.186 -0.098 -0.109 -0.335 0.022 -0.157 -0.049 0.118 0.060 0.331* 
p 0.283 0.250 0.543 0.497 0.053 0.890 0.327 0.807 0.467 0.711 0.037 
N 41 40 41 41 34 41 41 27 40 41 40 
IL-10 Correlation 
Coefficient 
-0.293 -0.420** 0.099 -0.117 -0.092 0.099 -0.128 0.116 -0.090 0.156 0.005 
p 0.063 0.007 0.537 0.465 0.605 0.540 0.424 0.565 0.581 0.330 0.973 
N 41 40 41 41 34 41 41 27 40 41 40 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; GFR: glomerular filtration rate; UPCR: urine protein creatinine ratio; CK: creatine kinase; hs-tropT: high 
sensitivity troponin-T; IL:  interleukin; IL-1Ra: inteleukin-1 receptor antagonist; sVCAM-1:  soluble vascular cellular adhesion molecule 1; TNF-alpha:  tumour necrosis 
factor-alpha; sST2: soluble ST2. 
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Supplementary Table S2 




















-0.064 0.049 -0.401** 0.191 0.083 -0.120 -0.203 0.007 -0.013 0.161 0.084 
p 0.689 0.762 0.009 0.231 0.607 0.457 0.204 0.967 0.943 0.315 0.602 
N 41 41 41 41 41 41 41 36 34 41 41 
IL-1Ra Correlation 
Coefficient 
0.071 0.047 -0.084 0.251 0.064 0.061 -0.086 0.153 0.058 0.267 0.185 
p 0.658 0.769 0.602 0.114 0.690 0.703 0.591 0.373 0.744 0.092 0.247 
N 41 41 41 41 41 41 41 36 34 41 41 
IL-6 Correlation 
Coefficient 
0.328* 0.143 0.050 0.115 0.092 0.140 0.086 0.098 0.206 -0.139 -0.097
P 0.036 0.372 0.756 0.475 0.566 0.382 0.593 0.568 0.243 0.385 0.546 





0.213 0.222 -0.025 0.065 -0.046 -0.017 0.166 -0.003 0.466** -0.129 -0.154
P 0.182 0.163 0.874 0.685 0.776 0.914 0.299 0.988 0.005 0.422 0.337 
N 41 41 41 41 41 41 41 36 34 41 41 
IL-18 Correlation 
Coefficient 
0.130 0.054 -0.111 0.065 -0.013 -0.196 0.017 0.050 0.037 0.244 0.184 
P 0.417 0.737 0.490 0.686 0.934 0.220 0.914 0.772 0.838 0.124 0.249 
N 41 41 41 41 41 41 41 36 34 41 41 
IL-2 Correlation 
Coefficient 
0.076 -0.062 -0.113 0.089 0.369* 0.149 -0.286 0.034 -0.187 -0.160 -0.235
P 0.637 0.698 0.482 0.578 0.017 0.352 0.070 0.845 0.289 0.318 0.139 





0.311* 0.192 -0.099 0.290 0.161 0.121 -0.067 -0.019 0.057 -0.047 -0.054
P 0.048 0.230 0.539 0.066 0.316 0.451 0.675 0.912 0.748 0.771 0.737 
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N 41 41 41 41 41 41 41 36 34 41 41 
IL-1 beta Correlation 
Coefficient 
0.171 0.003 0.057 -0.037 0.100 0.088 -0.068 0.118 -0.040 -0.045 -0.017
P 0.285 0.986 0.722 0.816 0.535 0.586 0.675 0.492 0.824 0.781 0.914 
N 41 41 41 41 41 41 41 36 34 41 41 
sST2 Correlation 
Coefficient 
0.208 0.231 -0.242 0.217 0.212 0.129 -0.256 -0.095 0.058 0.059 0.034 
P 0.191 0.146 0.128 0.172 0.184 0.423 0.106 0.582 0.746 0.714 0.832 





0.063 0.027 -0.256 0.020 0.188 0.164 -0.051 -0.005 0.012 0.142 0.124 
P 0.695 0.868 0.107 0.903 0.240 0.305 0.750 0.977 0.945 0.377 0.439 
N 41 41 41 41 41 41 41 36 34 41 41 
IL-10 Correlation 
Coefficient 
0.274 0.121 -0.171 0.067 0.173 0.236 -0.075 0.007 -0.025 0.100 0.070 
P 0.083 0.450 0.286 0.676 0.279 0.137 0.639 0.969 0.888 0.535 0.664 
N 41 41 41 41 41 41 41 36 34 41 41 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
ANA: anti-nuclear antibody ; anti-DsDNA: anti-double stranded DNA ; anti-RNP: anti-ribonucleoprotein  ; anti-B2GP1: anti-Beta 2 glycoprotein 1  ; IL:  interleukin; IL-
1Ra: interleukin-1 receptor antagonist; sVCAM-1:  soluble vascular cellular adhesion molecule 1; TNF-alpha:  tumour necrosis factor-alpha; sST2: soluble ST2. 
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Supplementary Table S3 
Correlations between various cytokine levels 










Coefficient 1.000 0.134 0.094 0.515** 0.160 0.195 0.365* 0.071 0.281 0.547** 
p 0.405 0.560 0.001 0.319 0.221 0.019 0.657 0.075 <0.001 
N 41 41 41 41 41 41 41 41 41 41 
IL-17 
Correlation 
Coefficient 0.134 1.000 0.449** 0.282 0.034 0.123 0.454** 0.333* 0.433** 0.340* 
P 0.405 0.003 0.074 0.832 0.444 0.003 0.034 0.005 0.030 
N 41 41 41 41 41 41 41 41 41 41 
IL-1Ra 
Correlation 
Coefficient 0.094 0.449** 1.000 0.184 0.001 0.175 0.240 0.271 0.243 0.314* 
P 0.560 0.003 0.249 0.993 0.274 0.130 0.086 0.125 0.046 
N 41 41 41 41 41 41 41 41 41 41 
IL-6 
Correlation 
Coefficient 0.515** 0.282 0.184 1.000 0.096 0.333* 0.371* 0.164 0.171 0.616** 
P 0.001 0.074 0.249 0.551 0.033 0.017 0.305 0.286 <0.001 
N 41 41 41 41 41 41 41 41 41 41 
sST2 
Correlation 
Coefficient 0.160 0.034 0.001 0.096 1.000 0.077 0.132 0.203 0.065 0.123 
P 0.319 0.832 0.993 0.551 0.632 0.410 0.203 0.685 0.442 
N 41 41 41 41 41 41 41 41 41 41 
sVCAM-1 
Correlation 
Coefficient 0.195 0.123 0.175 0.333* 0.077 1.000 0.228 0.419** 0.058 0.440** 
P 0.221 0.444 0.274 0.033 0.632 0.152 0.006 0.718 0.004 
N 41 41 41 41 41 41 41 41 41 41 
IL-10 
Correlation 
Coefficient 0.365* 0.454** 0.240 0.371* 0.132 0.228 1.000 0.300 0.388* 0.552** 
P 0.019 0.003 0.130 0.017 0.410 0.152 0.056 0.012 <0.001 
N 41 41 41 41 41 41 41 41 41 41 
IL-18 Correlation Coefficient 0.071 0.333* 0.271 0.164 0.203 0.419** 0.300 1.000 0.010 0.269 
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P 0.657 0.034 0.086 0.305 0.203 0.006 0.056 0.952 0.088 
N 41 41 41 41 41 41 41 41 41 41 
IL-2 
Correlation 
Coefficient 0.281 0.433** 0.243 0.171 0.065 0.058 0.388
* 0.010 1.000 0.504** 
P 0.075 0.005 0.125 0.286 0.685 0.718 0.012 0.952 0.001 




Coefficient 0.547** 0.340** 0.314* 0.616** 0.123 0.440** 0.552** 0.269 0.504** 1.000 
p <0.001 0.030 0.046 <0.001 0.442 0.004 <0.001 0.088 0.001 
N 41 41 41 41 41 41 41 41 41 41 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
IL:  interleukin; IL-1Ra: interleukin-1 receptor antagonist;  sVCAM-1:  soluble vascular cellular adhesion molecule 1; TNF-alpha:  tumour necrosis factor-alpha; 
sST2: soluble ST2. 
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Supplementary Table S4  


























































Median 0.00a 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00* 0.00 0.00 0.00 0.00 0.00 5.40 0.00 0.00 0.00 0.00 
25a 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
75b 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.79 0.00 0.00 0.00 0.00 0.00 24.79 0.00 0.00 0.00 0.00 
IL-17 
(pg/ml) 
Median 0.70 0.35 3.95 0.35 0.70 0.35 0.70 0.00 0.00 0.70 0.00 6.23 3.95 0.00 0.70 0.35 0.35 0.70 0.70 3.95 
25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
75 9.99 15.80 15.80 9.99 3.95 11.46 3.95 15.80 7.02 12.92 9.99 15.80 12.92 0.35 12.92 8.51 15.80 8.51 9.25 18.64 
IL-1Ra 
(pg/ml) 
Median 2401.87 1279.69 2494.69 2046.76 1999.53 2266.87 2363.60 1808.42 1788.92 2594.33 2093.99 5742.02* 2568.57 1440.52* 2093.99 6765.99 2046.76 2401.87 2046.76 6815.58 
25 1578.14 1091.55 1091.55 1290.49 1091.55 1446.66 1261.18 1290.49 1103.88 1315.18 1261.18 1999.53 1599.86 1029.05 1290.49 1103.88 1626.25 1268.89 1279.69 2568.57 
75 5062.39 1626.25 5062.39 4668.45 3892.72 5105.17 4668.45 5062.39 2494.69 8863.53 2697.65 11811.2 5147.94 2266.87 2697.65 10801.8 2494.69 5934.56 3295.19 9778.64 
IL-6 
(pg/ml) 
Median 16.03 11.08 13.69 19.81 10.14 19.81* 14.24 16.03 11.15 22.85* 14.38 16.50 16.03 14.04 14.38 14.86 12.13 20.07 14.10 22.85 
25 10.14 5.41 5.89 10.14 4.58 11.22 4.58 10.57 5.41 14.10 8.06 5.41 10.14 4.63 8.06 4.58 7.46 8.06 7.46 19.54 
75 43.90 32.57 35.77 56.27 13.69 60.49 72.01 33.86 32.57 72.27 40.23 56.27 40.23 57.17 40.23 56.27 14.38 56.27 42.07 33.86 
sST2 
(ng/ml) 
Median 49.35 37.04 26.48 50.40* 47.27 43.87 64.44 39.84 42.31 44.13 40.26 61.39 40.26 50.40 40.26 76.14 37.79 47.27 45.70 43.62 
25 26.48 31.28 19.09 38.56 19.70 32.55 38.56 26.48 26.40 33.82 26.40 43.62 26.48 37.79 26.48 49.35 26.48 31.27 26.44 33.82 




Median 1953.9 1833.7 1293.4 2399.2* 1148.1 2063.2* 1505.6 1953.9 1300.5 2696.6** 1848.4 1994.1 2172.5 1300.5* 1769.6 2835.0 1219.8 1953.9 1750.2 2696.6* 
25 1148.10 1291.60 939.59 1315.30 939.59 1300.50 1030.80 1293.40 939.59 1953.90 1276.10 1148.10 1537.30 980.25 1148.10 2347.00 939.59 1307.60 1091.70 2381.30 
75 2714.70 2072.70 1819.00 2977.30 2072.70 2966.35 2565.00 2977.30 1769.60 3496.40 2576.40 2714.70 2977.30 2209.85 2565.00 2977.30 2361.40 2977.30 2570.70 3578.50 
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SLEDAI-2K: SLE disease activity index; UD: undetectable; IL:  interleukin; IL-1Ra: interleukin-1 receptor antagonist;  sVCAM-1: soluble vascular cellular adhesion 
molecule 1; TNF-alpha:  tumour necrosis factor-alpha; sST2: soluble ST2. 
IL-10 
(pg/ml) 
Median 6.94 1.72 6.94 6.38 4.93 7.12 5.36 6.94 3.54 8.34 6.94 5.77 6.94 3.76 6.94 3.76 8.46 6.18 6.94 6.18 
25 0.00 0.00 0.00 2.15 0.00 1.08 2.15 0.00 0.00 5.36 0.00 4.93 2.15 0.00 0.00 0.00 4.93 0.00 0.00 3.44 
75 18.39 25.16 29.03 17.00 6.94 23.10 17.47 21.03 17.47 25.16 20.17 6.57 25.16 15.44 20.17 12.49 20.17 17.47 19.28 6.57 
IL-18 
(pg/ml) 
Median 431.99 293.85 536.05 404.43 362.01 438.41 361.09 444.82 398.45 431.99 399.83 597.83 444.82 326.36 397.07 660.02 326.36 431.99 405.81 444.82 
25 265.11 142.96 300.70 246.28 246.28 259.00 246.28 300.70 300.70 244.40 252.88 246.28 300.70 164.21 246.28 399.83 244.40 300.70 246.28 352.75 
75 908.25 518.77 1064.83 700.54 518.77 873.01 985.74 866.31 866.31 879.70 866.31 879.70 985.74 527.41 750.84 1342.74 750.84 908.25 887.28 491.44 
IL-2 
(pg/ml) 
Median 60.70 251.53 45.33 82.60 0.00 82.60 78.42 45.33 22.67 177.75 45.33 87.94 45.33 144.84 45.33 292.53 184.52 45.33 53.02 79.75 
25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.13 0.00 0.00 0.00 24.96 




Median 10.54 5.07 11.48 8.00 4.06 12.56 10.50 9.28 6.38 22.66* 8.64 12.55 11.48 7.69 8.64 29.08 11.29 9.28 8.96 10.54 
25 4.73 4.06 3.37 4.73 0.41 5.90 4.06 4.73 2.67 6.39 4.06 5.40 4.73 3.37 4.73 0.41 5.40 4.06 4.06 5.40 
75 22.66 14.56 14.86 31.98 5.40 25.15 31.98 22.66 13.64 47.89 22.66 17.89 18.49 34.08 17.89 47.89 26.18 18.49 22.66 17.89 
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Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus – a 
prospective cohort study 
Abstract 
Objectives 
To determine the outcome of subclinical lupus myocarditis (sLM) with regards to mortality, 
incidence of clinical LM (cLM) and change in imaging parameters (echocardiography and cardiac 
magnetic resonance [CMR]).  
Methods 
A clinical evaluation, echocardiographic and CMR analysis were performed on 49 systemic 
lupus erythematosus (SLE) patients at baseline and 36 patients after a twelve month follow-
up. cLM definition: clinical features of LM supported by echocardiographic evidence of 
myocardial dysfunction. sLM definition: CMR evidence of myocardial tissue injury (as per 
Lake Louise criteria) without cLM.   
Results 
Disease activity (SLEDAI-2K) improved from 13 (median;IQR:9-20) to 7 (IQR:3-11) 
(p<0.001). One patient without initial CMR evidence of myocardial injury developed cLM. 
Mortality (n=10) was similar between patients with and without CMR evidence of 
myocardial injury. Echocardiographic left ventricular ejection fraction (LVEF) (p=0.014) 
and right ventricular function (p=0.001) improved significantly. CMR LV mass index (LVMi) 
(p=0.011) and CMR-LVEF (p<0.001) improved, but not parameters identifying myocardial 
tissue injury where a trend towards improvement was counterbalanced by persistence 
(n=7) /development of new criteria (n=11). Change in CMR LVMi correlated with change in 
T2-weighted signal (r=386;p=0.024). Immunosuppression had no significant effect on CMR 
parameters. 
Conclusion 
CMR evidence of myocardial injury persisted despite improved SLEDAI-2K, cardiac function 
and CMR LVMi. sLM did not progress to cLM and had no prognostic implications. 
Immunosuppression did not influence CMR evidence of myocardial injury and cannot be 
recommended for treating sLM. Improvement in CMR LVMi correlated with reduction in 




Myocardial injury in systemic lupus erythematosus (SLE) may manifest as clinical lupus 
myocarditis (LM) or remain undetected (subclinical LM), evident only by histological evidence of 
myocardial injury on post-mortem.(1-4) 
Reports on the prevalence of subclinical LM are conflicting. A high prevalence of myocarditis (up 
to 80%) was found in earlier necropsy studies.(5) More recently, histological evidence of 
myocarditis was found in 37% of SLE patients on post-mortem in the absence of clinical 
myocarditis ante mortem.(1) Considering the clinical prevalence of 5-10%, these findings suggest 
a significant degree of subclinical involvement.(2)  
Non-invasive imaging including conventional echocardiography, speckle tracking 
echocardiography (STE) and cardiac magnetic resonance imaging (CMR), detects clinical as well 
as subclinical myocardial involvement in patients with SLE.(6–10) CMR identifies stages of 
myocardial injury through tissue characterisation. Inflammation is characterised by an increased 
T2-weighted signal and/or increased early gadolinium enhancement ratio (EGEr) whereas 
necrosis/fibrosis leads to late gadolinium enhancement (LGE).(11) Inflammatory changes are 
expected to improve but necrosis and fibrosis are regarded as less reversible. The presence of 
two out of three criteria supports the diagnosis of myocarditis based on the Lake Louise criteria 
(LLC).(11) Although CMR parameters of myocardial injury may correlate with SLE disease 
activity, there is a poor correlation with traditional clinical signs of myocardial 
involvement.(9,12) 
The outcome of clinical LM is regarded as favourable, yet more advanced disease at presentation 
has been associated with a poor outcome.(13)  Clinical LM is also known to have a negative effect 
on overall survival and damage accrual.(2) The significance and prognostic implications of 
subclinical LM are however not well researched, questioning the relevance of early detection and 
treatment of the asymptomatic patient.(14) 
Objectives: 
• To determine the outcome of subclinical LM with regards to mortality and clinical and
imaging characteristics over a period of twelve months
• To determine the incidence of clinical LM in the cohort of patients with subclinical LM




Materials and methods 
Patient selection 
A prospective cohort study was performed at Tygerberg Hospital, a tertiary referral centre in 
South Africa. Adult inpatients fulfilling the 2012 Systemic Lupus International Collaborating 
Clinics Classification (SLICC) criteria were screened for inclusion.(15) Exclusion criteria included 
existing myocarditis, cardiomyopathy (CMO), coronary artery disease, valvular/congenital heart 
disease and contra-indications to undergo CMR (magnetic factors; contra-indications to 
gadolinium contrast).(16,17) Inflammatory skeletal myopathy co-existing with myocarditis 
limits the application of the LLC, thereby excluding these patients from the study.(18)  Patients 
underwent a complete clinical, laboratory and imaging evaluation at inclusion, which was 
repeated after twelve months.  
Clinical data 
Duration and clinical features of SLE, measures of disease activity (SLE disease activity index 
[SLEDAI-2K]) and the Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology (SLICC/ACR) Damage Index (SDI) were recorded by an experienced 
rheumatologist.(19,20)  Intensified immunosuppressive therapy since inclusion was defined as 
an increased prednisone dose to ≥half a milligram/kilogram (mg/kg) for ≥one month, and/or the 
addition of immunosuppressive therapy (cyclophosphamide [CPM], mycophenolate mofetil 
[MMF], azathrioprine, rituximab or methotrexate) for ≥one month.  
Laboratory data      
Laboratory investigations included a complete blood count, inflammatory markers, complement 
levels (C3/C4), markers of cardiac myocyte injury (creatine kinase (CK); high-sensitive troponin 
T [hs-TropT]), renal function, urine analysis and an autoantibody screen.  
Echocardiographic analysis 
Patients underwent two-dimensional echocardiography using a M4S probe with a Vivid E9/E95 
ultrasound machine (General Electric Medical services, South Africa) according to standard 
guidelines.(21) STE was performed using Echopac software, version 2.0. Global longitudinal 
strain (GLS) was averaged from all 3 apical views.(22,23) Images were analysed by an 
echocardiographer, blinded to the clinical and CMR findings.  
Cardiac magnetic resonance analysis 
CMR analyses were performed using a Siemens Magnetom Aera 1.5 Tesla. This included steady 
state free precession cine imaging (TrueFISP in two, three, four chamber and short axis views), 
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T2-weighted, EGE and LGE sequences according to consensus guidelines.(24) Post-processing 
was performed on Syngo.via and Circle Cardiovascular Imaging software. Imaging specialists, 
blinded to the clinical and echocardiographic findings, reported on the presence/absence of 
myocardial injury according to tissue characteristics defined by the 2009 LLC.(11)  
Statistical analysis 
Continuous variables were summarised as mean, standard deviation (SD) with 95% confidence 
intervals (CI) or median (med) and interquartile range (IQR). Numerical data (inclusion 
and follow-up) was compared using the Paired t-test or related-samples Wilcoxon signed-rank 
test and categorical variables by using the related sample McNemar Change test.  
The Independent Samples t Test (2-tailed significance) or the independent samples Mann-
Whitney U test were used to compare different CMR/clinical groups.  Relationships amongst 
continuous variables were determined by Spearman’s correlation coefficients. The effect of time 
(within subjects effect) and intensified immunosuppression (between subjects effect) was 
calculated by the repeated measures Anova. A p<0.05 was considered as statistically significant. 
Outcome 
Clinical LM was defined as clinical features of LM supported by echocardiography and 
biochemical markers in keeping with myocarditis, without consideration of the CMR findings. 
Subclinical LM was defined as CMR evidence of myocardial tissue injury (as per Lake Louise 
criteria) without clinical features of LM.  Patients were divided into three groups, based on clinical 
and CMR parameters at inclusion: A. absence of CMR evidence of myocardial injury; B. presence 
of CMR evidence of myocardial injury with clinical LM; C. presence of CMR evidence of myocardial 
injury without clinical LM (subclinical). Data at follow-up were compared to parameters at the 
time of inclusion and compared among groups. All-cause mortality, interim hospitalisation and a 
new diagnosis of clinical LM were reported. The effect of intensified immunosuppression on CMR 
evidence of myocardial injury was evaluated.  
Ethical approval 
Written informed consent was obtained from all participants. The protocol was approved by the 
Health Research Ethics Committee of Stellenbosch University (Reference No: S16/01/002) and 
the study was conducted in accordance with the Declaration of Helsinki. 
Results 
Forty-nine patients were included in the original cohort.(25) Three patients were lost to follow-
up while ten patients died during the follow-up period. Mortality was related to SLE in two 
91
Stellenbosch University https://scholar.sun.ac.za
patients (neuropsychiatric SLE [NPSLE] and lupus nephritis [LN]) while five patients died due to 
infection related complications. In three patients the cause of mortality was unknown. Fifteen 
patients had 23 interim hospital admissions during the course of twelve months. Indications for 
hospitalisation included SLE flares/activity (n=14), antiphospholipid syndrome related 
thrombosis (n=3), infections (n=3) and other (non-SLE related; n=3). 
Clinical and laboratory follow-up detail 
A follow-up assessment was done in 36 patients after a mean of 363(±19.14) days. Patients were 
predominantly young females (32 female; 29[±9.8] years) with a median disease duration of 421 
days (range:325-8137). Details of baseline and follow-up clinical and laboratory results as well 
as chronic medication use are summarised in Table 1. Despite a significantly lower SLEDAI-2K 
at follow-up, 29 patients (80.6%) still had active disease (SLEDAI-2K≥3; median 7;IQR:3-11). 
At follow-up, more patients were on chloroquine whereas the median prednisone dosage was 
lower in the month preceding follow-up (Table 1). 
Imaging analyses at baseline and follow-up 
Echocardiographic functional parameters improved in the majority of patients (Table 2). 
Although the CMR left ventricular mass index (LVMi) and CMR left ventricular ejection fraction 
(LVEF) improved, parameters identifying myocardial tissue injury (T2-weighted signal, EGEr and 
LGE) did not change significantly from baseline to follow-up. 
Positive correlations were found between the delta (change in) CMR LVMi and delta T2-weighted 
and delta LV internal diameter index (LVIDi) (Figure 1A, B). A stronger positive correlation was 
found between delta CMR LVMi and delta T2-weighted signal in the subgroup (C) of patients with 
subclinical myocarditis at inclusion (r=0.636;p=0.048). There was also a trend towards a 
correlation between delta CMR LVMi and the delta SLEDAI-2K (Figure 1C). 
Outcome of patients with CMR evidence of myocardial injury: clinical and subclinical 
myocarditis  
23/49 patients had CMR evidence of myocardial injury at inclusion. A comparison of clinical and 
echocardiographic features of the three CMR/clinical groups is summarised in Table 3. Mortality 
was not significantly different between patients with CMR criteria for myocardial injury at 
inclusion versus those without. A single patient developed clinical LM during the follow-up 
period. This patient had no evidence of CMR tissue injury at inclusion.  
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Clinical LM with CMR evidence of myocardial injury 
9/49 patients had CMR evidence of myocardial injury with clinical features of myocarditis at 
inclusion (Table 3, group B).  Of these patients, two patients demised during the follow-up period, 
one due to sepsis. The second patient had no clinical signs of congestive cardiac failure (CCF) 91 
days after inclusion. No follow-up echocardiogram or CMR was done at the time. She defaulted 
immunosuppressive treatment and follow-up and demised at home 219 days after inclusion. LM-
related mortality could not be excluded.  
Of the nine patients with clinical LM at inclusion, follow-up clinical and imaging analyses were 
available in six patients (Table 3). No patient had residual clinical features of LM at follow-up. A 
single male patient had an interim admission with CCF within one month after his initial diagnosis 
of LM, with no residual clinical features of CCF at follow-up. 
The majority of functional echocardiographic parameters normalised in patients with clinical LM. 
This included LVEF (mean 52.7% ±8.2 to 60.2 ±3.7); wall motion score (WMS) (1.22±0.12 to 
1.01±0.03) and TAPSE (1.58cm ±0.41 to 2.05 ±0.36). The mean GLS remained impaired 
(baseline:-15.58% ±0.92; follow-up: -16.72 ±2.18) and normalised in only two patients. Although 
the mean LVIDi index was lower at follow-up (baseline:3.03 ±0.41; follow-up:2.88 ±0.28), it 
remained abnormal in 4/6 patients. 
Subclinical myocarditis: CMR evidence of myocardial injury without clinical myocarditis 
At inclusion, fourteen patients had CMR evidence of myocardial injury without clinical features of 
myocarditis (Table 3, group C).  Three patients died during the course of twelve months of which 
one was SLE-related (NPSLE), one secondary to septicaemia and one of an unknown cause. 
Mortality was not significantly different in comparison to other subgroups.  
Follow-up analysis was available in 10/14 patients. The presence of subclinical CMR myocardial 
injury at inclusion was not associated with the development of clinically evident LM during the 
course of follow-up. Clinical features at follow-up were not different from patients in other 
subgroups (Table 3). 
The mean LVIDi (all patients) did not significantly improve during the follow-up period (Table 2). 
This is also reflected by the significant difference still observed at follow-up in patients who had 
CMR evidence of myocardial injury (with and without clinical LM) and those without CMR 
evidence of injury at inclusion (Table 3). Other echocardiographic parameters at follow-up were 
similar among the subgroups. 
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Change in CMR tissue characteristics over time 
CMR tissue characteristics were compared at baseline and follow-up in the three CMR/clinical 
groups (Table 4; Group A-C). The CMR LVMi and LVEF improved in all three groups.  
Eight of 20 patients with no CMR evidence of myocardial injury at inclusion developed new 
criteria during the follow-up period (Figure 2A). This included a patient who developed LGE in a 
subendocardial distribution (total extent:12.5%) in keeping with an ischaemic event. She had no 
cardiovascular risk factors, no evidence of antiphospholipid syndrome and no cardiovascular 
symptoms at follow-up. 
A reduction in CMR criteria for tissue injury was observed in patients with myocardial injury at 
inclusion (Figure 2B, C). No new evidence of myocardial injury occurred in patients with initial 
clinical LM (Figure 2B). In patients with subclinical myocarditis (Figure 2C), EGEr normalised in 
three and remained unchanged in two patients. Two patients developed new increased EGEr. LGE 
resolved in two patients with new LGE developing in one patient.  
Overall, CMR evidence of myocardial injury persisted or developed de novo with one or more 
criteria present in 15 patients at follow-up v 16 at inclusion. 
A single patient continued to fulfil the CMR LLC for myocarditis at follow-up, despite the absence 
of clinical features of LM and significant improvement of all functional echocardiographic 
parameters. This included normalisation of LVEF (51 to 58%), WMS (1.25 to 1) and GLS (-13.2 to 
-21%). His LVIDi (2.89 to 2.94cm) and CMR LVMi (73.3 to 78.35g/m2) had however increased at 
follow-up.
Impact of intensified immunosuppressive therapy on CMR changes 
Twenty-five patients (51%) received intensified immunosuppressive therapy for SLE flares 
and/or active disease during the twelve-month period. Treatment consisted of prednisone at 
≥1/2mg/kg (n=24) and/or other immunosuppression (n=18) including CPM (n=5), MMF 
(n=3), combination therapy (CPM / MMF / azathioprine; n=3), azathioprine (n=5), rituximab 
(n=1) and methotrexate (n=1).  
The duration of follow-up (time) had a significant within-subjects effect on the CMR LVMi 
(p=0.012) and CMR LVEF (p=0.002) but not on other CMR parameters (similar to findings in 
Table 2). Intensified immunosuppression had no demonstrable between-subjects effect on the 




We have reported on the outcome of myocardial injury in SLE patients over a twelve-month 
period. Although patients showed significant improvement in SLE disease activity, the majority 
of patients continued to have active disease.   
Outcome of subclinical LM 
Ten patients had subclinical LM at inclusion. Whereas clinically evident LM is associated with an 
immediate risk of mortality and has a negative effect on overall survival and damage accrual, the 
prognostic implications of subclinical LM is not fully understood.(13)(2) In our cohort, no patient 
with subclinical LM developed clinically evident LM during the course of twelve months. Mortality 
as well as SLE disease activity and clinical SLE features at follow-up were similar among our three 
groups.  
A limited number of studies comment on the outcome of subclinical LM, focusing predominantly 
on CMR changes over time. In a study including a spectrum of auto-immune diseases, two out of 
four SLE patients had ongoing systemic disease which was associated with persistent abnormal 
T2 ratios on CMR (subclinical) despite immunosuppression.(26) Two additional studies found an 
improvement in T2-STIR and T2–relaxation over time was associated with improvement in SLE 
disease activity.(12)(27) In contrast to our patients however, patients at follow-up had inactive 
SLE. 
A clear correlation between subclinical myocardial injury and SLE disease activity is not 
consistently described.(27,28) In 110 SLE patients (50 newly diagnosed), CMR evidence of 
myocardial injury occurred irrespective of SLE disease activity.(9) LGE occurred in both recent 
as well as longstanding SLE patients, though more pronounced in patients with longstanding 
disease. A follow-up analysis was not done in this study population.  
In our own cohort, patients with subclinical LM had ongoing moderate disease activity after 
twelve months with only two out of ten patients having a low disease activity state (SLEDAI-
2K<3). Although we demonstrated a trend towards a reduction in the presence of CMR criteria as 
well as improved individual global parameters (T2-signal enhancement, EGEr and LGE), the 
persistence of CMR subclinical myocardial inflammation is likely explained by the associated 
persistence in SLE disease activity. 
Effect of intensified immunosuppression on CMR evidence of myocardial tissue injury 
We did not observe a significant effect of intensified immunosuppression during the interim 
period on CMR evidence of myocardial injury (including inflammatory changes). Although CMR 
criteria resolved in some patients (including inflammatory as well as necrotic / fibrotic changes), 
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other patients developed new criteria with no difference in exposure to intensified 
immunosuppressive therapy among CMR/clinical groups.  
Hinojar et al evaluated the effect of intensified immunosuppressive treatment on CMR changes in 
35 patients with suspected LM.(29) Patients who received intensified immunosuppression 
during the course of follow-up (six to twelve months) had a more significant improvement in 
native T1 and T2 values and a trend towards reduction in LGE extent. The LLC was not predictive 
of CMR treatment response on multivariable logistic regression analyses. It is however important 
to note that despite the fact that this particular cohort included only patients with clinically 
suspected LM, 92% of SLE patients had a SLEDAI of less than three at the time of inclusion. This 
stands in stark contrast to our cohort with a significantly higher SLEDAI-2K throughout the study 
(median 13 at inclusion and 7 at follow-up).  Despite these differences, the lack of a significant 
effect of immunosuppression on various LLC in our study mirrors the findings of Hinojar and 
colleagues.  
The inflammatory changes described in the LLC are expected to be reversible in contrast to less 
reversible LGE representing necrosis and fibrosis. Although the total extent of LGE was more at 
follow-up, six patients in our cohort showed improvement. This finding had also been described 
in the setting of viral myocarditis. In a follow-up study of 76 patients with acute myocarditis, a 
relative reduction in LGE extent of 42% was observed after 148 days.(30)  This is explained by 
the fact that lesions tend to shrink over time with a reduction in signal intensity associated with 
resolution of oedema and scar contraction. 
CMR LV mass index (LVMi) 
Over the twelve month period, CMR LVMi and CMR LVEF improved significantly (p=0.011 and 
<0.001 respectively) despite no significant improvement in morphological CMR parameters (T2-
weighted signal, EGEr, LGE).   
In patients with viral myocarditis, Zagrosek et al described a reduction in myocardial LV mass 
that was parallel to a reduction in signal intensity on T2-weighted images. No significant 
correlation was however observed between the two parameters.(31) Despite the heterogeneity 
of our cohort, including a spectrum of patients with and without CMR evidence of 
myocardial injury, we were able to demonstrate a positive correlation between the 
improvement in CMR LVMi and T2-weighted signal over the twelve-month period. This was 
most significant in patients with subclinical LM (Group C).  
This correlation has not been described in SLE associated myocardial injury and supports the 
theory that myocardial oedema, reflected by an increased T2-weighted signal, is associated with 
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an increased LV mass. It also suggests that CMR LVMi may provide an additional measure to 
monitor improvement in myocardial injury (clinically as well as subclinically) in SLE.  
CMR and echocardiographic functional parameters 
We have observed a disconnect between the change in functional (LVEF, TAPSE, CMR LVEF) and 
morphological (LVIDi, T2-weighted signal, EGEr, LGE) echocardiographic and CMR parameters 
over time. The functional improvement occurred regardless of persistence of structural / 
morphological changes described by CMR tissue characterisation and without significant 
improvement in echocardiographic WMS and GLS.  
It is well accepted that in both clinical as well as subclinical myocardial injury, global functional 
echocardiographic parameters such as LVEF may be unaffected in subtle / early stages of 
myocardial injury and are less sensitive than strain analysis (GLS), regional functional 
changes (WMS) or CMR evidence of injury.(6,11,12) The improvement of these more robust 
global functional parameters in our SLE cohort mirrors the lack of cardiovascular 
symptoms in the presence of CMR evidence of myocardial injury described typically in both 
clinical as well as post-mortem studies of SLE patients.(1,9) 
Limitations 
CMR was our diagnostic standard of myocardial injury without histological confirmation. 
Although endomyocardial biopsy (EMB) is regarded as the gold standard and a low risk 
procedure in experienced hands, the procedure remains invasive and could not be justified in the 
asymptomatic patient, a significant proportion of our cohort.(32)  
Although this is the largest known cohort of SLE patients with follow-up data, our numbers are 
limited, in particular within various subgroups. We are able to comment on trends 
while statistically significant results are limited by high confidence intervals. Our 
patients had persistent SLE disease activity over the follow-up period. Our results are 
therefore not applicable to SLE patients in clinical remission / with low disease activity. 
Native T1 and T2 mapping has been shown to add diagnostic benefit in patients with acute 
myocarditis.(33) In a 2018 update of the LLC, T1 and T2 mapping had been included whereas 
EGE was omitted, improving the diagnostic accuracy of the 2009 LLC.(34) Although T1 and T2 
mapping also has the ability to detect subclinical myocardial injury in SLE patients, software for 
these modalities were not available at our facility at the time of initiating our study and we have 




We have reported on the outcome of a cohort of SLE patients with and without CMR evidence of 
myocardial injury, including patients with clinical and subclinical LM. We have demonstrated 
persistence in CMR evidence of subclinical myocardial injury in SLE patients with moderate 
disease activity, regardless of improvement in other parameters including serological markers 
and global echocardiographic function. Our findings are in keeping with the disconnect seen in 
clinical features of SLE as well as cardiovascular symptoms (ante and post-mortem) and CMR 
evidence of myocardial injury. 
Our findings do not support subclinical myocarditis to be a precursor for the development of 
clinically evident LM. Over a period of twelve months, subclinical LM did not have any significant 
prognostic implications. These findings question the utility of CMR in SLE as a routine screening 
tool in the absence of clear clinical indications.   
Our data also do not provide any evidence that intensified immunosuppressive therapy has a 
significant impact on the outcome of the CMR changes seen in subclinical LM. There is therefore 
no evidence at this stage that subclinical LM according to CMR changes should dictate treatment 
in SLE.  
Improvement in CMR LVMi correlated with an improvement in T2-weighted signal representing 
myocardial oedema and may be used as an additional measurement in SLE myocardial injury, also 
in the follow-up of patients.  
Our results are limited to SLE patients with moderate disease activity after a follow-up period of 
twelve months with no apparent prognostic implications of subclinical LM. The long-term 
prognostic value of subclinical CMR myocardial injury in SLE needs to be studied over a longer 
period to guide our indications for screening as well as therapeutic decisions in the short term.   
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Comparison of baseline and follow-up characteristics including clinical features, 






Age (years) 29 (±9.80) 30 (±9.80) 1 
Hypertension 7 (19.4) 8 (22.2) 1 
Diabetes 1 (2.8) 1 (2.8) 1 
Dyslipidaemia 0 1 (2.8) 1 
Smoker 8 (22.2) 8 (22.2) 1 
Antiphospholipid 
syndrome 6 (16.7) 9 (25) 0.375 
Cardiovascular risk 
factors (any) 12 (33.3) 14 (38.9) 0.500 
SLE detail Baseline 
Median (IQR) or 
n (%) 
Follow-up 
Median (IQR) or 
n (%) 
p 
SLEDAI-2K 13 (9-20) 7 (3-11) <0.001 
SDI 0 (0-1.75) 1 (0-2.0) 0.075 
Mucocutaneous 
manifestations 24 (66.7) 18 (50) 0.180 
Haematological 
manifestations 30 (83.3) 29 (80.6) 1 
Musculoskeletal 
manifestations 18 (50) 9 (25) 0.012 
NPSLE 5 (13.9) 2 (5.6) 0.375 
Lupus nephritis 
• Class III/IV





Clinical lupus myocarditis  7 (19.4) 1 (2.8) 0.070 
Vasculitis 6 (16.7 3 (8.3) 0.453 
Laboratory results Baseline 
Mean (SD) or Median (IQR) 
Follow-up 
Mean (SD) or Median (IQR) 
p 
White cell count (x109/L) 6.73 (3.97-9.40) 5.68 (4.02-7.66) 0.293 
Lymphocyte count 
(x109/L) 1.05 (0.51-1.79) 1.13 (0.71-1.82) 0.768 
Haemoglobin  (g/dl) 9.51 (±1.98) 11.14 (±2.11) 0.004 
Platelet count (x109/L) 293 (214-402) 267 (206-363) 0.540 
ESR (mm/1st hour) 64 (33-108) 43 (28-65) 0.065 
CRP (mg/L) 23 (9-60) 12 (2.5-26) 0.015 
eGFR (ml/min/1.73m2) 125.29 (±26.24) 120.31 (±25.54) 0.063 
Albumin (g/L) 31 (±0.01) 40 (±3.48) 0.001 
UPCR (g/mmol) 0.56 (0.27-1.25) 0.29 (0.16-0.51) 0.004 
CK (IU/L) 35 (25-58) 80 (46-117) 0.004 
Hs-tropT (ng/L) 8 (4-21) 5 (3-10) 0.045 
ANA titre 1280 (320-1280) 640 (80-1280) 0.046 
Anti-SM antibody U/ml 49.4 (4.15-114.98) 18.1 (2.8-96.68) 0.016 
Anti-dsDNA antibody 
IU/ml 144 (66.25-176.25) 118.5 (28.75-148) 0.004 
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Anti-RNP antibody U/ml 110.15 (12.95-217.25) 37.8 (5.58-145.5) 0.001 
Anti-Ro/SSA U/ml 25 (3.13-91.28) 8.15 (2.48-37.4) 0.019 
Anti-La/SSB U/ml 6.55 (2.08-16.7) 2.3 (1.33-6.33) 0.041 
ACA (IgG) U/ml 5 (4-8) 5 (5-7) 0.108 
LA ratio 1.07 (0.89-1.19) 1.16 (1.04-1.46) 0.601 
aB2GP1 U/ml 1.9 (1.2-3.4) 1.3 (0.9-2.5) 0.048 
C3 0.81 (0.49-1.38) 1.02 (0.79-1.43) 0.334 
C4 0.11 (0.05-0.22) 0.15 (0.09-0.26) 0.010 








treatment 10 (27.8) 16 (44.4) 0.180 
Statin 0 1 (2.8) 1 
Aspirin 0 0 1 
Warfarin 1 (2.8) 8 (22.2) 0.016 
Diabetic medication 0 0 1 
Chloroquine 16 (44.4) 34 (94.4) <0.001 
Prednisone median dose 
(IQR) 15.25 (7.25-31.5) 8.75 (0-15) 0.015 
Immunosuppressive 
treatment 6 (16.7) 8 (22.2) 0.774 
SD: standard deviation; SLE: systemic lupus erythematosus; SLEDAI-2K: SLE disease activity index; SDI: 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) 
Damage Index; NPSLE: neuropsychiatric lupus; ESR: erythrocyte sedimentation rate; CRP: C-reactive 
protein; eGFR: estimated glomerular filtration rate; UPCR: urinary protein creatinine ratio: urinary 
protein creatinine ratio; CK: creatine kinase; Hs-tropT: high-sensitive troponin T; ANA: antinuclear 
antibody; anti-SM: anti-smith; anti-dsDNA: anti-double stranded DNA; anti-RNP: anti-ribonuclear protein; 












(95% CI of difference) 
LVID index by BSA 
(cm/m2) 
2.69 (±0.49) 2.70 (±0.38) 0.946 (-0.117 to 0.109) 
LVEF (%) 55 (±8) 58 (±7) 
0.014 (-7.130 to 
-0.870)
MA E/E’ 7.41 (±2.29) 7.51 (±2.36) 0.836 (-0.653 to 0.803) 
TAPSE (cm) 1.86 (±0.36) 2.12 (±0.40) 
0.001 (-0.406 to 
-0.114)
WMS median (range) 1.0 (1.0-2.0)a 1.0 (1.0-1.438) 0.056 
STE GLS (%) -16.032 (±3.208) -17.117 (±3.912) 0.092 (-0.241 to 0.980) 




p (95% CI) 
CMR LV Mass index 66.10 (±15.35) 59.34 (±16.49) 0.011 (1.62  to 11.91) 
CMR LVEF 54.86 (±9.32) 63.42 (±7.54) 
<0.001 (-12.81 to -
4.30) 
T2-weighted signal global 1.549 (±0.335) 1.438 (±0.329) 0.181 (-0.055 to 0.278) 
EGEr (global) 2.779 (±1.465) 2.992 (0.956) 0.396 (-0.838 to 0.341) 
LGE extent (%) median 
(range) 
0.0 (1.56-12.5)a 0.0 (0-12.5) 0.066 
SD: standard deviation; IQR: interquartile range; LVID: left ventricular internal diameter; BSA: body surface 
area; LVEF: left ventricular ejection fraction; MA: mitral annular; E/E': ratio of mitral peak velocity of early 
filling (E) to early diastolic mitral annular velocity (E'); TAPSE: tricuspid annular plane systolic excursion; 
WMS: wall motion score; STE: speckle tracking echocardiography; GLS: global longitudinal strain; CMR: 
cardiac magnetic resonance; LV: left ventricular; EGEr: early gadolinium enhancement ratio; LGE: late 
gadolinium enhancement  
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Table 3  
Outcome of clinical and subclinical myocardial injury groups: comparison of clinical and 
echocardiographic parameters after twelve months 
CMR/clinical  groups according to baseline CMR criteria for myocardial injury 
GROUP A 













compared to A 
GROUP C 




 n (%) 
p 
Significance 
compared to A 
Baseline total n=49 n=26 n=9 n=14 
Mortality 
SLE related 
5/26  (19.2) 
1/5 (20) 
2/9  (22.2) 
0/2  (0)
0.847 3/14 (21.4) 
1/3  (33.3) 
0.868 
Group A Group B p 
Significance  
compared to A 
Group C p 
Significance 
Compared to A 
Follow-up feature 
total n=36 
n=20 n=6 n=10 
SLEDAI-2K 8 (4-11) 4 (1-6) 0.176 7 (4-11) 0.588 
DELTA SLEDAI-2Ka -5 (-9 to -1) -18 (-27 to -9) 0.039 -3 (-9 to -1) 0.73 
SDI 1 (0-2) 2 (0-2) 0.656 1 (0-3) 0.588 
Clinical lupus myocarditis 
on follow-up 
1/20 (5) 0/6 0.576 0/10 0.472 
LN 1/20 (5) 1/6 (16.67) 0.347 1/10 (10) 0.605 
NPSLE 1/20 (5) 0/6 0.576 1/10 (10) 0.605 
Haematological 17/20 (85) 5/6 (83.3) 0.921 7/10 (70) 0.333 
Musculoskeletal 7/20 (35) 1/6 (16.67) 0.393 1/10 (10) 0.144 
Mucocutaneous 11/20 (55) 3/6 (50) 0.829 4/10 (40) 0.439 










p (95% CI)a 
Significance 




p (95% CI)a 
Significance 
compared to A 
LVID index by BSA 
(cm/m2) 
2.5 (±0.31) 2.88 (±0.28) 0.013 
(-0.679 to -
0.088 
3.0 (±0.32) <0.001 
(-0.76 to -0.26) 
MA E/E’ 8.03 (±2.16) 8,32 (±3.08) 0.791 (-0.30 to 
1.11) 
5.97 (± 1.68) 0.014 (0.45 to 
3.66 
LVEF (%) 59.79 (±7.13) 60.17 ( ±3.66) 0.867 (-5.04 to 
4.29) 




WMS 1.072 (±0.139) 1.010 (±0.026) 0.78 (-0.01 to 
0.13) 
1.025 (±0.060) 0.213 (-0.03 to 
0.12) 
TAPSE (cm) 2.16 (±0.46) 2.05 (±0.36) 0.614 (-0.32 to 
0.53) 
2.1 (±0.32) 0.743 (0.28 to 
0.39) 
STE GLS (%) -17.21 (±4.24) -16.84 (±3.78) 0.859 (-4.75 to 
3.99) 
-17.08 (±3.72) 0.937 (-3/56 to 
3.30) 
CMR: cardiac magnetic resonance; SLEDAI-2K: SLE disease activity index;  DELTA SLEDAI-2K: difference 
between baseline and follow-up SLEDAI-2K (negative value implies improvement); SDI: Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; LN: 
lupus nephritis; NPSLE: neuropsychiatric lupus; LVID: left ventricular internal diameter; BSA: body surface 
area; MA: mitral annular; E/E': ratio of mitral peak velocity of early filling (E) to early diastolic mitral 
annular velocity (E'); LVEF: left ventricular ejection fraction; WMS: wall motion score; TAPSE: tricuspid 
annular plane systolic excursion; STE: speckle tracking echocardiography; GLS: global longitudinal strain; 




Comparison between baseline and follow-up CMR parameters in clinical and subclinical 
myocardial injury groups:  
CMR / clinical  groups according to  




Baseline no CMR 
criteria and without 
cLM  
(n=20) Mean (±SD) 
GROUP B 
Baseline CMR 
criteria with cLM 
(n=6) Mean (±SD) 
GROUP C 
Baseline CMR criteria 
without cLM 
(subclinical) 
(n=10) Mean (±SD) 
Baseline Follow-up Baseline Follow-up Baseline Follow-up 















CI: -1.76 to 14.81 
p=0.135 
CI: -4.30 to 23.79 
p=0.166 
CI: -2.7 to 13.60 















CI: -11.17 to -1.08 
p=0.008 
CI: -30.0 to -7.52 
p=0.155 
CI: -17.95 to 3.35 

















CI -0.09 to 0.84 
p=0.051 
















CI -1.46 to -0.13 
p=0.716 
CI -1.48 to 1.98 
p=0.355 













pa p=0.063 p=0.176 p=0.414 
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CMR: cardiac magnetic resonance; cLM: clinical lupus myocarditis; SD: standard deviation; LV: left 
ventricular; CI: confidence interval; LVEF: left ventricular ejection fraction; EGEr: early gadolinium 
enhancement ratio; LGE: late gadolinium enhancement  
aSignificance: follow-up compared to baseline parameter 
  CI% confidence interval of the difference from baseline to follow-upb
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Figures 1 A-C 
Scatter plots depicting correlations between the change in the LV CMR mass index over twelve 
months (Delta CMR LV mass index) and the change in the T2-weighted signal (2A), change in 





 Figure 1C 
Delta: change from base line to follow-up; negative value represents improvement; CMR: cardiac 
magnetic resonance; LV: left ventricular; LVIDi: left ventricular internal diameter index (indexed for body 
surface area); SLEDAI-2K: Systemic lupus erythematosus disease activity index 2000
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Figure 2A  
Bar charts depicting change in CMR criteria from inclusion to follow-up in 20 patients with no 
CMR evidence of myocardial injury and no clinical LM at inclusion (Group A) 
Figure 2B 
Bar charts depicting change in CMR criteria from inclusion to follow-up in six patients 
with clinical LM and CMR myocardial injury at includion (Group B) 























Bar charts depicting change in CMR criteria from inclusion to follow-up in 10 patients 
with subclinical CMR myocardial injury at inclusion (Group C)  
EGEr: resolved in 3/5 patients, 2 persisted (unchanged) and two patients developed new 
increased EGEr; LGE: two resolved and one new 
CMR: cardiac magnetic resonance; LM: lupus myocarditis; EGEr: early gadolinium enhancement 













SUMMARY OF FINDINGS 
CHAPTER 1 
Clinical features and outcome of lupus myocarditis in the Western Cape, South Africa. 
Key findings 
In this retrospective analysis, medical records of 457 patients with systemic lupus erythematosus 
(SLE) attending the rheumatology clinic at Tygerberg Hospital between January 2008 and 
January 2014 were screened for inclusion. Lupus myocarditis (LM) was defined as clinical and 
echocardiographic evidence of impaired myocardial function attributed to active SLE.  
All available echocardiographic images (at diagnosis and most recent available) were retrieved 
from a digital image archive and re-analysed by a clinician experienced in echocardiography. 
The re-analysis included regional wall motion abnormalities (WMA) based on the 16-segment 
model.  
Twenty-eight patients (6.1%) met inclusion criteria. The majority of patients were female 
(92.9%) patients of mixed racial ethnicity (89.3%). Fifty-three per cent of patients presented 
within three months after being diagnosed with SLE and 75% had severely active disease (SLE 
disease activity index [SLEDAI] ≥12).  Concomitant lupus nephritis (LN) was present in 19/28 
patients. Clinical features of LM included congestive cardiac failure (CCF) (86%) and 
tachycardia (92.9%) while three patients (10.7%) presented in cardiogenic shock. Troponin-I 
levels were more frequently increased than creatine kinase (CK) levels (16/22 versus 10/25). 
On echocardiographic analyses, the left ventricular internal diameter (LVID) was preserved in 
60.7% of patients at diagnosis. Diastolic dysfunction and regional wall motion abnormalities 
(WMA) were present in >90% of patients. Seventeen patients (63%) presented with a left 
ventricular ejection fraction (LVEF) ≤35% while 25.9% of patients had a normal / mildly 
impaired LVEF (≥45%). 
Follow-up data was available after a median of 563 days (range: 4-1740) and a follow-
up echocardiogram was available in 19 patients (med 390 days; IQR: 93-680).  The LVEF 
improved from 35% to 47% (p=0.023) and wall motion score index from 1.88 to 1.5 
(p=0.017) following treatment. Overall mortality was high (12/28): five patients 
(17.9%) died due to lupus myocarditis (bimodal pattern). LVEF at diagnosis was lower in 




At the time of publication, this was the largest reported series on LM and the first in the South 
African context. In comparison to published data on LM, we found a similar prevalence but 
high mortality in a cohort of SLE patients from a predominantly mixed racial ancestry.(1,2) 
Lupus nephritis (LN) is known to be disproportionately more frequent and more severe 
in this population compared to LN in other ethnic groups.(3,4) Our study is the first to 
report on the poor outcome of LM in this particular population. Mortality due to LM was 
bimodal: patients either died soon after presenting with LM or at least 18 months later due to a 
relapse. 
Patients presented early in the course of their SLE and had a high disease activity. More than 
two thirds of our patients had concomitant LN, in keeping with what had been reported 
in the literature.(2,5) This high frequency of LN in association with LM could be 
explained by the common role of immune complex deposition in the pathogenesis of these 
serious manifestations of SLE. (6,7) 
Our study highlights some of the diagnostic challenges of LM. Clinical features vary from 
subtle (resting tachycardia) to cardiogenic shock while markers of myocyte injury (creatine 
kinase and troponin-I) may be normal. On echocardiographic evaluation, the majority of our 
patients had a non-dilated left ventricle (LV) (60.7%) and 25.9% had relative preservation of 
global LV function. These results emphasise the relative insensitivity of using LV dimensions 
and LV ejection fraction (LVEF) as isolated parameters in the diagnosis of early / subtle LM. On 
the other hand, more than 90% of our patients had diastolic dysfunction and WMA were 
detected in all 24 patients where this measurement was possible. These parameters 
should be regarded as standard measurements when assessing an SLE patient with 
suspected LM. 
A lower LVEF at diagnosis was found to be of prognostic significance, associated with both 
LM-related mortality as well as a persistent LVEF<40% following treatment, emphasising 
the importance of an early diagnosis prior to the development of significant LV dysfunction.  
Limitations 
Our study was a retrospective design that was limited by relatively small numbers. Re-analysis 
of all echocardiographic images was not always possible due to poor quality of the images and / 
or lack of appropriate views. At the time of the echocardiographic re-analysis, patients had a 
known diagnosis of LM. This could have led to expectation bias and /or diagnostic suspicion 




A prospective, multi-ethnic study in the South African context might enable us to identify specific 
independent predictors of a poor outcome of LM. Considering the high mortality found in our 
cohort, the entity of subclinical myocardial injury /subclinical LM remains an important area of 
interest.  Prospective studies will determine whether subclinical LM predicts the future 
development of clinically evident LM and whether the progression to clinical LM could be altered 
by early immunosuppressive therapy. 
CHAPTER 2 
Speckle tracking echocardiography in acute lupus myocarditis: comparison to 
conventional echocardiography 
Key findings 
In the same cohort of patients, echocardiographic re-analyses included the addition of global 
longitudinal strain (GLS) assessment through speckle tracking echocardiography (STE). Results 
were compared to that of a healthy control group, matched to our patient group with regards to 
age, gender and ethnicity.  
GLS correlated with both global (left ventricular ejection fraction (LVEF): r=-0.808; p=0.001) and 
regional (wall motion score index (WMSi): r=0.715; p<0.001) left ventricular function.  A weak 
correlation was seen between GLS and renal function (glomerular filtration rate: r=-0.502; 
p=0.081) but neither in other laboratory nor clinical parameters (including SLE disease activity). 
In patients presenting with a preserved LVEF (≥50%), the GLS (p=0.023), WMSi (p=0.005) and 
diastolic function (early diastolic mitral annular velocity) (p=0.004) were significantly impaired 
in comparison to the control group. Following treatment, significant improvement was seen in 
the LVEF (35% to 47% [p=0.023]) and WMSi (1.88 to 1.5 [p=0.017]) but not GLS. The initial LVEF 
(p=0.046) and GLS (p=0.095) were more impaired in patients with a poor cardiac outcome (final 
LVEF<40%). 
Conclusion    
To the best of our knowledge, this is the first report on the use of STE in a series of SLE patients 
with clinically evident lupus myocarditis. Our patients were predominantly young females with a 
recent onset of SLE and a high SLEDAI. At the time of diagnosis, we observed strong correlations 
between GLS (analysed by STE) and other parameters of LV function, including LVEF and the 
WMSi. In contrast to previous reports, GLS did not correlate with SLE disease activity.(8)  
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We have observed a weak correlation between renal function and GLS. Although 67.9% of our 
patients had concomitant LN, renal involvement was of recent onset and in the absence of 
advanced renal dysfunction (median glomerular filtration rate 122ml/min/1.73m2 (IQR:56-
168)). LV dysfunction is well described in end stage renal disease where impaired GLS is of 
diagnostic and prognostic value.(9) The possible correlation between mild, recent onset renal 
impairment and LV dysfunction, specifically impaired GLS has not previously been described.  
We demonstrated a significant improvement in both the LVEF and wall motion score following 
treatment for myocarditis, in contrast to GLS and diastolic parameters which did not improve 
significantly. Our findings are in keeping with previous reports demonstrating that GLS may 
detect myocardial dysfunction in SLE in the absence of other abnormalities on 
echocardiography.(8) 
Both a poor GLS and in particular LVEF at presentation were associated with a poor 
echocardiographic outcome (final LVEF<40%). In LM patients who presented with a relatively 
preserved LVEF (≥50%), the WMSi, GLS and diastolic functional parameters were significantly 
impaired compared to a control group, enabling recognition of more subtle myocardial 
dysfunction. STE provides us with an additional non-invasive, cost effective tool that adds to the 
diagnostic and prognostic value of echocardiography in patients with clinically evident LM. 
Limitations 
Our patients were hospitalized, symptomatic SLE patients. The results can therefore not 
be generalised to asymptomatic SLE patients with possible subclinical myocardial dysfunction. 
None of our patients had histological confirmation of their myocarditis. We are therefore not 
able to exclude other causes of cardiomyopathy including undiagnosed antiphospholipid 
syndrome with microthrombosis or microvascular occlusion with 100% certainty.(11) Patients 
included into the study had a known diagnosis of lupus myocarditis which could have led to 
expectation bias or diagnostic suspicion bias in the re-analysis of the echocardiographic data. 
Future research 
The diagnostic role of echocardiographic parameters including STE and WMSi as earlier, 
more sensitive parameters in clinical lupus myocarditis should be defined more clearly 
through prospective studies. The sensitivity and specificity of these echocardiographic 
parameters for the presence of LM could be evaluated through the inclusion of an 




Myocardial injury in systemic lupus erythematosus according to cardiac magnetic 
resonance tissue characterisation: clinical and echocardiographic features 
Key findings 
In this prospective cross-sectional study, a cohort of systemic lupus erythematosus 
(SLE) inpatients underwent cardiovascular magnetic resonance (CMR) screening for the 
presence of myocardial tissue injury according to the 2009 Lake Louise criteria (LLC).(12)  
One hundred and six SLE patients were screened between August 2016 and May 2018 of 
whom 49 patients were included. A total of 57 patients were excluded due to intolerance of 
or contra-indications to CMR.(13) Out of the 57 patients excluded, 27 were due to renal 
impairment.  
Patients included were predominantly young females (87.8%; mean age 29 years; SD±11) with 
a high SLE disease activity (median SLEDAI-2K:13; IQR:9-19.5). Nine patients had clinical 
lupus myocarditis (LM), defined as clinical features of myocardial dysfunction 
supported by echocardiography and biochemical markers in keeping with myocarditis, 
without consideration of the CMR findings. Twenty-three patients (46.9%) had CMR 
evidence of myocardial injury (presence of one or more LLC).  In 14/23 patients CMR evidence 
of myocardial injury occurred in the absence of clinical myocarditis, i.e. subclinical.  
Compared to patients without myocardial injury, patients with any evidence of myocardial 
injury (≥1 LLC; n=17) were more frequently anti-dsDNA positive (p=0.026) and patients 
fulfilling the LLC for myocarditis (≥2 LLC; n=6) had a higher SLE disease activity (p=0.022). The 
majority of laboratory and clinical parameters including treatment were not significantly 
different between groups. 
On multivariable logistic regression analyses, echocardiographic right ventricular 
function (tricuspid annular plane systolic excursion [TAPSE]) predicted inflammatory 
CMR changes (OR:0.045; p=0.006; CI:0.005-0.415) and global longitudinal strain (GLS) 
(assessed by speckle tracking echocardiography) predicted necrosis / fibrosis (OR:1.329; 
p=0.031; CI1.026-1.722). A model including the absolute lymphocyte count, TAPSE and left 
ventricular internal diameter index (LVIDi) was predictive of an increased early gadolinium 
enhancement ratio (EGEr) on CMR (ROC-curve analyses: Area under the curve: 0.901; 
p<0.001; sensitivity: 88.9%; specificity: 76.3%) with a negative predictive value of 97.4%. 
Conclusion 
We have reported one of the largest series of myocardial injury in SLE, and one of a 




injury frequently occurred and was subclinical in 28.6% of our cohort. Our findings are in keeping 
with reports of  myocardial injury seen in the lupus heart at autopsy.(16,17)  
Although inflammatory injury detected by CMR was associated with an SLE flare and lower 
lymphocyte count, the majority of clinical and laboratory parameters correlated poorly with 
myocardial injury according to CMR tissue characterisation. This disconnect between typical 
cardiac symptoms, SLE activity and myocardial involvement on CMR has also been described by 
other authors. The CMR changes observed may be a reflection of the persistent burden of 
inflammation in active SLE, irrespective of organ specific clinical manifestations.(18–20) 
Despite clear benefits, the utility of CMR in SLE is limited in clinical practice. We excluded 54% of 
the SLE patients screened for our study, the majority due to contra-indications to or intolerance 
of CMR. Confusion due to neuropsychiatric SLE, cardiorespiratory distress as well as a high 
incidence of LN and subsequent risk of nephrogenic systemic fibrosis, limits CMR as a diagnostic 
tool in SLE. 
Our multivariable analyses identified models predictive of myocardial inflammation, in particular 
an increased EGEr. Echocardiographic right ventricular dysfunction (including TAPSE) is known 
to be an independent predictor of adverse cardiac outcomes in patients with heart failure with a 
preserved ejection fraction. As far as we are aware, the association with and predictive value of 
TAPSE for the presence of EGE in SLE have not been described before. As a simple 
echocardiographic measure with low interobserver variability, the assessment of TAPSE in 
patients with SLE may provide a useful screening measure to identify patients with myocardial 
injury.  
Our predictive models, including echocardiographic parameters (TAPSE and LVIDi) were 
sensitive for the detection of potentially reversible inflammatory changes on CMR while GLS 
assessed by speckle tracking echocardiography was associated with fibrosis/necrosis. 
Echocardiography can be used as a cost-effective screening tool with a high negative predictive 
value, in particular when CMR is contra-indicated or unavailable.  
Limitations 
Our study included a spectrum of patients with moderate to high SLE disease activity, 
underrepresenting patients with low disease activity. The exclusion of a significant number of 
patients due to intolerance of or contra-indications to CMR may have contributed to selection 
bias. This does however reflect the practical limitations of CMR with gadolinium use in 
the management of sick SLE patients.  We acknowledge that T2-weighted imaging may be 
limited by a low signal-to-noise ratio and is susceptible to arrhythmia and motion artifact. 
Despite these limitations, T2-STIR has a high negative predictive value for myocardial 




Native T1 and T2-mapping are pixel-based CMR techniques that detect clinical and 
subclinical myocardial injury in SLE as well as non-SLE patients.(22,23) T1 and T2-mapping do 
not require the use of gadolinium and are useful alternatives in patients where 
gadolinium use is cautioned against.  In a 2018 update of the LLC, the use of T1 and T2-
mapping replaced EGE as diagnostic parameters, increasing the specificity of the 
criteria for the diagnosis of acute myocardial inflammation.(21) Software for these CMR 
modalities was not available at our facility at the time of initiating our study. Future 
studies including these techniques would enable us to also utilise CMR in SLE patients with 
concomitant renal impairment.  The relevance and long-term consequences of in particular 
subclinical myocardial injury need to be evaluated through further follow-up studies. This 
entity will be explored further in Chapter 5. 
CHAPTER 4 
Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. 
Key findings 
Despite expanding knowledge on the spectrum of cytokines acting as role players and potential 
biomarkers of organ specific manifestations in systemic lupus erythematosus (SLE), 
literature exploring the immunopathogenetic pathways of myocardial injury in SLE is limited.  
In this prospective cross-sectional study, serum cytokine levels (interleukin [IL]-1 beta (β), IL-1 
receptor antagonist [IL-1Ra], IL-2, IL-6, IL-10, IL-17, IL-18 and tumour necrosis factor [TNF]-
alpha),  markers of endothelial activation  (serum vascular cell adhesion molecule-1 
[sVCAM-1]) and markers of myocyte strain (soluble suppressor of tumourgenesis two [sST2]) 
were measured in a cohort of hospitalised SLE patients. Cardiovascular magnetic 
resonance imaging (CMR) was performed on all patients, identifying different stages 
of myocardial injury (inflammation and necrosis/fibrosis) according the 2009 Lake Louise 
criteria.(12)  
Forty-one patients with high SLE disease activity (median SLEDAI-2K:13; IQR:3-17) 
were included. Clinical features of SLE included lupus nephritis (LN) (n=12), 
neuropsychiatric SLE (n=6) and clinically evident lupus myocarditis (LM) (n=6). Nineteen 
patients had CMR evidence of myocardial injury. Inflammatory changes were present in 
13/19 patients (68.4%) while evidence of myocyte necrosis/fibrosis with late gadolinium 
enhancement (LGE) was present in 9/19 patients (47.4%). 
Increased serum levels of interleukin-18 (IL-18) (p=0.003), IL-1 receptor antagonist 
(IL-1Ra) (p=0.012) and IL-17 (p=0.045) were observed in SLE  patients  with  CMR  evidence of
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myocardial injury compared to those without. On multivariable logistic regression analyses, 
IL-1Ra was independently associated with inflammatory as well as necrotic/fibrotic myocardial 
tissue injuryon CMR. Anti-Ro/SSA (OR: 1.197; p=0.035) and the SLE damage index (OR: 4.064; 
p=0.011) were significant predictors of fibrosis/necrosis. As an individual parameter, an anti-
Ro/SSA antibody titre of ≥80 IU/ml had a sensitivity of 77.8% and specificity of 75% for the 
detection of LGE on CMR (area under the curve: 0.729; p=0.009; 95% CI: 0.528-0.930). 
Conclusion 
As far as we are aware, this is the first study to describe an association between specific 
serum cytokines and myocardial injury in SLE, identified by CMR tissue characterisation. 
Considering the pathogenetic role of IL-18 in the progression of viral myocarditis, our findings 
identified IL-18 as a possible role player in the pathogenesis of myocardial injury in SLE as 
well.(24,25) In contrast to previous reports, we did not observe a significant association 
between increased IL-18 levels and the presence of LN.(26) Our results may however be 
influenced by the fact that we have excluded patients with potentially more aggressive LN and 
associate renal impairment (due to contra-indications to gadolinium contrast use). 
Inflammatory bowel disease and rheumatoid arthritis are two of the various auto-
immune diseases linked to an imbalance between IL-1 and its natural antagonist, IL-1Ra.(27,28) 
Increased levels of IL-1Ra are found in SLE patients in comparison to controls, and even 
higher levels in patients with LN.(29,30) IL-1 has the ability to induce cardiac myocyte 
apoptosis and is known to have a negative inotropic effect.(31) Reduced IL-1Ra gene 
expression also occurs in the left ventricle of patients with a dilated cardiomyopathy 
compared to controls.(32) On multivariable logistic regression analyses, we found IL-1Ra to be 
independently associated with different stages of myocardial injury according to CMR tissue 
characterisation. Our findings support the possible role of IL-1Ra/IL-1 in the pathogenesis of 
SLE associated myocardial injury. 
Maternal anti-Ro/SSA antibodies are associated with inflammation, apoptosis and myocardial 
fibrosis in cases of fatal congenital heart block.(33) Evidence is also growing for conduction 
disturbances in the adult SLE patient with anti-Ro/SSA positivity.(34) Although we found no 
association between anti-Ro/SSA antibodies and conduction abnormalities, the anti-Ro/SSA 
antibody titre was predictive of fibrosis (LGE) in the multivariable regression analyses. As an 
individual parameter, an anti-Ro/SSA antibody titre of ≥80 IU/ml had a sensitivity of 77.8% and 
specificity of 75% for the detection of LGE on CMR. This novel description of an association 
between anti-Ro/SSA antibodies and LGE (representing myocardial fibrosis) may suggest a 
mechanism of injury to the adult myocardium, similar to what was described in the foetal 




Patients included were hospitalised SLE patients with predominantly active SLE, limiting the 
generalisation of our findings. Patients with significant renal impairment were excluded from our 
study due to contra-indications to gadolinium use. Our patients may therefore not represent the 
full spectrum of patients with LN and their associated cytokine profiles.   
We have based tissue characterisation on validated CMR criteria and not endomyocardial biopsy 
(EMB). Although EMB is regarded as the gold standard and a low risk procedure in experienced 
hands, it remains an invasive procedure. The majority of our patients did not have clinical 
features of myocarditis and performing an EMB could therefore not be justified.  
Future research 
Our study was a cross-sectional design with analyses done at a single time point. The relevance 
of observed associations with and predictors of chronic CMR changes need to be evaluated 
further by longitudinal cohort studies.  
The associations between reduced IL-1Ra/IL-1 and non-lupus cardiomyopathy as well as 
inflammation in other auto-immune conditions have all been demonstrated with regards to tissue 
IL-1Ra/IL-1 expression. Studies on IL-1Ra in SLE, including our own, have measured circulating 
levels of IL-1Ra rather than tissue expression. Future research in patients with clinically evident 
LM involving endomyocardial biopsy to evaluate myocardial tissue expression of IL18 and IL-
1Ra/IL-1 may provide better insight into the exact pathogenetic role of these cytokines in the 
development of myocardial injury in SLE and ultimately open the door to more targeted 
immunosuppressive therapies for LM.  
CHAPTER 5 
Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus – a 
prospective cohort study 
Key findings 
Chapter five focuses on the follow-up results of our prospective cohort study. Patients 
were divided into three groups based on clinical and cardiovascular magnetic resonance 
(CMR) parameters at the time of inclusion:         
• absence of CMR evidence of myocardial injury
• presence of CMR evidence of myocardial injury with clinical lupus myocarditis (LM)
• presence of CMR evidence of myocardial injury without clinical LM (subclinical)
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Data at follow-up were compared to parameters at the time of inclusion and compared among 
groups. All-cause mortality, interim hospitalisation and a new diagnosis of clinical LM 
were reported. The effect of intensified immunosuppression during follow-up on CMR 
evidence of myocardial injury was evaluated.   
Of the 49 patients included in the original cohort, three patients were lost to follow-up 
whereas ten patients died during the follow-up period. Mortality was related to 
systemic lupus erythematosus (SLE) in two patients (neuropsychiatric SLE [NPSLE] and 
lupus nephritis [LN]) while five patients died due to infection related complications. The 
cause of mortality was unknown in three patients. Mortality was similar between patients 
with and without CMR evidence of myocardial injury.   
A follow-up assessment was done in 36 patients after a mean of 363 days (±19.14) including 
clinical, laboratory and imaging evaluation. SLE activity (SLEDAI-2K) improved from 13 (median; 
IQR:9-20) to 7 (IQR:3-11) (p<0.001). The presence of subclinical CMR myocardial injury at 
inclusion was not associated with the development of clinically evident LM during the course of 
follow-up. A single patient developed clinical LM during the follow-up period. The patient had no 
CMR evidence of myocardial injury at the time of inclusion. Clinical features at follow-up were not 
significantly different between the various subgroups.  
Echocardiographic left ventricular ejection fraction (LVEF) (p=0.014), right ventricular function 
(tricuspid annular plane systolic excursion [TAPSE]) (p=0.001) and regional wall motion 
abnormalities (p=0.056) improved significantly after twelve months but not strain analyses 
(global longitudinal strain [GLS]) nor the left LV internal diameter index (LVIDi).  
CMR LV mass index (p=0.011) and CMR LVEF (p<0.001) improved with follow-up but not 
parameters identifying myocardial tissue injury according to the Lake Louise criteria (T2-
weighted signal and/or increased early gadolinium enhancement ratio (EGEr) and late 
gadolinium enhancement (LGE)). A change in CMR LV mass index over twelve months correlated 
with the change in T2-weighted signal (myocardial oedema) (r=386;p=0.024).  
A trend towards a reduction in the presence of CMR criteria was counterbalanced by persistence 
(n=7) /development of new criteria (n=11) in patients. Overall, CMR evidence of myocardial 
injury persisted or developed de novo with one or more criteria present in 15 patients at follow-
up v 16 at inclusion.  
Twenty-five patients (51%) received intensified immunosuppressive therapy during the twelve-
month period for SLE flares and/or active disease. Intensified immunosuppression had no 




We have reported on the 12-month outcome of a cohort of SLE patients with and without CMR 
evidence of myocardial injury, including patients with clinical and subclinical LM. Despite a 
significantly lower SLE disease activity at follow-up, >80% of patients still had active SLE. 
Literature reporting on the outcome of subclinical LM in particular is sparse with small numbers 
of patients included in reports.(18,34,35) Also, reported studies included patients with inactive 
SLE / a low disease activity state, a stark contrast to our own group. Although we observed a trend 
towards a reduction in the presence of CMR criteria as well as improved individual parameters 
(T2-signal enhancement, EGEr and LGE), CMR subclinical myocardial injury persisted in patients 
with predominantly active SLE.  
CMR evidence of myocardial injury was observed regardless of improvement in SLE serological 
markers and global echocardiographic function. Our findings are in keeping with the disconnect 
seen between CMR evidence of myocardial injury and clinical features of SLE as well 
as cardiovascular symptoms that had been described both ante and post-mortem.(19,36,37)  
Our findings do not support subclinical LM to be a precursor for the development of clinically 
evident LM. Over a period of twelve months, subclinical LM did not have any significant 
prognostic implications. These findings question the relevance of CMR as a routine screening tool 
in SLE patients in the absence of clear clinical indications.(38) 
We did not observe a significant effect of intensified immunosuppression during the interim 
period on CMR evidence of myocardial injury (including inflammatory changes). Although CMR 
criteria resolved in some patients (including inflammatory as well as necrotic / fibrotic changes), 
other patients developed new criteria with no difference in exposure to intensified 
immunosuppressive therapy among CMR/clinical groups. This lack of a significant effect of 
immunosuppressive therapy on the various LLC applied in the SLE patient has also been 
described by other authors.(21) Our results therefore do not support the use of 
immunosuppressive therapy in SLE patients with subclinical myocardial injury as identified by 
CMR criteria.  
Improvement in CMR LV mass index correlated with an improvement in T2-weighted signal 
representing myocardial oedema. In viral myocarditis, a reduction in myocardial LV mass was 
found to be parallel to a reduction in signal intensity on T2-weighted images, without a 
significant correlation found between the two parameters.(39) We were able to 
demonstrate a positive correlation between the improvement in CMR LV mass index and T2-
weighted signal, a novel finding in SLE.  CMR LV mass index may be used as an additional 
measurement in SLE myocardial injury, also in the follow-up of patients.  
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We have observed a disconnect between the change in functional (LVEF, TAPSE, CMR LVEF) and 
morphological (LVIDi, T2-weighted signal, EGEr, LGE) echocardiographic and CMR parameters 
over time. The improvement of these more robust global functional parameters in our SLE cohort 
mirrors the lack of cardiovascular symptoms despite the presence of CMR evidence of myocardial 
injury described typically in both clinical as well as post-mortem studies of SLE patients.(16,19) 
Limitations 
Although this is the largest reported cohort of SLE patients with follow-up clinical and imaging 
data, our numbers were limited in particular within various subgroups. We were able to comment 
on trends while statistically significant results were limited by high confidence intervals. Our 
patients had persistent SLE disease activity over the follow-up period. Our results might therefore 
not be applicable to SLE patients in clinical remission / with low disease activity. 
Future research 
The presence of subclinical myocardial injury did not have any significant prognostic implications 
over a twelve-month period.  From the Lumina cohort it was concluded that clinical LM was 
associated with a reduced survival after 5 years and a higher damage accrual.(2) The long-term 
prognostic value of subclinical CMR myocardial injury in SLE needs to be studied over a longer 
period to guide our indications for screening as well as therapeutic decisions in the short term.   
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1. 2015: South African Arthritis and Rheumatism (SARAA) biannual national congress; 
Oral presentation: Lupus myocarditis in the Western Cape, South Africa: analysis of clinical and 
echocardiographic features.
2. 2015: Stellenbosch University Faculty of Health Sciences, Academic Year day; Oral 
presentation: Lupus myocarditis in the Western Cape, South Africa: analysis of clinical and 
echocardiographic features.
3. 2015: European League Against Rheumatism (EULAR) , annual congress, Abstract 
presentation. EULAR15-1100; Lupus myocarditis in the western cape, South Africa: Analysis of 
clinical and echocardiographic features.
4. 2016: 26th World Congress of the WSCTS, Cape Town; Poster presentation: Speckle 
tracking echocardiography in acute lupus myocarditis: comparison to conventional 
echocardiography.
5. 2017: South African Arthritis and Rheumatism (SARAA) biannual national congress; 
Oral presentation: Speckle tracking echocardiography in acute lupus myocarditis: comparison 
to conventional echocardiography.
6. 2018: World Congress of Internal Medicine; Invited speaker; Oral presentation: 
Myocardial dysfunction in SLE: diagnostic challenges and developments.
7. 2019: South African Arthritis and Rheumatism (SARAA) biannual national congress; 
Oral presentation: Clinical and echocardiographic characteristics of myocardial injury in SLE, 
classified according to cardiac magnetic resonance criteria.
8. 2019: Annual European Congress of Rheumatology (EULAR). Poster presentation. 
Submission N°: 4071 Title: Clinical and echocardiographic characteristics of myocardial injury 
in systemic lupus erythematosus, classified according to cardiac magnetic resonance criteria. 
Madrid, Spain.
9. 2019: European Society of Cardiology congress (ESC). Poster presentation. Myocardial 
injury in systemic lupus erythematosus defined by cardiac magnetic resonance imaging: clinical 
and echocardiographic characteristics. Paris, France.
10. 2020: Stellenbosch University Faculty of Health Sciences, Academic Year day. Poster 
presentation.  Serum cytokine levels associated with myocardial injury in systemic lupus 
erythematosus.
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